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Abstract
Amyotrophic Lateral Sclerosis (ALS) is a progressive motor neurodegenerative disorder
with an average life expectancy of 2-5 years post-diagnosis. Common pathological features
associated with ALS are the formation of cytoplasmic inclusions of intermediate filaments and
RNA-binding proteins within motor neurons. The formation of intermediate filament
cytoplasmic inclusions is believed to be driven by a loss of stochiometric expression between
five neuronal intermediate filament proteins—NFL, NFM, NFH, INA and PRPH—where there is
a selective suppression of the steady-state levels of NEFL, INA and PRPH mRNA. Further, three
RNA-binding proteins—TDP-43, FUS and RGNEF—have been shown to co-aggregate with
each other in ALS motor neurons indicating a possible common mechanism that leads to their
dysregulation.
In the last decade, microRNAs (miRNAs)—small RNA molecules generally responsible
for post-transcriptional regulation of gene expression—were observed to be massively
dysregulated in the spinal cord tissue of ALS patients, providing a possible explanation for the
changes observed in intermediate filament steady-state mRNA levels and RNA-binding protein
dysregulation in ALS. Further, TDP-43 and FUS regulate miRNA biogenesis, indicating there
may be a regulatory network between RNA-binding proteins and miRNAs that is disrupted in
ALS. I hypothesize that a regulatory network between specific RNA-binding proteins and
miRNAs is disrupted in ALS leading to changes in miRNA processing which contributes to
intermediate filament and RNA-binding protein pathology.
In this dissertation, I have examined: 1) whether ALS-linked miRNA(s) contribute to the
selective suppression of NEFL, PRPH, and INA; 2) whether ALS-linked miRNAs regulate the
expression of NEFM and NEFH; 3) whether ALS-linked miRNAs regulate the expression of
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RNA-binding proteins whose metabolism is dysregulated in ALS (TDP-43, FUS, and RGNEF);
and, 4) whether TDP-43 and FUS are in a regulatory network with ALS-linked miRNAs.
Overall, 12 ALS-linked miRNAs were identified to regulate either intermediate filament or
RNA-binding protein expression, and further, a novel negative feedback loop between TDP-43
and two miRNAs (miR-27b-3p and miR-181c-5p) was identified. This dissertation highlights
that changes to miRNA levels, as seen in ALS, would contribute to overall ALS pathology,
making them viable avenues for potential therapeutics.

Keywords: MicroRNA, ALS, RNA-binding proteins, TDP-43, intermediate filaments,
neurofilaments, RNA, neurodegeneration, regulatory networks
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Lay Abstract
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder defined by the
progressive loss of motor function such as walking, reaching grabbing, standing, etc., eventually
confining individuals to a wheelchair. ALS is generally fatal within 2-5 years of diagnosis. This
disease results from the dramatic loss of a specific cell-type within the brain and spinal cord
tissue called motor neurons. Decades of research has tried to understand what causes the loss of
motor neurons in ALS, and while much progress has been made, there remains a considerable
amount that is not understood regarding the underlying cause(s) of ALS. Recent research has
shown that small molecules known as microRNAs (miRNAs) are reduced in ALS motor
neurons. MiRNAs regulate the levels of gene expression within our cells which is critical for
cells to efficiently respond to environmental cues (i.e. stress) and maintain overall cell health.
Lack of these small molecules, as seen in ALS motor neurons, has been shown to cause motor
neuron death in mice, indicating the importance of miRNAs to motor neuron function. In this
dissertation, I explored the potential consequence of reduced miRNA levels, as seen in ALS, and
how this may relate to what we already know about ALS pathology. Further, I explored potential
molecular pathways that may explain why miRNA reduction occurs in ALS. I have found that
the loss of a specific pool of miRNAs in ALS may contribute to overall ALS pathogenesis. In
addition, I have identified a novel molecular network between miRNAs and TDP-43—a protein
that is dysregulated in 97% of all ALS cases—which may explain the loss of miRNAs seen in
ALS motor neurons. Overall, this thesis implicates miRNAs as major contributors to ALS
pathogenesis and identifies a disrupted molecular network between miRNAs and TDP-43,
providing new avenues to explore potential therapeutics for ALS.
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Epigraph
In the long history of humankind those who learned to collaborate and improvise most effectively
have prevailed.
-

Charles Darwin
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Dedication
To the individuals and families who have had to endure the extreme challenges of ALS. It
is your continued bravery and relentless fight that inspires the research community to find a cure
without surrender.
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Amyotrophic lateral sclerosis (ALS) is generally a late-onset neurodegenerative disease
that results in motor neuron loss causing death within 2-5 years after diagnosis. Several genetic
and pathological features of ALS have given us insights into the etiology of the disease (Strong,
2017). However, despite these efforts, very few therapeutics have been successful in treating
ALS. Therefore, we need to continue to explore the biological mechanisms underpinning ALS if
we are to find novel drug targets that may slow or halt the progression. Recent work has shown
that microRNAs (miRNAs) may be a major contributor to the disease pathogenesis.
MicroRNAs (miRNAs) are endogenous small non-coding RNAs that regulate gene
expression via formation of a ribonucleoprotein complex with Argonaute (AGO) proteins and
complementary base pairing with their target mRNAs (Lee et al., 1993; Slack et al., 2000).
Despite the apparent simplicity of miRNA function, their expression and mRNA targets are
highly dependent on the stage of development, environmental cues, aging and cellular type. This
highly dynamic process allows for the fine-tuning of gene expression depending not only on the
global needs of the cell, but also somatotopically-specific needs such as the maintenance of the
synaptic junction or the response to neuronal injury (van Rooij et al., 2007; Wilczynska and
Bushell, 2015). In this introduction, we will discuss motor neurons, ALS pathology, miRNA
biology and their role in motor neuron disease, and finally, potential mechanisms that may
contribute to the dysregulation of miRNAs seen in ALS.
1.1 Motor Neurons
Motor neurons are classified as either somatic or visceral. Visceral motor neurons are
responsible for innervating smooth and cardiac muscle allowing for involuntary contractions. In
contrast, somatic motor neurons innervate skeletal muscle to perform voluntary movement
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(Goulding, 1998; Guthrie, 2007). This dissertation will focus on somatic motor neurons
(henceforth referred to as “motor neurons”).
In general, motor neurons can be further grouped into those whose projections remain
within the central nervous system (CNS) and those that do not. Upper motor neurons (UMNs)
are a group of descending supraspinal neurons, the majority of which arise from the primary
motor cortex, premotor cortex and the supplementary motor area (Dum and Strick, 2005; Nachev
et al., 2008). UMNs arising in these cortical regions course through the corticospinal tracts with
the majority (75-90%) crossing at the level of the medulla to ultimately innervate contralateral
spinal motor neurons. The remaining 10-25% innervate ipsilateral spinal motor neurons. UMNs
send excitatory chemical signals via glutamate to activate spinal motor neurons (Fig. 1.1A).
Spinal motor neurons belong to the category of lower motor neurons (LMNs) that, in concert
with the muscle fibers that they innervate through their axonal terminals, constitute the motor
unit (Lemon, 2008; Welniarz et al., 2016). The interaction between the axon terminals and
skeletal muscle occurs at the neuromuscular junction (NMJ) where acetylcholine release across
the synapse induces muscle contractions which allow us to perform basic motor functions such
as standing, walking, reaching, grabbing, etc. (Fig 1.1B).
1.1.1 Axonal Transport
Axonal transport is necessary for motor neurons to send signals to other cells within the
body. An individual motor neuron axon can extend for upwards of a meter, giving rise to a
unique set of metabolic demands. Mitochondria, ribonucleoprotein (RNP) granules, and vesicles
must be positioned at specific sites along the length of the axon depending on somatotopic needs
and thus requiring a high degree of regulation (Fig. 1.1C) (Lin and Sheng, 2015; Vuppalanchi et
al., 2009). Critical to the integrity of the axonal projection are key cytoskeletal proteins,
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Figure 1.1. Motor neuron transmission. (A) The glutamatergic synaptic connection between
lower motor neurons (LMNs) and upper motor neurons (UMNs). This synapse drives excitation
of the LMN through a process that is dependent on the influx of Ca++ into the presynaptic
terminus which in turn triggers release of glutamate into the synaptic cleft. There, glutamate
stimulates the influx of Na+ and Ca++ into the post-synaptic LMN, which leads to its
depolarization. (B) Transport across the long axon of motor neurons. Neurons must be constantly
transferring mitochondria, vesicles and RNPs granules to localized spots in the axon depending
on the need of the cell. Transport is bidirectional along the axon where the molecular motor
kinesin drives anterograde transport, whereas dynein provides retrograde transport. This is
crucial for the proper distribution of proteins, transcripts and organelles. (C) Neuromuscular
junction. When the action potential has reached the neuromuscular junction, there is an influx of
Ca++ into the axonal presynaptic bouton resulting in the synaptic release of acetylcholine. This
causes the efflux of K+ and the influx of Na+ leading to the depolarization of the muscle fiber.
The influx of Na+ causes the opening of sodium voltage-gated channels along the muscle fiber,
allowing for the action potential to propagate through the muscle fiber (indicated by the golden
arrows), generating the muscle contraction.
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including microtubules which provide the highway that guides axonal transport, and
neurofilaments which are key to maintaining the cytoskeletal architecture of the axon and thus
indirectly, the degree of myelination (Hirokawa et al., 2010; Szaro and Strong, 2010). Further,
axons and synapses are highly dynamic structures that are constantly changing in an activitydependent manner, and thus, there is a constant redistribution of mitochondria depending on
localized energy demands (Miller and Sheetz, 2004). This is especially true for motor neurons as
their axonal length requires precise movement of mitochondria to meet their high energy
demands (Hinckelmann et al., 2013).
Beyond mitochondrial trafficking, the transport of mRNA along the axon allows for
somatotopically-specific protein synthesis. To accommodate this, mRNAs and translational
machinery are incorporated into RNP granules and transported to distal regions along the axon
for localized translation (Sutton and Schuman, 2006; Vuppalanchi et al., 2009). It is widely
accepted that during RNP transport that the mRNA within the granule is translationally silent, a
state that is suggested to be largely mediated by various RNA-binding proteins (Bramham and
Wells, 2007). However, it has also been shown that proteins essential for miRNA processing are
found within these RNP transport granules (Barbee et al., 2006), suggesting that the posttranscriptional regulation of mRNA within RNPs is likely an interaction between RNA-binding
proteins and regulatory RNA molecules, allowing for localized protein synthesis and even
mRNA degradation.
1.1.2 Regeneration
One of the fundamental differences between mature UMNs and LMNs is the ability for
LMNs to regenerate. In general, the peripheral nervous system (PNS) in which LMNs reside
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provides an environment where neurons can survive and regenerate subsequent to axonal
damage. This is not the case in the CNS (Fitch and Silver, 1997; Fu and Gordon, 1997). This
phenomenon has been attributed to the lack of neurotrophic factors and an abundance of
inhibitory proteins present after a nerve injury in the CNS (Schwab, 1996). For example, the
increased expression of neurotrophic factors brain-derived neurotrophic factor (BDNF) and
fibroblast growth factor 2 (FGF-2) and their receptors – trkB and FGFR-1, respectively –
promotes LMN regeneration in response to a nerve injury. However, within the CNS, the
expression of these receptors and ligands are reduced after nerve injury, creating a less
permissive environment for regeneration (Funakoshi et al., 1993; Kobayashi et al., 1996; Lewin
and Barde, 1996). Interestingly, ectopic expression of BDNF within the CNS after a neuronal
injury enhances the regenerative capacity of the neurons, suggesting it is an essential protein for
nerve recovery (Giehl and Tetzlaff, 1996; Kobayashi et al., 1997).
Further, the upregulation of cytoskeleton proteins including actin, tubulin and peripherin also
assist with the regeneration of LMNs by restructuring the axon as it recovers (Bisby and Tetzlaff,
1992; Chadan et al., 1994; Jiang et al., 1994). However, there is a downregulation in
neurofilament expression after a nerve injury, which has been shown to allow for efficient
transport of actin, tubulin and peripherin to distal regions of the injured axon (Tetzlaff et al.,
1996; Zhu et al., 1998). This change in cytoskeleton proteins after an axonal injury is far less
robust within the CNS, and thus, could be another reason why regeneration is not able to occur
within UMNs (Kost and Oblinger, 1993; Tetzlaff et al., 1991). This tightly coordinated change in
the expression of cytoskeleton genes within the PNS allows for efficient axonal repair, and thus,
a transient network of regulatory elements, such as miRNAs, must play an essential role in this
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regenerative process. Disruption of molecular pathways that are critical to motor neuron function
like axonal transport and regeneration have been shown to be disrupted in patients with ALS.
1.2 ALS
ALS is a neurodegenerative disease which is defined by the loss of both upper and lower
motor neurons within the brain and spinal cord tissue, respectively (Strong et al., 2005). This
debilitating disease ultimately leads to a person being confined to a wheelchair with the inability
to perform basic motor tasks including and not limited to reaching, grabbing, standing, walking,
speech, swallowing and breathing (Strong et al., 2017). Currently, there are limited treatments
for this disease which has an expected survival time of 2-5 years post-diagnosis.

1.2.1 Demographics of ALS
Generally, ALS is a late onset disease with an average age of diagnosis between 40-70
years of age with an incidence rate of two out of 100,000 people (Zarei et al., 2015). Ninety
percent of ALS cases have no familial history (sporadic ALS [sALS]), and within those cases,
only about 12-13% carry a known genetic mutation to explain the etiology of their disease. The
remaining 10% of ALS cases are familial (fALS), and in those cases, about two-thirds have a
known genetic defect (Mathis et al., 2019; Taylor et al., 2016). By far, in both sporadic and
familial ALS cases, the most common genetic alteration is a hexanucleotide (GGGGCC) repeat
expansion in C9ORF72 making up about 25-40% of familial and 10% of sporadic genetic cases.
This is followed by mutations in SOD1, TDP-43 and FUS, respectively, which total to about
30% within familial cases and 2-3% within sporadic cases (Majounie et al., 2012; Taylor et al.,
2016). There have been several other genes that contain disease causative mutations which
accumulate to ~12% of familial and <1% of sporadic ALS cases (Table 1.1). While it is clear
that genetic alterations play a critical role within the disease etiology for some patients, the vast
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Table 1.1. Known genes that carry disease causative variants of familial and sporadic ALS
Gene ID

Chromosome
Location

Mode of
inheritance*

Protein Function

% of fALS
cases**

% of sALS
cases**

C9ORF72

9p21.2

AD

Nucleocytoplasmic transport

25-40%

10%

SOD1
TARDBP

2q22.11
1p36.22

AD, AR
AD

Superoxide dimutase
DNA/RNA-binding protein

20%
5%

2%
<1%

FUS

16p11.2

AD

DNA/RNA-binding protein

5%

<1%

OPTN
NEK1
VCP

10p13
4q33
9q13.3

AD, AR
Not determined
AD

4%
2-3%
2%

<1%
<1%
<1%

TIA-1

2p13.3

AD

2%

<1%

(Mackenzie et al., 2017)

hnRNPA1
hnRNPA2B1
UBQLN2

7p15.2
12q13.3
Xp11.21

AD
AD
X-linked

<1%
<1%
<1%

<1%
<1%
<1%

KIF5A

12q13.3

AD

<1%

<1%

TBK1
PFN1
DNAJC7

12q154.2
17p13.2
17q21.2

AD
AD
Not determined

Autophagy
Kinase and DNA repair
Autophagy
DNA/RNA-binding protein,
stress granule formation
RNA-binding protein
RNA-binding protein
Autophagy
Anterograde transport of
organelles and RNP granules
Autophagy and inflammation
Actin polymerization
Heat Shock 40 protein

(DeJesus-Hernandez et al.,
2011; Renton et al., 2011)
(Rosen et al., 1993)
(Sreedharan et al., 2008)
(Belzil et al., 2009; Vance
et al., 2009)
(Maruyama et al., 2010)
(Kenna et al., 2016)
(Johnson et al., 2010)

<1%
<1%
<1%

<1%
<1%
<1%

SQSTM1

5q35.3

AD

Autophagy

<1%

-

VAPB
SEXT

20q13.33
9q34.13

AD
AD

Axonal transport
DNA/RNA helicase

<1%
?

?

ALS2

2p33.2

AR

Rho nucleotide exchange factor

?

?

SPG11

15q21.1

AR

Transmembrane protein

?

?

?

-

(Kim et al., 2013)
(Kim et al., 2013)
(Deng et al., 2011)
(Brenner et al., 2018;
Nicolas et al., 2018)
(Freischmidt et al., 2015b)
(Wu et al., 2012)
(Farhan et al., 2019)
(Fecto et al., 2011; Le Ber
et al., 2013)
(Nishimura et al., 2004)
(Chen et al., 2004)
(Hadano et al., 2001; Yang
et al., 2001)
(Hentati et al., 1998;
Orlacchio et al., 2010)
(Sapp et al., 2003)

ALS7
20p13
AD
Unknown
*Autosomal Dominate (AD); Autosomal Recessive (AR)
**Percentages represent approximate values. May vary in different ALS cohorts studied.

Reference
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majority of cases have no known genetic cause, suggesting that environmental factors may also
play a critical role in ALS. Thus, we must further explore changes to both RNA and protein if we
are to understand the progression of the disease at the molecular level.
1.2.2 ALS Pathology
The formation of neuronal cytoplasmic inclusions (NCIs), consisting of aberrantly
aggregated proteins, is a common pathological phenomenon is several neurodegenerative
diseases, including ALS. The most common protein groups found to be aberrantly aggregated in
ALS are intermediate filaments and RNA-binding proteins (Strong, 2017). The formation of
intermediate filament inclusions is believed to be driven by changes to stochiometric expression
between cytoskeleton proteins (Szaro and Strong, 2010), whereas RNA-binding protein
inclusions are believed to be driven by changes to their low-complexity domain (LCD; i.e. posttranslational modifications, or mutations) that make the protein more prone to aggregate
(Franzmann and Alberti, 2019; Molliex et al., 2015; Murakami et al., 2015; Murray et al., 2017;
Patel et al., 2015). The formation of RNA-binding protein cytoplasmic aggregates is the most
common pathology seen in ALS, indicating that RNA dysregulation may be a major driver of
ALS (Keller et al., 2012; Strong, 2017).
In 1981, Davidson et al. demonstrated using tinctorial stains that there was an 31% and
42% reduction in total RNA content within ALS lumbar and cervical motor neurons,
respectively, providing the first evidence of RNA dysregulation in ALS (Davidson and
Hartmann, 1981; Davidson et al., 1981). It was subsequently demonstrated that an overall
reduction in polyadenylated RNA in ALS motor neurons bearing neurofilament NCIs was
present when assessed using in situ hybridization (Bergeron et al., 1994), suggesting a
dysregulation of coding RNA. These works would kick-off decades of research that would later

11
show issues in mRNA expression, splicing, polyadenylation, transport, stability, and further,
dysregulation of non-coding RNAs in ALS motor neurons. In this section, we will discuss the
various RNA-binding protein pathologies followed by what we currently understand about RNA
dysregulation in ALS as these two phenomena are highly connected.
1.2.2.1 RNA-binding Protein Pathology
1.2.2.1.1 TDP-43
TAR DNA-binding protein 43 kDa (TDP-43) is a ubiquitously expressed nuclear protein
that has a diverse set of functions which include: mRNA transcription, mRNA splicing, RNA
export, mRNA translation, miRNA biogenesis, long non-coding RNA (lncRNA) processing, and
stress granule formation (Ratti and Buratti, 2016). Re-localization of TDP-43 from the nucleus to
the cytoplasm and the subsequent formation of NCIs in motor neurons is the most common
pathological feature of ALS, being observed in 97% of all cases (Ling et al., 2013).
Several of the ALS-linked mutations and phosphorylation sites associated with TDP-43
pathology are harbored in the LCD (Buratti, 2015). LCD’s are intrinsically disordered domains
which can form either alpha-helical or pleated beta-sheet structures regulating the solubility of
the protein (Franzmann and Alberti, 2019). Both aberrant mutations and phosphorylation within
the LCD of TDP-43 promotes beta-sheet structures which lead to the eventual accumulation and
formation of insoluble protein aggregates (Barmada et al., 2010; Choksi et al., 2014; Liachko et
al., 2010). The primary phosphorylation sites of TDP-43 associated with pathological aggregates
in motor neurons of ALS patients are serine 409/410, amino acids that are found in the LCD
(Neumann et al., 2009a; Neumann et al., 2006). This suggests that conformational changes
within the LCD of TDP-43 contributes to its pathogenic role in ALS; however, the exact
mechanism(s) that lead to these changes are still unclear.
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Mixed results have been seen in whether or not overexpression of wild-type TDP-43 in
mouse models can actually lead to the formation of pathological aggregates in motor neurons
(Mitchell et al., 2015; Xu et al., 2010). However, in sporadic ALS cases with no known genetic
background, increased expression of TDP-43 protein and mRNA levels within the spinal cord
and motor neurons has been observed, and further, the overexpression of other proteins with
LCD’s similar to TDP-43 have been shown to form insoluble aggregates in both in vitro and in
vivo models (Koyama et al., 2016; Mitchell et al., 2013; Patel et al., 2015; Swarup et al., 2011;
Xu et al., 2010).TDP-43 has been shown to co-aggregate with several other LCD-containing
proteins including FUS, TIA-1 and MATR3 in ALS motor neurons (Keller et al., 2012; LiuYesucevitz et al., 2010; Tada et al., 2018; Volkening et al., 2009). These observations suggest
that the simple accumulation of TDP-43 alone may not sufficient to drive this protein into
insoluble aggregates and that the presence of other LCD-containing proteins may be needed.
Further investigation is needed.
1.2.2.1.2 FUS, EWSR1 and TAF15 (FET) Proteins
Fused in liposarcoma (FUS), Ewing sarcoma (EWSR1), and TATA-binding associated
factor 15 (TAF15) make up the family of FET proteins that are mainly responsible for genomic
maintenance, RNA transcription, mRNA splicing, mRNA metabolism and miRNA production.
FET proteins are a highly conserved set of proteins that are primarily nuclear and expressed in
every cell (Andersson et al., 2008; Ballarino et al., 2013; Morlando et al., 2012; Svetoni et al.,
2016).
In ALS, all three of these proteins have been shown to re-localize from the nucleus to the
cytoplasm and produce cytoplasmic aggregates, or contain mutations associated with the disease
(Belzil et al., 2009; Couthouis et al., 2012; Couthouis et al., 2011; Kwiatkowski et al., 2009;
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Neumann et al., 2009b; Ticozzi et al., 2011; Vance et al., 2009). Out of the three FET proteins,
FUS immunoreactive NCIs are the most often observed in ALS, being present in about 1% of all
ALS cases. EWSR1 and TAF15 inclusions have been seen in only a small number of ALS cases
(>0.1%) (Ling et al., 2013). Similar to TDP-43, FET proteins contain an LCD that is believed to
be the major driver of pathological aggregate formation in ALS.
Causative FUS mutations for ALS tend to be concentrated within the nuclear localization
sequence (NLS) and also in the LCD (Taylor et al., 2016). This suggests that the loss of nuclear
localization of FUS is critical to the pathogenesis of ALS. Further, the accumulation of wild-type
FUS leads to phase separation and insoluble protein aggregates in a process that can be
accelerated by mutations in the LCD of FUS (Mitchell et al., 2013; Patel et al., 2015). Several
rodent and in vitro models have shown that the overexpression of FUS is sufficient to drive
cytoplasmic aggregation and that this aggregation is dependent on its’ LCD (Kato et al., 2012;
Mitchell et al., 2013; Murakami et al., 2015). Increased levels of FUS protein have also been
observed in sALS spinal cord with no known genetic history (Hawley et al., 2017). Thus, the
pathological formation of aggregates by FUS may be concentration dependent, where mutations
accelerate phase separation and the formation of cytoplasmic aggregates by promoting the
accumulation of FUS through the LCD.

1.2.2.1.3 HnRNPA1 and HnRNPA2B1
Heterogeneous nuclear Ribonucleoprotein A1 and A2B1 (hnRNPA1 and hnRNPA2B1,
respectively) are primarily nuclear proteins that are involved in mRNA splicing, stability,
transport and miRNA processing (Zhao et al., 2018). Both these proteins contain mutations
within their LCD in less than 1% of ALS cases (Kim et al., 2013; Molliex et al., 2015).
Interestingly, muscle biopsies from ALS patients revealed that hnRNPA1 and hnRNPA2B1
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mutations can lead to cytoplasmic aggregates within muscle tissue, although no aggregates were
observed in motor neurons (Kim et al., 2013). While neither protein specifically has been shown
to aggregate in motor neurons, loss of TDP-43 nuclear localization results in aberrant splicing of
hnRNPA1, promoting an alternative isoform called hnRNPA1B that has an extended LCD.
Interestingly, hnRNPA1B does form cytoplasmic aggregates in ALS motor neurons where there
are also pathological aggregates of TDP-43 (Deshaies et al., 2018). These findings suggest that
hnRNP’s may play multiple roles in the pathogenesis of ALS affecting both muscle and motor
neuron cell populations.
1.2.2.1.4 RGNEF
Rho Guanine Nucleotide Exchange Factor (RGNEF) is both a guanine exchange factor
involved in the RhoA signaling pathway and an RNA-binding protein. The mouse homologue,
p190RhoGEF, was first described in murine tissues and was shown to activate RhoA and interact
with microtubules (van Horck et al., 2001). Further, work showed that p190RhoGEF interacted
with and destabilized mouse Nefl mRNA preventing neurofilament aggregation—a common
feature seen in ALS (Lin et al., 2004). This provided the first clue that RGNEF may be involved
in the pathogenesis of ALS.
Several guanine exchange factors and RNA-binding proteins are associated with
neurodegenerative diseases, but RGNEF is the only protein that shares these two functions and is
also associated with neurodegeneration (Droppelmann et al., 2014). Still, little is known about
RGNEF’s role in RNA regulation although it has been shown to negatively regulate the mRNA
stability of NEFL through interactions with the 3’UTR (Droppelmann et al., 2013a). Further,
RGNEF has been shown to interact with NEFL mRNA only in ALS, but not control, spinal cord
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homogenates (Volkening et al., 2010), and therefore, may play a major role in intermediate
filament pathogenesis associated with ALS.
In terms of pathology, RGNEF has been observed in ubiquitin-positive aggregates and to
co-localize with TDP-43 and FUS cytoplasmic aggregates (Keller et al., 2012). Further, several
mutations in ARHGEF28 (gene name of RGNEF) have been associated with ALS (Droppelmann
et al., 2013b; Farhan et al., 2017; Ma et al., 2014; Song et al., 2020; Zhang et al., 2016).
However, while there is a definite association between RGNEF and ALS, it is still unclear
whether these mutations alone are causative of the disease.
1.2.2.1.5 ATXN2
Ataxin 2 (ATXN2) is an RNA-binding protein that is primarily expressed within the
cytoplasm where it regulates mRNA stability, RNA polyadenylation and mRNA translation. In
~5% of all ALS cases, ATXN2 contains a polyglutamine (polyQ) repeat element (CAG) that is
greater than 37 repeats, while healthy individuals tend to have ~15-22 repeats (Ostrowski et al.,
2017; Zhao et al., 2018). Expanded repeats of this gene has been associated with other
neurodegenerative diseases including Spinal Cerebellar Ataxia (SCA), frontotemporal dementia
and Parkinson’s disease (Houlden and Singleton, 2012; Majounie et al., 2007; Rubino et al.,
2019). The exact role that these repeat expansions play in disease is relatively unclear. However,
the repeat expansion of ATXN2 in ALS appears to enhance TDP-43 and FUS toxicity, while the
suppression of ATXN2 expression using antisense oligos (ASOs) reduces TDP-43 toxicity in fly
and rodent ALS models overexpressing TDP-43, making it a possible therapeutic target of ALS
(Elden et al., 2010; Farg et al., 2013).
1.2.2.1.6 MATR3
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Matrin 3 (MATR3) is an DNA/RNA-binding protein that is involved with mRNA
transcription, export and stability, and primarily found within the nuclear matrix. In less than 1%
of ALS cases, there is a missense or splicing mutation in the MATR3 gene (Leblond et al., 2016;
Taylor et al., 2016). Mutations in MATR3 still result in it being primarily nuclear within ALS
motor neurons; however, some have reported either MATR3 diffusely localized to the
cytoplasm, or in cytoplasmic inclusions with TDP-43 (Johnson et al., 2014; Tada et al., 2018).
Transgenic mice overexpressing ALS-mutant MATR3 F115C showed muscle atrophy, but no
effect on spinal motor neurons, indicating that MATR3 mutations may have a greater impact on
muscle than motor neurons (Moloney et al., 2018). Others have observed in primary rat neuronal
cell culture models that MATR3 mutations enhance neuronal death, where neurotoxicity is
dependent on its nuclear localization, not cytosolic localization, as we have seen with other ALSassociated RNA-binding proteins (Malik et al., 2018). Overall, a lot still needs to be understood
about MATR3 mutations and its relation to the pathogenicity of ALS.
1.2.2.1.7 TIA-1
TIA1 cytotoxic granule associated RNA-binding protein (TIA-1) is a primarily nuclear
protein involved in RNA processing and translation (Del Gatto-Konczak et al., 2000; Dixon et
al., 2003; Forch et al., 2000; Piecyk et al., 2000). However, TIA-1 is better known for its role in
stress granule assembly (Gilks et al., 2004; Kedersha et al., 2000; Kedersha et al., 1999). During
periods of cellular stress, TIA-1 leaves the nucleus and enters the cytoplasm where it nucleates
and initiates the formation of stress granules, which contain several ALS-related RNA-binding
proteins including TDP-43, FUS, hnRNPA1, hnRNPA2B1, ATXN2 and MATR3 (Gilks et al.,
2004; Kedersha et al., 2000; Zhao et al., 2018). Stress has been suggested to be a seed to
cytoplasmic aggregation of proteins associated with ALS as TIA-1 has been shown to form
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pathological aggregates in ALS motor neurons that co-localize with TDP-43 (Liu-Yesucevitz et
al., 2010; Volkening et al., 2009). More recently, several ALS-associated mutations have been
observed within the LCD of TIA-1 (Mackenzie et al., 2017; Yuan et al., 2018; Zhang et al.,
2018b). While patients with these mutations did show TDP-43 cytoplasmic aggregates in motor
neurons, no TIA-1 was observed in cytoplasmic aggregates. Despite this finding, mutations
within the LCD of TIA-1 still promoted the phase separation of TDP-43 into insoluble
aggregates in in vitro motor neuron models, indicating that TIA-1 mutations and its LCD likely
contribute to TDP-43 pathology (Mackenzie et al., 2017).
1.2.2.2 Other Major Protein Pathologies in ALS
Several other proteins have been observed in ALS motor neurons to form cytoplasmic
aggregates that are not categorized as RNA-binding proteins. However, here I will discuss two
other major protein pathologies—SOD1 and C9ORF72—that have been also shown to contribute
to RNA dysregulation in ALS.
1.2.2.2.1 SOD1
Cu/Zn-superoxide dimutase 1 (SOD1) cytoplasmic protein aggregation is seen in 2% of
all ALS cases. Mutations in SOD1 (mtSOD1) leads to misfolding of the protein causing reduced
activity and increased accumulation of free radicals that are toxic to cells (Kaur et al., 2016).
Interestingly, mutant, but not wild-type, SOD1 binds to the 3’ untranslated region (UTR) of
NEFL and VEGF mRNA, destabilizing these mRNA molecules and reducing their steady-state
levels (Li et al., 2009; Lin et al., 2004; Lu et al., 2007; Menzies et al., 2002). Therefore, while
not classically an RNA-binding protein, mtSOD1 appears to acquire a gain-of-function where it
negatively regulates the levels of NEFL and VEGF through direct interactions with their 3’UTRs.
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VEGF is a critical trophic factor known to promote motor neuron survival, while NEFL is critical
for cytoskeleton formation (Oosthuyse et al., 2001; Szaro and Strong, 2010). This highlights that
mtSOD1 toxicity not only disrupts cytoskeleton formation, which is critical for motor neuron
structure and function, but as well reducing the expression of trophic factors critical for motor
neuron survival. MtSOD1, due to protein misfolding, appears to have a high affinity for
adenylate- and uridylate-rich elements (ARE’s) located in the 3’UTRs of NEFL and VEGF, and
thus, while these are currently the only two RNA molecules known to be affected by mtSOD1,
there could be other RNA molecules with ARE regions that mtSOD1 could target (Li et al.,
2009).
1.2.2.2.2 C9ORF72
Chromosome 9 open reading frame 72 (C9ORF72) GGGGCC intronic repeat expansions
are the most common genetic variant associated with ALS where less than 24 repeats is
considered a normal state, between 24-100 repeats represents an intermediate state (between
normal and pathological), and over 100 repeats represents a pathological state (DeJesusHernandez et al., 2011; Mathis et al., 2019; Renton et al., 2011). This expansion leads to aberrant
translation—non-ATG or RAN-translation—of C9ORF72 creating dipeptide repeats (poly-GA,
poly-GP, poly-GR, poly-PA and poly-PR dipeptides) that are known to form cytoplasmic
aggregates that are linked to neurotoxicity (Mori et al., 2013a; Mori et al., 2013b; Wen et al.,
2014). Through a gain-of-function mechanism via the dipeptide repeats several RNA processing
pathways are affected including RNA transcription, splicing and translation (Kwon et al., 2014;
Suzuki et al., 2018; Zhang et al., 2018c). Further, in several in vitro and in vivo models, the
dipeptide repeats have been shown to bind to multiple nucleoporin proteins which blocks nuclear
export of RNA molecules (Freibaum et al., 2015; Shi et al., 2017; Zhang et al., 2015).
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Overall, several proteins associated with ALS are in involved in the regulation of coding
and non-coding RNA pathways making it clear that RNA dysfunction is likely a major
contributor in the disease pathogenesis.
1.2.2.3 RNA Dysregulation in ALS
1.2.2.3.1 Cytoskeleton Pathology and RNA Dysregulation in ALS
Intermediate filaments are a critical component that provide cellular structure, and in
particular, provide axonal structure to neurons which allow for axonal transport and signaling
which are necessary for neuronal survival (Szaro and Strong, 2010). In mature neurons, there are
three intermediate filaments, generally called neurofilaments, that are critical for axonal
structure; neurofilament light (NFL), medium (NFM) and heavy (NFH). Together they form a
triplet protein structure where NFL either forms homopolymers or heteropolymers with NFM
and NFH. Neither NFM or NFH alone can form homopolymers and are therefore dependent on
NFL to form the cytoskeleton structure of an axon (Carpenter and Ip, 1996). Further, peripherin
(PRPH) and α-internexin (INA) are two intermediate filaments responsible for forming the early
cytoskeleton structure in developing neurons, but also interact with the neurofilament triplet
protein structure in mature neurons (Athlan and Mushynski, 1997; Kaplan et al., 1990; Yuan et
al., 2006; Yuan et al., 2012). These five intermediate filaments are under tight spatiotemporal
control to maintain axonal structure and integrity (Szaro and Strong, 2010).
In ALS, several of these intermediate filaments have been shown to form pathological
aggregates within motor neurons, including NFH, NFM and PRPH (He and Hays, 2004; Keller
et al., 2012; Mendonca et al., 2005; Migheli et al., 1993; Mizuno et al., 2011; Munoz et al., 1988;
Strong et al., 2005). It is believed that loss of spatiotemporal control leads to an alteration in the
stoichiometry between the intermediate filaments causing intermediate filament aggregation
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(Szaro and Strong, 2010). This is because in several ALS mouse models where intermediate
filaments have either been knocked-out, or knocked-in, intermediate filament aggregation was
observed that was representative of what was seen in the disease, and in most cases, led to motor
neuron death (Beaulieu and Julien, 2003; Beaulieu et al., 1999; Cote et al., 1993; Kriz et al.,
2000; Lee et al., 1994; Robertson et al., 2002; Zhu et al., 1997). Further, in motor neurons of
patients with sALS with no known genetic background, there is reduced expression of NEFL,
PRPH and INA mRNA levels with no change to NEFM or NEFH levels (Wong et al., 2000).
These changes in mRNA levels between intermediates filaments causes a change in
stoichiometry that could result in intermediate filament aggregation.
While intermediate filament mRNA dysregulation is a well-known phenomenon in ALS,
it is unclear what causes this RNA dysregulation. Two ALS-related RNA-binding proteins—
TDP-43 and RGNEF—have been shown to interact with the 3’UTR and regulate NEFL mRNA
by either increasing or reducing the mRNA levels, respectively (Droppelmann et al., 2013a;
Volkening et al., 2009). Interestingly, NEFL mRNA in spinal cord homogenates was only bound
to RGNEF when homogenates were derived from ALS patients and not from controls
(Volkening et al., 2010). This suggests that dysregulation of TDP-43 and RGNEF, as seen in
ALS motor neurons, may alter NEFL mRNA steady-state levels, contributing to changes in
intermediate filament stoichiometry.
Further, our group has shown several ALS-linked miRNAs interact with the NEFL
3’UTR to regulate mRNA stability including: miR-146a*, miR-524-5p, miR-582-3p miR-b1336,
and miR-b2403. Expression levels of miR-524-5p, miR-582-3p, miR-b1336 and miR-b2403
have all been shown to be reduced in ALS spinal cord but increase mRNA stability when
interacting with the NEFL 3’UTR. In contrast, miR-146a* has been shown to be increased in
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ALS spinal cord but decreases mRNA stability when interacting with the NEFL 3’UTR
(Campos-Melo et al., 2013; Ishtiaq et al., 2014). These observations suggest that miRNA
dysregulation may be a major contributor to reduced NEFL mRNA levels in ALS motor neurons,
and to overall changes in intermediate filament stoichiometry. However, research still needs to
be done to understand why there is a selective suppression of NEFL, PRPH and INA in ALS
motor neurons while sparing the remaining intermediate filaments.
1.2.2.3.2 Splicing Dysregulation in ALS
Several ALS-related RNA-binding proteins are known to be involved in mRNA splicing
including: TDP-43, FUS, TAF15, EWSR1, valosin-containing protein (VCP), hnRNPA1 and
hnRNPA2B1 (Perrone et al., 2020). Thus, it is not surprising that mis-splicing of mRNA in
motor neurons and spinal cord is a common phenomenon found in patients with ALS.
TDP-43 dysregulation has been heavily associated with mis-splicing of several genes
including, but not limited to CFTR, MAPT, SMN2, hnRNPA1 and STMN2 (Bose et al., 2008;
Buratti and Baralle, 2001; Deshaies et al., 2018; Gu et al., 2017; Klim et al., 2019). In particular,
mutations in the C-terminal end of TDP-43 have been associated with a gain-of-function where
TDP-43 creates an alternative splicing event which skips exons that would normally be included
(Fratta et al., 2018). These are known as “skiptic exons”. Further, loss of TDP-43 nuclear
localization has been associated with loss-of-function splicing by which exons that would not
normally be a part of the final transcript are placed in the transcript due to the absence of TDP-43
(Fratta et al., 2018). These are known as “cryptic exons.” Both skiptic and cryptic exons have an
increased prevalence in mouse models that contain gain or loss-of-function of TDP-43,
respectively (Fratta et al., 2018). More recently, reduced TDP-43 levels within iPSC-derived
motor neurons resulted in the production of a cryptic exon in the gene stathmin-2 (STMN2)—a
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protein necessary for axonal regeneration—which leads to early termination of translation and
loss of protein production. Further, this cryptic exon in STMN2 showed increased prevalence in
ALS motor neurons where reduced STMN2 protein was also observed (Klim et al., 2019).
TDP-43 also functions in the splicing of hnRNPA1. However, loss of TDP-43 nuclear
localization promotes the production of the hnRNPA1B transcript, an alternative splice isoform
which produces a protein that has an extended LCD and promotes the formation of hnRNPA1B
cytoplasmic aggregates in ALS motor neurons (Deshaies et al., 2018).
ALS-associated mutations in VCP have been shown to result in mis-splicing of Splicing
Factor Proline and Glutamine rich (SFPQ) transcript causing the retention of intron 9 as shown
in iPSC-derived motor neuron models (Luisier et al., 2018). The retention of this intron leads to
increased binding of the SFPQ protein on the SFPQ transcript resulting in the protein exiting the
nucleus and forming cytoplasmic aggregates. Clearance of SFPQ from the nucleus can be seen in
motor neurons of mtVCP, mtSOD1, and sporadic ALS cases (Luisier et al., 2018). This provides
an interesting mechanism by which mis-splicing, or intron retention, may directly contribute to
the cytoplasmic aggregation of nuclear proteins as seen in ALS.
Finally, FUS and other FET proteins (TAF15 and EWSR1) are known to interact with the
spliceosome and regulate the splicing of several transcripts in the central nervous system (Kapeli
et al., 2016; Orozco and Edbauer, 2013; Rogelj et al., 2012; Svetoni et al., 2016; Yu and Reed,
2015; Zhou et al., 2002). FUS splicing events have been shown to be critical for neuronal
function and survival (Lagier-Tourenne et al., 2012). Loss of FUS nuclear localization due to
ALS-associated mutations has been known to cause massive changes in splicing within brain
tissue of rodent models and in vitro neuronal models (Dormann et al., 2010; Kapeli et al., 2016;
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Lagier-Tourenne et al., 2012; Reber et al., 2016; Zhou et al., 2013b). Overall, mis-splicing of
transcripts appears to be a major contributor to the disease pathogenesis.
1.2.2.3.3 Altered Polyadenylation in ALS
Recent research has shown that altered poly(A) may be a contributing factor to the
disease pathogenesis as a consequence of the loss of TDP-43 nuclear localization. In particular,
TDP-43 regulates the poly(A) of STMN2 as shown in iPSC-derived motor neuron models, but
loss of TDP-43 regulation promotes an early poly(A) termination site during transcription of
STMN2 (Melamed et al., 2019). This leads to loss of STMN2 protein which, as mentioned
previously, is a protein considered necessary for axonal regeneration (Klim et al., 2019). This
early poly(A) termination of STMN2 has been observed in patients with ALS, indicating altered
polyadenylation could be a factor contributing to motor neuron degeneration (Melamed et al.,
2019). While STMN2 is one example of altered polyadenylation in ALS, it would be worth
exploring the extent of poly(A) dysregulation due to loss of TDP-43 nuclear function to
understand the scope of this alteration across the transcriptome.
1.2.2.3.4 Dysregulation of RNA Export in ALS
Disruption in nucleocytoplasmic transport is a major phenomenon that occurs in ALS due
to dysregulation of nuclear pore complexes (Chou et al., 2018; Freibaum et al., 2015; Taylor et
al., 2016; Zhang et al., 2018a; Zhang et al., 2015). Nuclear pore complexes have been shown to
interact with insoluble TDP-43. Mouse models and iPSC-derived motor neuron models
containing disease-related mutations in TDP-43 showed impaired poly(A)-containing RNA
export causing it to accumulate in the nucleus (Chou et al., 2018). Further, ALS-related
mutations in MATR3 and C9ORF72 have also been shown to cause nuclear mRNA export
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defects (Boehringer et al., 2017; Zhang et al., 2015). However, whether this is a global effect or
if specific mRNA molecules are being retained is still in question.
1.2.2.3.5 Non-coding RNA Dysregulation in ALS
Non-coding RNA molecules that have been associated with the pathogenesis of ALS
include miRNAs, long non-coding RNA’s (lncRNA’s) and small nucleolar RNA’s (snoRNA’s)
(Campos-Melo et al., 2013; Chen and Chen, 2020; De Felice et al., 2014; Emde et al., 2015;
Figueroa-Romero et al., 2016; Nishimoto et al., 2013; Riva et al., 2016). Although several
snoRNA’s have been shown to be upregulated in ALS motor neurons, the significance of this
finding and how it contributes to the pathogenesis of ALS is still unclear (Riva et al., 2016).
LncRNA NEAT1_2 has been observed to be increased in the motor neurons of sALS
patients (Nishimoto et al., 2013). NEAT1_2 is an essential component for nuclear paraspeckle
formation—RNP granules that regulate gene expression via nuclear retention of mRNA (Fox and
Lamond, 2010). Increased NEAT1_2 levels coincide with an increase number of paraspeckles in
sALS motor neurons where NEAT1_2 has been shown to interact with TDP-43 and FUS proteins
(Nishimoto et al., 2013). Interestingly, ALS-linked mutations in FUS have been shown to cause
paraspeckle dysfunction, but also lead to greater NEAT1_2 levels, indicating that FUS may be
needed to form paraspeckles, and the loss of these structures could contribute to the pathology of
the disease (An et al., 2019).
As previously discussed, miRNAs have been the most extensively studied non-coding
RNA molecules in ALS. The majority of miRNAs, but not all, have been shown to be reduced in
the spinal cord and motor neurons of ALS patients (Campos-Melo et al., 2013; De Felice et al.,
2014; Emde et al., 2015; Figueroa-Romero et al., 2016; Reichenstein et al., 2019). It is tempting
to hypothesize that this may be because several RNA-binding proteins that are dysregulated in
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ALS are also involved in miRNA biogenesis. These include TDP-43, FUS, TAF15, EWSR1,
hnRNPA1, and hnRNPA2B1 (Alarcon et al., 2015; Ballarino et al., 2013; Guil and Caceres,
2007; Kawahara and Mieda-Sato, 2012; Kim et al., 2014; Morlando et al., 2012). However, very
little is known about how miRNAs become dysregulated in the first place and whether this
change in miRNA expression really has an impact on the disease pathogenesis. In this
dissertation, my goal is to try and understand possible mechanisms for why miRNAs are reduced
in ALS motor neurons and whether if any of the miRNAs affected result in altered expression of
genes associated ALS. For example, does reduced miRNA expression alter intermediate filament
stoichiometry, or lead to increased expression of LCD-containing proteins which may promote
their aggregation? To understand miRNA dysregulation, we must first understand miRNA
regulation. In the next section, I will discuss miRNA biogenesis, regulation and function, and
then briefly discuss our current understanding of the role of miRNAs in motor neuron function
and disease.
1.3 MiRNAs
MiRNAs are evolutionary conserved non-coding RNAs (ncRNAs) of 18-22 nucleotides
that post-transcriptionally regulate the expression of most mammalian genes. First discovered in
Caenorhabditis elegans over 25 years ago, miRNAs are the dominant class of small RNAs in
somatic cells (Ha and Kim, 2014; Lee et al., 1993). The human genome harbours more than
2,500 mature miRNAs that play major roles in a variety of biological pathways such as
apoptosis, cell proliferation, development, differentiation and pathological processes (Bartel,
2018). Each miRNA contains a unique nomenclature used to identify them (Table 1.2).
1.3.1 MiRNA Biogenesis
1.3.1.1 Canonical miRNA Biogenesis Pathway
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Table 1.2. MiRNA nomenclature.
Examples of miRNAs

Symbol

Meaning

miR-218

“miR-“

Abbreviation for “miRNA”

miR-218

“218”

Unique identifier for specific miRNA

“miR-1”

Name listed without asterisks
represent predominant miRNA
product that originates from
precursor miRNA

“*”

Asterisk refers to miRNA which is
on the opposite arm from
predominant product on the precursor
miRNA

“-5p, -3p”

Suffixes determine whether the
miRNA originated from the 5’ end (5p) or 3’end (-3p) of precursor
miRNA molecule

“a, b”

Letters beside miRNAs with the
same unique identifier refer to
miRNAs that are a part of the same
family. If miRNAs are in the same
family, they contain the exact same
seed sequence, but the full mature
miRNA sequence is not the same

“-1, -2, -3”

Numbers, written as such beside the
unique identifiers, refer to duplicate
miRNAs. These miRNAs have the
exact same mature miRNA sequence
but originate from different areas of
the genome

miR-1

miR-1*

miR-124-5p or miR-124-3p

miR-27a-3p or miR-27b-3p

miR-9-1-5p, miR-9-2-5p or miR-9-3-5p
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In mammals, the majority of miRNAs are encoded within introns of either protein-coding
or non-coding genes (Rodriguez et al., 2004). Several miRNA loci close in proximity are
generally co-transcribed, thus constituting a miRNA cluster. Most miRNAs are transcribed by
RNA polymerase II (Pol II); however RNA Pol III has been also shown to transcribe some viral
and human miRNAs (Borchert et al., 2006; Pfeffer et al., 2005). MiRNA transcription is
controlled by RNA Pol II-associated transcription factors such as MYC, ZEB1 and ZEB2 and
epigenetic regulators (Cai et al., 2004; Davis-Dusenbery and Hata, 2010; Lee et al., 2004).
Transcription products - primary miRNAs that are over 1 kb in length (pri-miRNAs) - contain a
stem-loop structure in which mature miRNA sequences are embedded. Similar to mRNAs, primiRNA transcripts contain a 7-methyl guanylate cap at the 5' end and a poly(A) tail at the 3' end
(Davis and Hata, 2009). The nuclear RNAse III-type endonuclease DROSHA, and its essential
cofactor DiGeorge syndrome chromosomal region 8 (DGCR8), form the microprocessor
complex to target and cleave pri-miRNAs at the stem-loop to release the ~65 nt length precursor
miRNA (pre-miRNA) (Denli et al., 2004; Gregory et al., 2004; Han et al., 2004; Lee et al.,
2003). The pre-miRNA is then exported to the cytoplasm by exportin-5 and Ras-related nuclear
protein guanosine-5'-triphosphate (Ran-GTP) (Bohnsack et al., 2004; Lund et al., 2004; Yi et al.,
2003). It has been reported that exportin-5 is necessary but not critical for miRNA maturation,
suggesting that other mechanisms complement its function (Kim et al., 2016).
Pre-miRNA is cleaved by another RNAse III-type endonuclease called DICER, releasing
the small miRNA duplex (Hutvagner et al., 2001; Ketting et al., 2001). DICER associates with
the cofactors human immunodeficiency virus transactivating response RNA-binding protein
(TRBP) and protein activator of the interferon-induced protein kinase (PACT), which do not
seem to be essential for DICER-mediated pre-miRNA processing (Chendrimada et al., 2005;
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Haase et al., 2005; Lee et al., 2013; Lee et al., 2006). However, it has been shown that TRBP is
an integral cofactor for DICER processing in RNA-crowded environments, acting as a
gatekeeper to preclude DICER from engaging with pre-miRNA-like substrates (Fareh et al.,
2016). After DICER processing, the miRNA duplex is loaded into AGO proteins (AGO 1-4 in
humans) to form the RNA-induced silencing complex (RISC). Subsequently, the miRNA is
unwound into two separate strands. The guide strand, which is determined during the AGO
loading step based on relative thermodynamic stability, is usually much more prevalent and more
biologically active than the passenger strand (miRNA*) (Ha and Kim, 2014; Kawamata and
Tomari, 2010). After AGO-mature miRNA binding, AGO seeks target mRNAs that are
complementary to the miRNA seed sequence. Of note, miRNA silencing likely occurs by
submicroscopic complexes in the cytoplasm that are constantly exchanging with cytoplasmic
RNA granules called processing bodies (p-bodies) (Leung and Sharp, 2013). Finally, an
interesting observation is that most mature miRNAs are also present in the nucleus, indicating
that mature miRNAs can shuttle between the nucleus and cytoplasm. Exportin-1 (XPO1) and
importin-8 (IPO8) have been shown to mediate the translocation to the nucleus of not only
miRNAs, but also AGO proteins (Castanotto et al., 2009; Weinmann et al., 2009). Within the
nucleus, miRNAs can function in gene activation or in an unconventional manner regulating the
biogenesis and functions of miRNAs and long non-coding RNAs (lncRNAs) (Liang et al., 2013)
(Fig. 1.2).
1.3.1.2 Non-canonical miRNA Biogenesis Pathway
Several alternative mechanisms of miRNA biogenesis have been described besides the
canonical pathway, although only about 1% of conserved miRNAs are produced independently
of DICER or DROSHA in vertebrates (Ha and Kim, 2014). The most common non-canonical
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pathway is used for mirtron production: miRNAs encoded in introns at the exon junction site.
Mirtron miRNAs bypass the DROSHA-DGCR8 complex. Pre-miRNAs are instead generated by
mRNA splicing, lariat debranching and trimming (Berezikov et al., 2007; Ruby et al., 2007).
DROSHA-mediated processing is also bypassed in the case of miRNAs derived from shRNAs,
tRNAs or tRNA-like precursors, small nucleolar RNAs (snoRNAs) or snoRNA-like viral RNAs
(Babiarz et al., 2008; Cazalla et al., 2011; Ender et al., 2008).
In some cases, such as miR-451, miRNAs can also be generated by DICER-independent
miRNA biogenesis. After DROSHA cleavage, pre-miR-451 is directly loaded and sliced by
AGO2 (Cifuentes et al., 2010). Then, a poly(A)-specific ribonuclease (PARN) trims down the 3ʹ
end of pre-miR-451 to produce the mature miR-451 (Yoda et al., 2013).
Another class of miRNAs undergo DROSHA and DICER dependent biogenesis, but an
additional processing step is included in between the two RNases. Precursors of these miRNAs
carry a shorter (one-nucleotide long instead of two) 3ʹ overhang. Terminal uridylyl transferases
(TUT2, TUT4 and TUT7) target these pre-miRNAs and extend their 3’end by 1 nucleotide
through monouridylation for efficient DICER processing (Heo et al., 2012) (Fig. 1.3). Of
interest, TUTs can also trigger pre-miRNA degradation through oligouridylation of 3' trimmed
pre-miRNAs and pre-let-7 (see section “Regulation of miRNA expression”) (Kim et al., 2015).
1.3.2 Regulation of miRNA Expression
MiRNA expression can be regulated at multiple levels. Transcription is the first control
point of the miRNA biogenesis. Of note, one-third of intronic miRNAs have transcription
initiation regions independent of their host promoters. RNA Pol II-transcribed miRNA promoters
are generally similar to mRNA promoters in terms of frequencies of CpG islands, TATA
elements, TFIIB recognition elements, initiator elements (Inr), motif ten elements (MTE) and
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Figure 1.2. MiRNA biogenesis of canonical miRNAs. The first part of miRNA processing
occurs in the nucleus. Pri-miRNA is transcribed by RNA polymerase II or III (RNA pol II/III)
and then cleaved by DROSHA/DGCR8 to form pre-miRNA. Pre-miRNA is exported to the
cytoplasm by exportin-5 and then cleaved by DICER. MiRNA duplex is loaded into argonaute
proteins (AGO 1–4) and subsequently unwound into two separated strands. For most miRNA
targets, AGO is recruited to a complex that contains GW182 proteins (RNA-induced silencing
complex, RISC) that induces translational repression and degradation of the mRNA targets.
TDP-43 and FET family, RNA-binding proteins linked to amyotrophic lateral sclerosis (ALS),
interact with DROSHA and/or DICER, regulating miRNA processing at both primary and
precursor levels.
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Figure 1.3. Non-canonical pathways of miRNA processing. For mirtron production, miRNAs
encoded in introns at the exon junction site, miRNAs bypass DROSHA/DGCR8 and premiRNAs are instead generated by mRNA splicing, lariat debranching and trimming. In other
cases, miRNAs can also be generated by DICER independent miRNA biogenesis. After
DROSHA cleavage miRNA is directly loaded and sliced by AGO2. PARN then trims down the
3’ end of the pre-miRNA to produce the mature miRNA. A third class of miRNAs undergo
DROSHA and DICER dependent biogenesis, but an additional processing step is included in
between the two RNAases. Precursors of these miRNAs carry a shorter 3’ overhang. Terminal
uridylyl transferases (TUT2, TUT4 and TUT7) target these pre-miRNAs and extend their 3’ end
by 1 nucleotide through monouridylation for efficient DICER processing.
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downstream promoter elements (DPE). Also, some transcription factors that control mRNA
production regulate the transcription of miRNAs encoded in introns of protein coding genes
(Davis and Hata, 2009; Ozsolak et al., 2008).
Changes in the methylation of miRNA promoters or miRNA sequences can impact on the
expression of miRNAs. The methylation status of some miRNA genes has been associated with
cancer. For instance, hypermethylation of the CpG island upstream of the tumor suppressor miR33b, is responsible for its downregulation in gastric cancer (Yin et al., 2016). Also, methylation
of promoters of the miR-200b cluster is associated with metastasis in advanced breast cancer
(Wee et al., 2012). Interestingly, methylation of the 5’ monophosphate of pre-miR-23b and premiR-145 inhibits the processing of these miRNAs by DICER (Xhemalce et al., 2012). This is
because the interaction between DICER and the 5’ monophosphate is necessary for the efficient
processing of pre-miRNAs (Park et al., 2011). MiRNA promoters are also regulated by histone
modifications. Some miRNAs have been reported to be up- or down-regulated after the treatment
with histone deacetylase (HDAC) inhibitors (Nasser et al., 2008; Saito and Jones, 2006; Scott et
al., 2006). For instance, acetylation regulates the expression of miR-133a during chronic pressure
overload-induced cardiac fibrosis (Renaud et al., 2015). Single nucleotide polymorphisms
(SNPs) in miRNA genes can also affect miRNA biogenesis (Duan et al., 2007). For example,
SNPs in miR-1206 and miR-612 genes within two cancer risk loci affect the expression of both
mature miRNAs (Kim et al., 2012).
RNA editing (adenosine to inosine catalyzed by adenosine deaminase that acts on RNA;
(ADARs)) also impacts on miRNA processing. Let-7 pri-miRNA editing impairs the biogenesis
of this miRNA and drives leukemia stem cell self-renewal (Zipeto et al., 2016). Another type of
regulation of miRNA biogenesis is by RNA-tailing (nucleotidyl addition to the 3ʹ end of RNA).
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For example, LIN28 proteins recruit terminal uridylyl transferases TUT4 and TUT7 C6 to induce
oligouridylation of pre-let-7 (Hagan et al., 2009; Heo et al., 2008; Heo et al., 2009). This oligo-U
tail blocks DICER processing, and facilitates miRNA decay by 3’-5’ exonuclease DIS3L2
(Chang et al., 2013; Ustianenko et al., 2013). Some miRNA transcripts, like most mRNAs, are
methylated at N6-adenosine (m6A). This modification acts as a mark for pri-miRNA processing.
RNA-binding protein hnRNPA2B1 binds to m6A, interacts with DGCR8, and promotes primiRNA cleavage to produce pre-miRNA (Alarcon et al., 2015). Finally, levels of certain
miRNAs are controlled by regulating miRNA stability. For instance, levels of miR-122 are
stabilized by monoadenylation via the non-canonical cytoplasmic poly(A) polymerase GLD-2
(TUT2) in mammals (D'Ambrogio et al., 2012; Katoh et al., 2009). Moreover, a highly
complementary mRNA target can induce miRNA degradation through 3’ addition of a single
non-templated uridine followed by 3’ to 5’ trimming of the miRNA with a 2′-O-methyl group
added by Hen1 enzyme in Drosophila (Ameres et al., 2010; Baccarini et al., 2011).
Recently, another layer of complexity has been added into miRNA regulation. Levels of
mature forms of miR-122 are post-transcriptionally regulated by modulating its processing in
a target-dependent manner during recovery from starvation-related stress (Bose and
Bhattacharyya, 2016).
1.3.3 Mechanisms of miRNA Function
MiRNAs are able to regulate gene expression by several mechanisms (Fig. 1.4). In RNA
silencing, miRNAs function as a guide to recognize target mRNAs, whereas AGO proteins
function as effectors by recruiting factors that induce translational repression and/or mRNA
decay (Ha and Kim, 2014). The 5’ region of the miRNA (seed, nucleotides 2 to 7) is crucial for
target recognition through the complementary base pairing of miRNA recognition elements
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Figure 1.4. Mechanisms of action of miRNAs. (A) MiRNAs promote mRNA degradation by
recruiting deadenylases on the target mRNA via GW182 and also through the dissociation of
PABP, increasing the accessibility of the poly(A) tail to deadenylases. (B) MiRNAs inhibit
translation at the initiation step, however the exact mechanism is still unclear. Three mechanisms
have been proposed; (i) PABP displacement mediated by GW182; (ii) recruitment of the
translational repressors through GW182; and (iii) dissociation of eukaryotic initiation factor-4A
(eIF4A) from the cap-binding complex eIF4F. (C) MiRNAs also induce upregulation of their
targets. MiRNAs have been implicated in gene activation triggered by promoter-targeted small
RNAs, known as RNA activation (RNAa). (D) Upregulation of certain transcripts can also be
mediated by miRNA binding to mRNA 3’untranslated regions (3’UTRs), resulting in either
translation activation or RNA stability enhancement. MiR-346-dependent upregulation of
telomerase reverse transcriptase (TERT) occurs through the binding to TERT mRNA 3’UTR and
is mediated by G-rich RNA sequence binding factor 1 (GRSF1). MiR-346 facilitates the
recruitment of TERT mRNA to ribosomes to promote translation. In another example, miR-4661
uses the binding sites of the tristetraprolin (TTP) in the IL-10 3’UTR preventing TTP-mediated
IL-10 mRNA degradation in macrophages.
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(MREs) that are mostly localized in the mRNA 3’untranslated region (UTR). Currently, MREs
in 3’UTRs are determined using prediction algorithms and then validated with functional
analysis. However, seedless 3’UTR MREs have been described, as well as MREs localized
within 5’UTRs and coding regions (Forman et al., 2008; Lal et al., 2009; Moretti et al., 2010). To
provide an alternative view of human miRNA targets, a protocol termed cross-linking, ligation
and sequencing of hybrids (CLASH) was developed for high-throughput identification of
miRNA-target RNA duplexes associated with AGO and is independent of bioinformatic
predictors. Transcriptome-wide data set revealed that binding of most miRNAs to their targets
includes the seed region, but around 60% of seed interactions are noncanonical. Of interest, seed
interactions are generally accompanied by non-seed base pairing (Helwak et al., 2013).
MiRNAs downregulate target mRNAs through translational repression and mRNA
destabilization, with mRNA destabilization dominating most miRNA-mediated repression
(Eichhorn et al., 2014; Guo et al., 2010; Hendrickson et al., 2009). Although miRNAs inhibit
translation at the initiation step, the exact mechanism is still unclear. Three mechanisms have
been proposed i) PABP displacement mediated by GW182 (Moretti et al., 2012; Zekri et al.,
2013), ii) recruitment of the translational repressors through GW182 (Kamenska et al., 2014;
Meijer et al., 2013; Waghray et al., 2015) and iii) dissociation of eukaryotic initiation factor-4A
(eIF4A) from the cap-binding complex eIF4F (Fukao et al., 2014; Fukaya et al., 2014).
At the same time, mRNA destabilization is a consequence of miRNA-mediated deadenylation of
target mRNAs which causes these mRNAs to undergo decapping and 5’ –3’decay (BehmAnsmant et al., 2006; Rehwinkel et al., 2005; Wu et al., 2006). MiRNAs promote mRNA decay
by recruiting the deadenylase complex CCR4–NOT or PAN2–PAN3 on the target mRNA via
GW182 (Braun et al., 2011; Fabian et al., 2011). Also, miRNAs promote mRNA decay through
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the dissociation of PABP, increasing the accessibility of the poly(A) tail to deadenylases (Moretti
et al., 2012).
Beside well-known downregulatory functions, there is increasing evidence that miRNAs
can also induce upregulation of their targets (Campos-Melo et al., 2014; Valinezhad Orang et al.,
2014; Vasudevan et al., 2007). MiRNAs, similar to double stranded RNAs (dsRNAs), have been
implicated in gene activation triggered by promoter-targeted small RNAs, known as RNA
activation (RNAa). For instance, the expression of cyclin B1 (Ccnb1) depends on RNAa by
miRNAs and components of miRNA biogenesis in mouse cells. Chromatin immunoprecipitation
(ChIP) analysis had shown that AGO1 is selectively associated to the Ccnb1 promoter and miR744, which induces Ccnb1 expression, increases enrichment of RNA Pol II and trimethylation of
histone 3 at lysine 4 (H3K4me3) at the Ccnb1 transcription start site. At a functional level, shortterm expression of miR-744 enhances cell proliferation, but prolonged overexpression causes
tumor suppression (Huang et al., 2012).
Finally, the upregulation of certain mRNA transcripts can also be mediated by miRNA
binding to mRNA 3’UTRs, resulting in either translation activation or RNA stability
enhancement. For example, miR-346-dependent upregulation of telomerase reverse transcriptase
(TERT) occurs through the binding of miR-346 to TERT mRNA 3’UTR. When miR-346 is
bound to the TERT mRNA 3′UTR, its middle sequence motif forms a “bulge loop”, facilitating
the G-rich RNA sequence binding factor 1 (GRSF1)-mediated recruitment of TERT mRNA to
polysomes to promote translation (Song et al., 2015). A similar mechanism of GRSF1 interaction
with AGO2 in a miR-346-dependant manner, leading to upregulate the expression of AGO2, has
been described for cervical cancer (Guo et al., 2015). It has also been reported that miR-4661
uses the binding sites of the RNA-binding protein tristetraprolin (TTP) in the IL-10 3’UTR AU-
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rich elements, thus preventing TTP-mediated IL-10 mRNA degradation in macrophages (Ma et
al., 2010).
1.4 MiRNAs in Motor Neuron Function
Transgenic mouse models containing loss of DICER function set the foundation for the
importance of miRNA regulation within motor neurons. These experiments showed that in early
development, loss of DICER function within motor neuron progenitor cells leads to aberrant
motor neuron development in the lateral motor column, while in adult mice, loss of DICER
expression in motor neurons resulted in progressive motor neurodegeneration (Chen and
Wichterle, 2012; Haramati et al., 2010). With these two studies, it became apparent that the
production of miRNAs is a critical factor to overall motor neuron function and survival. There is
very little known about the miRNome (the full spectrum of miRNAs being expressed) of motor
neurons. However, as we further discover miRNAs related to motor neuron development and
degeneration, it becomes increasingly evident that there are specific miRNAs needed to regulate
cytoskeleton integrity, neuronal development, signalling and function, synaptic plasticity, and
overall survival of motor neurons which we have termed “MotomiR’s” (Table 1.3).
1.4.1 MiRNAs in Motor Neuron Diseases
Given the several roles of miRNAs in regulating motor neuron differentiation, structure,
activity and cytoskeletal integrity, it is not surprising that alterations in the expression of
miRNAs have been increasingly linked to human motor neuron degenerative disorders. These
alterations can be in the miRNAs and/or MREs such as changes in the expression, editing and
methylation, mutations and SNPs, and also alterations in competing endogenous RNAs
(ceRNAs) involved in the regulation of the interaction of miRNAs and their targets.
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Table 1.3. List of current MotomiRs and their function*
MotomiR

Genes shown
to regulate

Role within motor
neurons

Organism/Cell
models used to
describe function

References

miR-9

OC1, FoxP1,
NEFH,
MAP1B,
MCPIP1

Development,
cytoskeleton
maintenance, cell
survival

Chick, mouse
neuronal
precursor cells,
mouse

(Dajas-Bailador et al., 2012;
Haramati et al., 2010;
Luxenhofer et al., 2014;
Otaegi et al., 2011; Xu et al.,
2016)

miR-124

REST, Stat3,
Kfl6

Development,
regeneration

Mouse

(Nagata et al., 2014;
Visvanathan et al., 2007)

miR-146*,
miR-524, miR582, miRb1336, &
miR-b2403

NEFL

Cytoskeleton
maintenance

In vitro
interactions done
in HEK293T cells

miR-218

TEAD1,
FOXP2, LHX1,
SLC6A1,
BCL11A,
SLC1A1

Development,
membrane
excitability, NMJ
synaptic connections

Mouse

(Amin et al., 2015; Thiebes
et al., 2015)

miR-8

FasIII, Nrg,
wg, lar

Synaptic plasticity

Drosophila

(Lu et al., 2014; Nesler et
al., 2013)

miR-958 &
miR-289

Lar

Synaptic plasticity

Drosophila

(Nesler et al., 2013)

miR-375

PAX6, CCND2,
p53

Development, cell
survival

Human neural
progenitor cell
cultures

(Bhinge et al., 2016)

miR-310-313

Khc-43

Synaptic vesicle
release

Drosophila

(Tsurudome et al., 2010)

miR-128 &
miR-20a

PDZ-RhoGEF

Axonal growth,
regeneration

Rat cortical
neuron cultures

(Sun et al., 2013)

miR-153

SNAP-25

Axonal growth,
synaptic vesicle
release

Zebrafish

(Wei et al., 2013)

miR-196

Hoxb8

Development

Drosophila

(Asli and Kessel, 2010)

miR-183

mTOR

Neurite growth

Rat primary
spinal motor
neuron cultures

(Kye et al., 2014)

miR-206

BDNF, HDAC4

NMJ Regeneratoin

Mouse

(Miura et al., 2012;
Williams et al., 2009)

(Campos-Melo et al., 2013;
Ishtiaq et al., 2014)
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miR-34

Nrx-IV, Hts

NMJ synaptic
connections

Drosophila

(McNeill et al., 2020)

miR-126

Sema3, NRP

NMJ synaptic
connections

In vitro motor
neuronal models

(Maimon et al., 2018)

miR-137

Calpain-2

Regeneration,
survival

In vivo rat motor
neurons

(Tang et al., 2018)

*Table adapted from Hawley et al., 2017a
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1.4.1.1 MiRNA Dysregulation in Spinal Muscular Atrophy (SMA)
SMA is an autosomal recessive disease characterized by progressive loss of lower motor
neurons and atrophy of muscle (Burghes and Beattie, 2009). Proximal SMA has an incidence of
∼1:10,000 newborns and is the most frequent SMA type (Wirth et al., 2006). SMA is caused by
homozygous deletion or mutation of survival motor neuron 1 (SMN1) (Lefebvre et al., 1995).
SMN has been found to play roles in RNA metabolism, specifically in snRNP (small nuclear
ribonucleoproteins) biogenesis, alternative splicing, trafﬁcking of RNA-binding proteins and
translation of target mRNAs in neurites. SMN also binds to fragile X mental retardation protein
(FMRP), KH-type splicing regulatory protein (KSRP) and FUS, which are important for miRNA
biogenesis and function (Akten et al., 2011; Fallini et al., 2014; Fallini et al., 2011; Gubitz et al.,
2004; Hubers et al., 2011; Piazzon et al., 2008; Tadesse et al., 2008; Trabucchi et al., 2009;
Yamazaki et al., 2012). In fact, several lines of evidence have involved miRNAs in SMA. It was
reported that mice lacking the miRNA-processing enzyme DICER selectively in motor neurons
display hallmarks of SMA (Haramati et al., 2010). Also, SMN protein has been shown to alter
miRNA expression and distribution in neurons (Kye et al., 2014; Wang et al., 2014).
Specifically, miR-183 is increased in neurites of SMN-deficient neurons. Inhibition of
miR-183 expression in the spinal cord of an SMA mouse model prolongs survival and improves
motor function of Smn-mutant mice (Kye et al., 2014). SMN protein also downregulates the
expression of miR-9a. Interestingly, miR-9a levels have shown a positive correlation with SMA
severity (Wang et al., 2014). A more recent study has shown that miR-431, involved in motor
neuron neurite length, also plays a role in the SMA motor neuron phenotype. By integrating
miRNA:mRNA profiles, it was observed that miR-431 expression is highly increased in spinal
motor neurons, and a number of its putative mRNA targets are signiﬁcantly downregulated in
motor neurons after SMN loss (Wertz et al., 2016). Another miRNA involved in SMA motor
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neuron phenotype is miR-375. Besides its role in neurogenesis, miR-375 protects neurons from
apoptosis in response to DNA damage. Motor neurons derived from a SMA patient have shown
reduced levels of miR-375, elevated p53 protein levels, and higher susceptibility to DNA
damage induced apoptosis (Bhinge et al., 2016).
Recently, the ﬁrst vertebrate system allowing transgenic spatio-temporal control of the
smn1 gene was developed using stable miR-mediated knockdown technology in zebraﬁsh. The
expression of anti-smn1 miRNAs in motor neurons reproduced most hallmarks observed
previously in the ubiquitous knockdown model. In addition, smn1 knockdown in zebraﬁsh motor
neurons is sufﬁcient to induce late-onset motor neuron degeneration (Laird et al., 2016). Finally,
the potential use of miR-9, miR-206 and miR-132 as biomarkers in SMA has been proposed. It
was shown that there is differential expression of all three miRNAs in spinal cord, skeletal
muscle and serum samples in SMA mouse models, while only miR-9 and miR-132 were
differentially expressed in serum samples of SMA patients (Catapano et al., 2016).

1.4.1.2 MiRNA Dysregulation in ALS
Numerous studies in ALS models and patient samples have demonstrated a mass
disruption of miRNA expression in ALS (Butovsky et al., 2012; Dobrowolny et al., 2015; Koval
et al., 2013; Marcuzzo et al., 2014; Parisi et al., 2013; Toivonen et al., 2014; Williams et al.,
2009; Zhou et al., 2013a). The most consistent observation from the mtSOD1 mice is the
upregulation of miR-9 and miR-206 (Dobrowolny et al., 2015; Toivonen et al., 2014; Williams et
al., 2009; Zhou et al., 2013a). Specifically, miR-9 expression is upregulated in mtSOD1 mouse
spinal cord (Dobrowolny et al., 2015; Shi et al., 2004; Tan et al., 2012; Zhao et al., 2009; Zhou et
al., 2013a), while miR-206 expression is upregulated in muscle in both mtSOD1 and SMA
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mouse models (Valsecchi et al., 2015). Of note, mtSOD1 disease progression is accelerated with
downregulation of miR-206 expression (Williams et al., 2009).
The first miRNA profile of human spinal cord tissue was obtained in 2013 and observed
a massive downregulation of miRNAs in ALS (Campos-Melo et al., 2013). This disruption was
subsequently shown to be specific to motor neurons (Emde et al., 2015). The reduction of
miRNA levels has been previously indicated to be a consequence of the inhibition of DICER
pre-miRNA processing activity (Emde et al., 2015). Of note, the downregulation of miRNAs has
also been observed in other ALS-derived tissues such as in motor cortex, fibroblasts, serum
/plasma, and CSF (Benigni et al., 2016; Freischmidt et al., 2015a; Raman et al., 2015; Takahashi
et al., 2015; Wakabayashi et al., 2014). A consistent upregulation of miR-206 in muscle (de
Andrade et al., 2016; Russell et al., 2013) and in serum samples of ALS patients has also been
reported (de Andrade et al., 2016; Toivonen et al., 2014). The latter appears to correlate with the
rate of clinical deterioration (de Andrade et al., 2016). Although studies in larger cohorts are
necessary, these results suggest that miR-206 could be a potential biomarker for ALS.
While miRNAs have clearly been shown to be reduced within the spinal cord and motor
neurons of ALS patients (Campos-Melo et al., 2013; Emde et al., 2015), the exact cause of this
mechanism is still unclear. However, a major contributor to reduced miRNA levels in ALS
motor neurons is that several ALS-associated RNA-binding proteins have been shown to be
involved in miRNA biogenesis as discussed earlier, including: TDP-43, FUS, TAF15, EWSR1,
hnRNPA1 and hnRNPA2B1 (Alarcon et al., 2015; Ballarino et al., 2013; Kawahara and MiedaSato, 2012; Kim et al., 2014; Kooshapur et al., 2018; Morlando et al., 2012). The common
pathological feature among all these proteins in ALS is that they have been found to re-locate
from the nucleus to the cytoplasm in motor neurons, and subsequently form cytoplasmic
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aggregates. This indicates a loss of nuclear function of RNA-binding proteins in ALS may
contribute to the changes in miRNA processing. Interestingly, cellular stress has been shown to
transiently induce the re-localization of many ALS-related nuclear RNA-binding proteins to the
cytoplasm providing a potential mechanism that could induce the pathology of these proteins in
ALS and disrupt miRNA biogenesis.
1.5 Stress Granules
The compendium of genes that have been associated with ALS have shown a high
enrichment for RNA-binding proteins, indicating that changes to RNA processing in motor
neurons is a major factor to the disease progression (Andersen and Al-Chalabi, 2011; Chen et al.,
2013; Therrien et al., 2016). Further, many of the ALS-associated RNA-binding proteins are
responsible for the formation, assembly, and disassembly of stress granules—transient
ribonucleoprotein (RNP) granules that form during periods of cellular stress and contain
translationally silent mRNA (Anderson and Kedersha, 2008; Aulas and Vande Velde, 2015;
Buchan, 2014). ALS-linked RNA-binding proteins associated with stress granules include: TDP43, FUS, ATXN2, hnRNPA1, hnRNPA2B1, TAF15, EWSR1, RBM45, C9ORF72 and TIA1
(Andersson et al., 2008; Colombrita et al., 2009; Kim et al., 2013; Li et al., 2015; Mackenzie et
al., 2017; Maharjan et al., 2017; Nonhoff et al., 2007). This list contains many of the ALSrelated RNA-binding proteins that are involved in miRNA biogenesis mentioned in the previous
section. Based on this information, it is widely believed that stress granules may be the seed to
pathological aggregate formation of RNA-binding proteins ultimately leading to changes in
miRNA processing in ALS.

1.5.1 Stress Granule Assembly and Disassembly
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When cells face adverse conditions within their environment (e.g. oxidative, osmotic, or
proteasomal stress), cells start to produce structures called stress granules (Gilks et al., 2004;
Kedersha et al., 2000; Kedersha et al., 1999). The purpose of these granules is to act as a triage
for mRNA, where mRNA can be either stored within the stress granule, transferred to processing
bodies (p-bodies) for degradation, or go back into polysomes to be translated (Anderson and
Kedersha, 2008; Aulas and Vande Velde, 2015).
Phosphorylation of eIF2α appears to be an early trigger that initiates stress granule
assembly; however, there are cases of stress granule assembly that are independent of eIF2α
phosphorylation (Kedersha et al., 2002; Kim et al., 2007; McEwen et al., 2005; Shenton et al.,
2006). The phosphorylation of eIF2α results in reduced formation and activity of translational
machinery (Shenton et al., 2006). This is followed by an accumulation of RNA-binding proteins
and RNA molecules into granules that lack a membrane structure (Anderson and Kedersha,
2008; Baradaran-Heravi et al., 2020; Gilks et al., 2004). TIA-1 and G3BP1 are two RNA-binding
proteins that early on were thought to be critical for proper stress granule formation. However, as
we learn more about stress and stress granules, we are starting to understand how truly dynamic
and diverse these structures are. Thus, while some proteins are critical for the formation of stress
granules for certain stresses, they might not be critical for others (Aulas et al., 2015; Gilks et al.,
2004; Kedersha et al., 2016; Markmiller et al., 2018). For example, G3BP1 is critical for the
formation of stress granules during oxidative stress, but it is not needed for stress granule
assembly during periods of osmotic stress (Kedersha et al., 2016; Solomon et al., 2007). Further,
proteomics of stress granules has shown different stresses and different cell types result in
different protein profiles (Markmiller et al., 2018). This suggests that stress granule formation
and proteomic profile are highly dynamic and context dependent.
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After cellular stress disappears, stress granules start disassembling as the cell goes back
to its homeostatic state allowing translation of previously silent mRNA to begin again (Molliex
et al., 2015). Several mechanisms have been implicated in stress granule disassembly, including:
reduced stress results in the formation and increased activity of translational machinery
destabilizing the granule structure; inhibition of RNA helicases that promote assembly and
maintenance of stress granules; heat shock proteins disassemble RNP complexes; and,
ubiquitination of proteins via VCP allowing for stress granules to be targeted by autophagy
pathways (Buchan et al., 2013; Cherkasov et al., 2013; Jain et al., 2016; Kroschwald et al., 2015;
Meyer and Weihl, 2014; Protter and Parker, 2016; Wheeler et al., 2016). All these pathways
likely work together to allow for efficient disassembly of stress granules. It is also clear that
stress granule disassembly is an active process that requires ATP hydrolysis (Jain et al., 2016;
Meyer and Weihl, 2014; Protter and Parker, 2016).
In all of this, LCD-containing proteins appear to be critical for the formation of stress
granules by allowing them to phase separate and form liquid droplets, which produces dynamic
interactions with p-bodies, other stress granules and the cytosol of the cell (Aulas et al., 2015;
Gilks et al., 2004; Kato et al., 2012; Mackenzie et al., 2017; Molliex et al., 2015; Murray et al.,
2017; Patel et al., 2015). Structurally, this is because the LCD participates in β-pleated sheet
formation and forms amyloid-like interactions similar to what is seen in prion disease (Molliex et
al., 2015; Murakami et al., 2015; Patel et al., 2015). These interactions are critical for the
formation of RNA granules which lack a membrane to contain its components (BaradaranHeravi et al., 2020; Taylor et al., 2016). Therefore, phase transition into reversible liquid droplets
is a critical mechanism for the formation of stress granules. While the LCD’s are necessary for
quick assembly of stress granules, it can also be a detriment to the cells if proteins are left to
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accumulate, risking the formation of hydrogels (Kato et al., 2012; Li et al., 2013; Molliex et al.,
2015).

1.5.2 Hydrogels
LCD-containing proteins in both cell-free and cell in vitro models have been shown to
form hydrogels (Kato et al., 2012; Molliex et al., 2015; Murakami et al., 2015; Murray et al.,
2017). Hydrogels are defined by the aggregation of proteins leading to phase transition into
liquid droplets and eventually irreversible gelatin structures (Murakami et al., 2015). The
formation of these hydrogel structures is primarily driven by the LCD. (Kato et al., 2012;
Molliex et al., 2015; Murakami et al., 2015; Murray et al., 2017).
As discussed, several ALS-related proteins are LCD-containing proteins, including: TDP43, FUS, hnRNPA1, hnRNPA2B1, TAF15, EWSR1, RBM45 and TIA-1 (Baradaran-Heravi et
al., 2020). ALS-linked mutations within the LCD of TDP-43, FUS and hnRNPA1 have been
shown to increase the rate at which these proteins phase separate and form hydrogel-like
structures (Conicella et al., 2016; Kim et al., 2013; Molliex et al., 2015; Murakami et al., 2015).
Since LCD-containing ALS-related proteins tend to form insoluble aggregates, several
researchers have focused on therapeutics that prevent the accumulation of these proteins.
However, little research has been done on the dysregulation of miRNAs in ALS, and potential
changes to their regulation on the expression of ALS-related genes that could be a major
contributor to the accumulation of these proteins.

1.6 Putting it all together: ALS, cell stress and miRNA dysfunction
Based on the number of ALS-linked genes associated with stress granules, improper
stress granule formation has been suggested to be a key precursor to the pathogenesis of ALS
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(Aulas and Vande Velde, 2015; Li et al., 2013; Taylor et al., 2016). Intriguingly, out of the 190
RNA-binding proteins identified by Treiber and colleagues to be involved in miRNA processing,
33.2% were associated with stress granules (Treiber et al., 2017). This high enrichment of stress
granule associated RNA-binding proteins found with pre-miRNA molecules provides some
insight into how miRNAs are able to dynamically change their expression under different
physiological conditions (Wilczynska and Bushell, 2015). Interestingly, cellular stressors like
endoplasmic reticulum (ER) or oxidative stress have been known to impair miRNA biogenesis
reducing overall miRNA expression (Emde et al., 2015). Many RNA-binding proteins during
cellular stress are re-localized to stress granules, including TDP-43, FUS, TAF15, EWSR1,
hnRNPA1, hnRNPA2B1 and ATXN2, which could explain the reduction in miRNA processing
during cellular stress, as many of these proteins are involved with miRNA biogenesis (Alarcon et
al., 2015; Andersson et al., 2008; Ballarino et al., 2013; Colombrita et al., 2009; Guil and
Caceres, 2007; Kawahara and Mieda-Sato, 2012; Kim et al., 2013; Kim et al., 2014; Li et al.,
2015; Morlando et al., 2012; Nonhoff et al., 2007). Therefore, reduced miRNA levels, and by
inference reduced activity, during periods of stress could result in accumulation of LCDcontaining proteins due to reduced miRNA-mediated silencing, indicating a potential negative
feedback loop between miRNAs and RNA-binding proteins that is lost in ALS. Further, during
periods of chronic or repeated stress, excessive protein accumulation due to low miRNA levels
could result in the formation of insoluble aggregates.
Further, prolonged stress that alters the levels of miRNAs that target intermediate
filaments would likely alter the stoichiometry of intermediate filament expression in a fashion
that would promote their aggregation. Overall, changes to altered miRNA levels, as seen in ALS,
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likely alters the regulation of RNA-binding protein and intermediate filament expression, thus
contributing to the resulting pathology of these two protein groups in ALS.

1.7 Hypothesis and Aims
Taken together, the downregulation of miRNAs in ALS could be due to altered function
and localization of RNA-binding proteins that would normally promote miRNA production,
which in turn, leads to loss of miRNA regulation of ALS-associated RNA-binding proteins and
intermediate filaments contributing to their pathogenesis.
Hypothesis: A negative feedback loop between specific RNA-binding proteins and miRNAs is
disrupted in ALS leading to changes in miRNA processing that contributes to RNA-binding
protein and intermediate filament pathology.
Aim 1: Determine if ALS-linked miRNAs contribute to the selective suppression of NEFL,
PRPH, and INA intermediate filaments as seen in ALS motor neurons – Chapter 2.
Aim 2: Determine if ALS-linked miRNAs regulate the expression of NEFM and NEFH, which
may contribute to the loss of stoichiometry seen between intermediate filaments in ALS –
Chapter 3.
Aim 3: Determine if ALS-linked miRNAs regulate the expression of RNA-binding proteins
(TARDBP, FUS, and RGNEF) associated with ALS – Chapter 4.
Aim 4: Determine if TDP-43 and FUS are in a negative feedback network with ALS-linked
miRNAs that is dependent on their nuclear localization – Chapter 5.
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Chapter 2
MiR-105 and miR-9 regulate the mRNA stability of neuronal intermediate filaments.
Implications for the pathogenesis of amyotrophic lateral sclerosis (ALS).
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2.1 Abstract
Intermediate filament aggregation within motor neurons is a hallmark of ALS
pathogenesis. Changes to intermediate filament stoichiometry due to altered mRNA steady-state
levels of NEFL, PRPH and INA is thought to drive protein aggregation, yet the exact cause of
these changes is unknown. MicroRNAs (miRNAs)—master regulators of gene expression—are
largely dysregulated within ALS motor neurons and are known to be major contributors to the
disease. We show that miR-105 and miR-9 are downregulated within the spinal cord of ALS
patients and target NEFL, PRPH and INA 3’UTRs to regulate gene expression. Further, both
miR-105 and miR-9 were observed to regulate the mRNA stability of these three intermediate
filaments endogenously within a neuronal-derived cell line. Our data demonstrates that miR-105
and miR-9 can regulate the mRNA stability of these key intermediate filaments whose
metabolism is dysregulated in ALS, and thus, these miRNAs likely contribute to their
pathogenesis.
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2.2 Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal disease which is characterized by
progressive degeneration of motor neurons (Strong, 2017). One major neuropathological
hallmark of the disease is the formation of neuronal cytoplasmic inclusions (NCIs) containing
intermediate filaments, which include neurofilament light, medium and heavy (NFL, NFM, and
NFH, respectively), and peripherin (PRPH) (He and Hays, 2004; Hirano et al., 1984; Keller et
al., 2012; Kondo et al., 1986; Xiao et al., 2006)
In general, intermediate filaments are essential proteins that make up the cytoskeleton
and are needed for proper cellular structure and signaling within neurons. Neurofilament
assembly requires NFL to form homopolymers, and as well as heteropolymers with NFM and
NFH, to form a triplet protein structure (Carpenter and Ip, 1996; Szaro and Strong, 2010).
Further, PRPH and α-internexin (INA) intermediate filaments are responsible for the formation
of the early cytoskeleton within developing neurons, but both also interact with the
neurofilament triplet protein structure within mature neurons (Yuan et al., 2006; Yuan et al.,
2012). Together these intermediate filaments maintain a specific stoichiometry that ensures
appropriate cell structure, axonal transport, and overall neuronal health (Lariviere and Julien,
2004; Szaro and Strong, 2010).
Alterations to intermediate filament stoichiometry within motor neurons of mammalian
ALS-models induces the formation of NCIs similar to those observed in ALS spinal motor
neurons (Beaulieu et al., 1999; Kriz et al., 2000; Lee et al., 1994; Zhu et al., 1997). Further, in
motor neurons of sporadic ALS (sALS) patients with no known genetic background, NEFL,
PRPH and INA mRNA steady-state levels are selectively reduced with no effect on NEFM or
NEFH (Wong et al., 2000), suggesting that the loss of intermediate filament stoichiometry results
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from the loss of proper regulation of intermediate filament mRNA metabolism (Strong, 2010;
Strong et al., 2004; Szaro and Strong, 2010; Thyagarajan et al., 2007).
While alterations in mRNA metabolism seem to be critical to the pathogenesis of ALS
(Strong, 2010), it is still unclear the etiology of neuronal intermediate filament mRNA
dysregulation. However, microRNAs (miRNAs)—critical regulators of gene expression
generally through interactions with the 3’ untranslated region (UTR)—have been shown to be
largely dysregulated within the spinal cord and motor neurons of sALS patients (Campos-Melo
et al., 2013; Emde et al., 2015; Figueroa-Romero et al., 2016). Several of these ALS-linked
miRNAs have been shown to regulate ALS-associated RNA-binding proteins (Dini Modigliani
et al., 2014; Hawley et al., 2017b), suggesting that the loss of proper miRNA regulation is a
contributing factor to the disease. Further, several miRNAs have been shown to regulate the
mRNA levels of NEFL (Campos-Melo et al., 2013; Ishtiaq et al., 2014), which may explain the
selective reduction of NEFL mRNA steady-state levels in sALS. However, the cause of PRPH
and INA mRNA reduction, and whether the selective reduction of NEFL, PRPH and INA mRNA
in sALS is caused by a common mechanism is still unknown.
In this study, we aim to identify a specific pool of ALS-linked miRNAs that may explain
the selective reduction of NEFL, PRPH and INA mRNA steady-state levels. Our data revealed
that within the pool of miRNAs that is dysregulated in sALS, miR-105 and miR-9 are critical
regulators of neuronal intermediate filaments; however, only miR-105 directly interacts with the
NEFL, PRPH and INA 3’UTRs to regulate mRNA levels, suggesting that its dysregulation is a
key part to the etiology of altered intermediate filament mRNA expression in sALS.
2.3 Methods and Materials
2.3.1 Tissue Samples
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ALS patient and neuropathologically healthy, age-matched control spinal cord tissue was
collected and stored at -80oC, or formalin-fixed and paraffin-embedded (Table 2.1). All ALS
cases used in this study were clinically and neuropathologically confirmed using the El Escorial
Criteria (World Federation of Neurology Research Group on Neuromuscular Disease, 1994). The
research was approved by “The University of Western Ontario Research Ethics Board for Health
Sciences Research Involving Human Subjects (HSREB)”. Written consent for autopsy was either
received from the patient antemortem, or the next of kin in accordance with the London Health
Sciences Center consent for autopsy. All ALS patients were genetically screened and confirmed
to have no mutations in SOD1, TARDBP, FUS, or expanded repeats in C9ORF72.
2.3.2 MiRNA Selection
Candidate miRNAs were selected if they had predicted miRNA recognition elements
(MREs) within the 3’UTRs identified in human spinal cord using miRanda software, and if they
meant the criteria that we have previously reported (Hawley et al., 2017b).
2.3.3 Real-time PCR
In order to determine miRNA changes in the spinal cord, total miRNA extraction was
done on ventral lumbar human spinal cord using the mirVana miRNA extraction kit (Life
Technologies Inc., Ambion, Carlsbad, CA, USA) in accordance with the manufactures protocol.
Reverse transcription and real-time PCR was performed on miRNA extracts using miRCURY
LNATM Universal RT microRNA PCR (Exiqon, Woburn, MA, USA) and ExiLENT SYBR
Green master mix (Exiqon, Woburn, MA, USA) kits, respectively, in accordance with the
manufacturer’s instructions. Candidate miRNA expression was normalized and examined
between ALS patients and control subjects as previously described (Hawley et al., 2017b).
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Table 2.1. Patient demographics.
Cases

Gender

Control

ALS

Symptom
onset

Age of
death

Cause of Death

F
M
F
M
M
F
F
M

Age of
symptom
onset
-

-

62
74
68
68
75
53
74
67

Heart Attack
Stroke
Unknown
Brain Tumor
Unknown
Pneumonia
Leukemia
Unknown

F

58

60

Unknown

M

69

Unknown
Upper/lower
limbs

72

Unknown

F

40

Bulbar

41

Systemic Failure

M

55

Unknown

61

Pneumonia

M

64

F

69

M

63

Unknown

64

Unknown

F

47

Bulbar

49

Respiratory
Failure

Upper/lower
limbs
Respiratory
Symptoms

67
71

Respiratory
Failure
Respiratory
Failure
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Total RNA extraction from IMR-32 cells was done using TRIzol reagent (Life Technologies
Inc., Ambion, Carlsbad, CA, USA) followed by cDNA synthesis using the SuperScript IV VILO
reverse transcriptase according to the manufactures protocol (Invitrogen, Life Technologies Inc.,
Mississauga, ON, Canada). Changes to NEFL, PRPH, or INA mRNA levels were measured via
real-time PCR using the TaqMan Fast Advanced Master Mix and TaqMan Gene Expression
Assays (Applied Biosystems, Thermo Fisher Scientific). Intermediate filament expression levels
were normalized to 18S, and then quantified using the 2-ΔΔCT method.
2.3.4 Fluorescent In Situ Hybridization (FISH)
Neuropathologically intact human spinal cord was examined for candidate miRNA
expression within motor neurons. Spinal cord tissue was formalin-fixed, paraffin embedded, and
then cut into 7µm sections. Samples were UV treated overnight prior to experiment to reduce
autofluorescent lipofuscin signaling. MiRNA FISH was performed as previously described (de
Planell-Saguer et al., 2010). MiRNA probes were double DIG tagged (Exiqon, Woburn, MA,
USA), and were targeted using a DIG-HRP secondary antibody (1:100; Roche, Indianapolis, IN,
USA) and Tyramide Signal Amplification tagged with a Cy3 fluorophore (PerkinElmer,
Waltham, MA, USA). Spinal motor neurons were examined for positive expression of candidate
miRNAs using the Olympus FV1000 confocal microscope.
2.3.5 Cell Culture and Plasmid Construction
HEK293T and IMR-32 cells were cultured in Dulbecco’s Modified Eagle’s Media
(DMEM) and Eagle’s Minimum Essential Medium (EMEM), respectively, with 10% Fetal
Bovine Serum (FBS) and incubated at 37oC with 5% CO2.
NEFL, PRPH, and INA 3’UTRs identified in human spinal cord were individually cloned
into the pmirGLO vector in between SalI and NheI restriction enzyme sites and downstream of
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the firefly luciferase gene (Promega, Madison, WI, USA). Mutations made within the 3’UTRs
were done as previously reported (Hawley et al., 2017b) using the Site-Directed Mutagenesis Kit
II (Aligent Technologies Canada Inc., Missasauga, ON, Canada) in accordance with the
manufacturer’s instructions. Cloned fragments and mutated sites were confirmed with Sanger
sequencing.

2.3.6 Luciferase Assay and Relative Quantitative RT-PCR
HEK293T cells were seeded 24 and 48 hours prior to transfection for luciferase and RTqPCR assays, respectively, as previously reported (Hawley et al., 2017b). PmirGLO vectors
containing either the NEFL, PRPH, or INA 3’UTR were transfected into HEK293T cells either
with or without miRNA mimics for luciferase and relative quantitative RT-PCR assays in
accordance to what has been previously done (Campos-Melo et al., 2013; Hawley et al., 2017b)
using the Lipofectamine 2000 protocol (Life Technologies Inc., Invitrogen, Burlington, ON,
Canada). Luciferase activity was measured 24 hours post-transfection using the Dual-GLO
Luciferase Assay System (Promega, Madison, WI, USA). For RT-PCRs firefly and renilla
cDNAs were amplified and data was normalized in accordance to what has been previously
described (Campos-Melo et al., 2013). Data for luciferase and RT-qPCR assays was quantified
and plotted as relative difference of firefly expression from the control when in the presence of
miR-105, miR-140-5p, miR-9, or let-7a (negative control) and is represented as mean ± SEM.

2.3.7 Statistical Analysis
Student’s t-test was performed when comparing two conditions. One-way ANOVA
followed by Tukey’s post-hoc was done when doing multiple comparisons between groups. Data
was considered significant if p<0.05.
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2.4 Results
2.4.1 MiR-105 and miR-140-5p are downregulated in sALS and expressed in motor
neurons.
Spinal cord obtained from neuropathologically intact subjects was used to identify NEFL,
PRPH and INA 3’UTRs isoforms expressed within this tissue. We confirmed that already known
3’UTRs of NEFL [1838 bases – GenBank NM_006158], PRPH [325 bases – GenBank
NM_006262] and INA [1638 bases – GenBank NM_032727] were present in human spinal cord
(data not shown).
Subsequently, using the miRanda prediction tool, 15 miRNAs were identified to have
MREs within the NEFL, PRPH and INA 3’UTRs expressed in human spinal cord. However, we
previously demonstrated that the expression of 6 of these miRNAs are not dysregulated in sALS
(Campos-Melo et al., 2013). Thus, we focused on those 9 miRNAs that we previously reported
to be dysregulated in sALS, or possessed MREs in the NEFL, PRPH or INA 3’UTR, but for
which expression levels had not been characterized in sALS (Fig. 2.1). Of note, miR-9 has a
non-canonical binding site within the PRPH 3’UTR (seed region is from +3 to +8, rather than +2
to +7). Since miR-9 is predicted to regulate all intermediate filaments of interest, and several labs
have shown its relationship to sALS (Campos-Melo et al., 2013; Campos-Melo et al., 2018;
Emde et al., 2015; Haramati et al., 2010; Hawley et al., 2017a; Zhang et al., 2013), we decided
miR-9 was critical to examine.
Our previous work has shown that miR-9 is expressed within motor neurons and
significantly downregulated within the spinal cord of sALS patients (Campos-Melo et al., 2013;
Campos-Melo et al., 2018), and others have shown this downregulation is specific to motor
neurons (Emde et al., 2015). Thus, the remaining 8 miRNA candidates were further examined
within the spinal cord tissue of sALS patients (n=8) and control subjects (n=5). Real-time PCR
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Figure 2.1. MiRanda predicted 15 miRNAs to have MREs in NEFL, PRPH, and INA
3’UTRs. A) Venn diagram showing 15 miRNAs that have MRE sites within the NEFL, PRPH
and INA 3’UTRs according to miRanda software. However, we have shown previously that six
miRNAs are not dysregulated in sALS (Campos-Melo et al., 2013). Thus, only those outlined in
the black box were considered for further analysis. B) Schematic showing NEFL, PRPH and INA
3’UTRs expressed in neuropathologically intact human spinal cord (n=3), and the location of the
MREs of miRNA candidates within each 3’UTR.
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confirmed our previous reports that miR-105 and miR-140-5p were significantly downregulated
within the spinal cord tissue of sALS patients (Campos-Melo et al., 2013), while miR-185, miR1179, miR-1297, miR-3120, miR-4306 and miR-b4335 showed no significant change (Fig. 2.2).
Since miR-105 and miR-140-5p were both downregulated in the spinal cord of sALS
patients, we wanted to determine if these miRNAs were normally expressed within human motor
neurons, as what has been seen with miR-9 (Campos-Melo et al., 2018; Emde et al., 2015). Both
miR-105 and miR-140-5p are highly expressed within motor neurons (Fig. 2.3), suggesting that
the observed downregulation of these two miRNAs is likely occurring in motor neurons.
2.4.2 MiR-105 regulates a reporter linked to NEFL, PRPH and INA 3’UTRs.
NEFL, PRPH and INA 3’UTRs were individually linked to the firefly luciferase reporter
gene to determine if candidate miRNAs altered the expression of the reporter gene. Both miR105 and miR-140-5p significantly increased luciferase activity when in the presence of the NEFL
3’UTR strongly suggesting that miR-105 upregulates NEFL levels. Further, miR-105
significantly increased or decreased luciferase activity when in the presence of either the PRPH
or INA 3’UTRs, respectively, while miR-140-5p had no effect. Further, miR-9 significantly
reduced luciferase activity when in the presence of either the NEFL, PRPH, or INA 3’UTR (Fig.
2.4A). Let-7a was used as negative control and had no effect on luciferase activity when in the
presence of any intermediate filament 3’UTR.
Subsequently, we determined whether the changes observed in luciferase activity were
due to changes at the mRNA level (Fig. 2.4B). Changes to luciferase mRNA levels when linked
to either the NEFL, PRPH, or INA 3’UTR matched changes seen to luciferase activity when in
the presence of miR-105. MiR-9 significantly reduced luciferase mRNA levels in the presence of
either the NEFL or PRPH 3’UTR, but had no effect on the luciferase mRNA levels when in the
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presence of the INA 3’UTR. MiR-140-5p had no effect on the mRNA levels of the luciferase
gene when in the presence of either the NEFL, PRPH, or INA 3’UTR (Fig. 2.4B). Since miR140-5p had no effect on the mRNA levels when interacting with NEFL, PRPH or INA 3’UTRs,
only miR-105 and miR-9 were further examined.
2.4.3 MiR-105 directly interacts with the NEFL, PRPH and INA 3’UTRs to regulate
reporter expression.
MREs of miR-105 and miR-9 were mutated at the +2 and +3 positions in the NEFL,
PRPH and INA 3’UTRs to determine if these miRNAs needed to directly interact with the
3’UTRs to regulate luciferase activity. Indeed, miR-105 had significantly reduced effects on
increasing luciferase activity when the NEFL 3’UTR was lacking the miR-105 MRE; however,
the effect was not completely abolished. This indicates miR-105 likely stabilizes NEFL by
binding to the 3’UTR, but possibly also through an indirect mechanism by which miR-105
regulates another target that stabilizes NEFL. Further, the PRPH 3’UTR lacking the miR-105
MRE completely abolished the ability for miR-105 to upregulate luciferase activity (Fig. 2.5A).
Interestingly, miR-105 has multiple MREs within the INA 3’UTR, and thus, we aimed to
determine if miR-105 targeted a specific MRE to reduce luciferase activity. Indeed, mutations
only in the MRE closest to the 5’end of the 3’UTR, or site 1 (S1), abolished the ability of miR105 to reduce luciferase activity. Mutations in the MREs closer to the 3’end, or sites 2 and 3 (S2
and S3, respectively), had no effect on the ability of miR-105 to reduce luciferase activity,
indicating the S1 MRE is critical for miR-105 function (Fig. 2.5A).
MiR-9 has two MREs within the NEFL 3’UTR, but only one MRE in the PRPH and INA
3’UTRs. Removal of the S1 MRE within the NEFL 3’UTR lead to a significant reversal in the
reduction of luciferase activity via miR-9, but the effect was not completely abolished. It was
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Figure 2.2. Differential expression of miRNA candidates within sALS spinal cord tissue.
We examined the expression of candidate miRNAs in the spinal cord of sALS patients (n=8)
compared to control subjects (n=5) using real-time PCR. MiR-105 and miR-140-5p are
significantly downregulated in the spinal cord of sALS patients, while all other candidates
showed no significant change in expression compared to the control population. Data was
expressed miRNA fold-change (ALS/Control) ± SEM, and significance was determined using a
Student’s t-test (* = p<0.05).
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Figure 2.3. MiR-105 and miR-140-5p are expressed in human spinal motor neurons. FISH
was used to examine the expression of both miR-105 and miR-140-5p within human ventral
lumbar spinal cord. Both miRNAs showed strong expression within motor neurons of a control
case (n=1). MiR-548c was used as a negative control. Motors neurons were identified based on
size, as they are the only cells 50-70µm in size within the ventral spinal cord. Scale bar
represents 10µm.
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Figure 2.4. MiR-105 regulates luciferase activity and mRNA expression when it contains
either the NEFL, PRPH, or INA 3’UTR. HEK293T cells were transfected with the pmirGLO
plasmid containing either the NEFL, PRPH, or INA 3’UTR, or cells were co-transfected with the
pmirGLO plasmid containing the intermediate filament 3’UTRs and either miR-105, miR-1405p, or miR-9. A) Reporter gene assay showing changes in luciferase activity from control when
either miR-105, miR-140-5p, or miR-9 interact with either the NEFL, PRPH or INA 3’UTR. B)
Relative quantitative RT-qPCR showing changes in luciferase mRNA levels from control when
either miR-105, miR-140-5p, or miR-9 interact with either the NEFL, PRPH or INA 3’UTR.
Positive and negative values represent up- and downregulation, respectively. Let-7a was used as
a negative control. Firefly luciferase expression was normalized to renilla luciferase expression,
and then further normalized to account for the effect of the miRNA on the pmirGLO plasmid
itself to determine the exact effect of the miRNA when it interacts with the respective
intermediate filament 3’UTR. Data is represented as mean (n=3) ± SEM. Significance was
determined using a Student’s t-test (*** = p<0.001; ** = p<0.01; * = p<0.05; NS = p>0.05).
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only when the S2 MRE was removed that miR-9 no longer silenced luciferase activity (Fig.
2.5B), indicating the S2 MRE within the NEFL 3’UTR is crucial for miR-9 mediated silencing.
Mutations within the MRE of miR-9 in the PRPH 3’UTR lead to the eradication of the ability of
miR-9 to reduce luciferase activity. However, elimination of the miR-9 MRE in the INA 3’UTR
had no effect on its ability to reduce luciferase levels, indicating that miR-9 regulates INA
expression through an indirect mechanism (Fig. 2.5B). Overall, these data indicate that miR-105
directly binds to the 3’UTR of NEFL, PRPH and INA to regulate expression, while miR-9 only
directly targets the NEFL and PRPH 3’UTRs.
2.4.4 MiR-105 and miR-9 regulate the mRNA stability of endogenous NEFL, PRPH and
INA.
The human neuron-derived cell line IMR-32, endogenously expresses NEFL, PRPH and
INA, as well as miR-105 and miR-9 (Fig. 2.6). Therefore, we decided to determine whether miR105 and miR-9 regulated these intermediate filaments endogenously. Overexpression of miR-105
lead to a significant increase in NEFL, while inhibition of miR-105 had a significant decrease on
NEFL mRNA levels. Interestingly, overexpression of miR-105 was observed to have little effect
on PRPH mRNA levels, yet its inhibition drastically reduced PRPH expression, which suggests
that miR-105 is needed to stabilize the PRPH transcript. In contrast, miR-105 overexpression
lead to a significant decrease, while miR-105 inhibition lead to a 2-fold increase (p = 0.08) in
INA mRNA levels (Fig. 2.7A). This data indicates that miR-105 is a stabilizer of NEFL and
PRPH, and a destabilizer of INA mRNA, consistent with what we observed in our luciferase
assays.
Further, overexpression of miR-9 within IMR-32 cells lead to a significant decrease in
NEFL and PRPH mRNA levels which is consistent with alterations seen in the relative
quantitative RT-PCR and the luciferase assay, while the inhibition of miR-9 lead to a significant
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increase in NEFL and PRPH mRNA (Fig. 2.7B). As expected, based on our relative quantitative
RT-PCR, overexpression of miR-9 had little effect on INA mRNA stability. However, inhibition
of miR-9 within IMR-32 cells lead to a significant increase in INA mRNA. This could indicate
that the indirect mechanism by which miR-9 suppresses INA expression, as suggested by our
luciferase and site-directed mutagenesis assays, is lost upon inhibition of miR-9 (Fig. 2.7B).
This data shows that both miR-105 and miR-9 regulate this network on intermediate filaments
within a human neuronal-derived cell line, further emphasizing that alterations to these miRNAs
is a major contributing factor to aberrant intermediate filament stoichiometry seen in sALS
spinal cord.
2.5 Discussion
In this study, we aimed to determine whether a specific pool of ALS-associated miRNAs
contributes to changes in the mRNA metabolism of intermediate filaments that is observed in
ALS spinal motor neurons. We identified two miRNAs—miR-105 and miR-9—to be central
regulators of NFL, PRPH and INA, but only miR-105 binds directly to all intermediate filament
3’UTRs. Further, we showed that miR-105 is highly expressed in motor neurons and has reduced
levels within the spinal cord of sALS patients, suggesting that the regulation of these
intermediate filaments in spinal motor neurons is disrupted in sALS via miR-105.
Elucidating the mechanism that causes the selective reduction of NEFL, PRPH and INA
has major significance in understanding ALS progression for several reasons. First, NFL is a
necessary component of the neurofilament triplet protein structure, as NFM and NFH alone
could not form a stable cytoskeleton (Szaro and Strong, 2010). Second, both INA and PRPH
provide the early cytoskeleton for developing neurons, and thus, without the neurofilament triplet
protein structure, INA and PRPH could potentially act as replacements for the neuronal
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Figure 2.5. MiR-105 regulates firefly luciferase expression through direct interactions with
the NEFL, PRPH, and INA 3’UTR. HEK293T cells were co-transfected with either the
pmirGLO plasmid containing the wild-type 3’UTR, or mutated form, and either with or without
miR-105 or miR-9. A) Changes to luciferase activity from control when miR-105 either contains
or lacks MREs within either the NEFL, PRPH, or INA 3’UTR. MiR-105 has three MREs within
the INA 3’UTR, and thus each MRE was individually examined. B) Changes to luciferase
activity from control when miR-9 either contains or lacks MREs within either the NEFL, PRPH,
or INA 3’UTR. MiR-9 has two MREs within the NEFL 3’UTR, and thus each MRE was
individually examined. Firefly luciferase expression was normalized to renilla luciferase
expression, and then further normalized to account for the effect of the miRNA on the pmirGLO
plasmid to determine the exact effect of the miRNA when it interacts with the respective 3’UTR.
Data is represented as mean (n=3) ± SEM. Significance was determined using a one-way
ANOVA followed by a Tukey’s post-hoc (*** = p<0.001; ** = p<0.01; * = p<0.05; NS =
p>0.05).
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Figure 2.6. Real-time PCR indicating expression of intermediate filaments and miRNAs of
interest in IMR-32 cells. A) Expression of NEFL, PRPH and INA mRNA within IMR-32 cells.
B) Expression of miR-105 and miR-9 in IMR-32 cells. Values represented as mean (n=3) CT ±
SEM.
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Figure 2.7. MiR-105 and miR-9 regulate the endogenous mRNA expression of NEFL,
PRPH and INA. IMR-32 cells were transfected with either a miR-105 or miR-9, or let-7a
(negative control) mimics, or inhibitors. Basal levels of intermediate filament mRNAs were
measured in IMR-32 cells transfected with let-7a. Values above and below one represents either
an increase or decrease in expression, respectively. Changes to the expression of intermediate
filaments was measured using real-time PCR, and quantified using the 2-ΔΔCT method, where
values were first normalized to 18S RNA levels prior to comparison. Data was represented as
mean (n=5) ± SEM. Significance was calculated using a one-way ANOVA followed by a
Tukey’s post-hoc (*** = p<0.001; ** = p<0.01; * = p<0.05; NS = p>0.05).
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cytoskeleton (Athlan and Mushynski, 1997; Kaplan et al., 1990; Yuan et al., 2006; Yuan et al.,
2012). In fact, there is an increase in INA and PRPH expression within injured neurons which
allows for replacement of the cytoskeleton structure at the injured site (McGraw et al., 2002;
Troy et al., 1990). However, since there is a selective reduction of NEFL, PRPH, and INA
expression within spinal motor neurons of ALS patients (Wong et al., 2000), these motor
neurons have no mechanism by which they can support and/or replace their cytoskeleton
structure.
Reduction of miR-105 has generally been associated with tumor and cancer formation as
it is responsible for regulating several tumor suppressor genes (Honeywell et al., 2013; Liu et al.,
2016; Lu et al., 2017; Zhang et al., 2017). However, this is the first time, to our knowledge, that
miR-105 has been associated with the regulation of neuronal intermediate filaments. According
to our results, reduced levels of miR-105 leads to decreased levels of NEFL and PRPH, and
increased levels of INA mRNA. However, this does not match what is actually seen in sALS
motor neurons, as all three intermediate filaments show decreased levels (Wong et al., 2000).
Thus, while miR-105 appears to be a central regulator of ALS-linked intermediate filaments, the
dysregulation of this miRNA in sALS is probably a contributing factor to the dysregulation of
intermediate filaments, and not the sole cause.
Beyond miR-105, we examined miR-9 given that it had previously been shown to be
reduced in ALS spinal cord and motor neurons. We observed that miR-9 also was capable of
reducing the expression of NEFL, PRPH and INA. Previous work has shown that miR-9 is a
critical part of the intermediate filament pathway through the regulation of NEFH (Campos-Melo
et al., 2018; Haramati et al., 2010). While Haramati et al. had also observed that miR-9 does not
regulate mouse Nefl, it is noteworthy that miR-9 lacks MREs within the mouse Nefl 3’UTR. In
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contrast, human NEFL 3’UTR has two sites for miR-9 binding. Further, our results suggest that
loss of miR-9 expression in ALS would lead to an increase in all three of these intermediate
filaments, which does not match what we have previously observed in sALS motor neurons
(Wong et al., 2000). However, based on our data, loss of miR-9 expression would still alter the
intermediate filament stoichiometry, which is the main factor that drives intermediate filament
pathogenesis (Szaro and Strong, 2010). Overall, our findings indicate that miR-105 and miR-9
are necessary components to maintain intermediate filament stoichiometry, and thus, loss of
these miRNAs in sALS likely contribute to intermediate filament dysregulation.
An intriguing finding in this study was the MRE site preference of miR-105 and miR-9
within the INA and NEFL 3’UTRs, respectively. Despite having three MREs within the INA
3’UTR, miR-105 only bound to one site (S1) to regulate mRNA stability, while miR-9 binds
both MREs to reduce NEFL levels, with binding to the S2 MRE having a greater effect on NEFL
downregulation than binding to the S1 MRE. It is a common phenomenon for a single miRNA to
have multiple MREs within a transcript, where interactions with each MRE has either a
synergistic or differential effect on transcript stability and translational output (Jangra et al.,
2010; Nasheri et al., 2011; Ott et al., 2011). For example, miR-122 has four MREs within the
Hepatitis C Virus (HCV). When miR-122 binds to the S1 or S2 MRE it promotes viral
translation (Jangra et al., 2010). In contrast, interactions with the S4 MRE suppresses viral
translation while binding to the S3 MRE has no effect on overall translational output of the virus
(Henke et al., 2008; Nasheri et al., 2011). The exact reason why a miRNA binds to some MREs
and not others or has differential effects on transcript stability at different MREs is unknown.
Considering there are other trans-acting factors that regulate mRNA stability, how a miRNA
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functions at a particular MRE is likely affected by the other trans-acting factors that are binding
within that area.
Further, while removing the miR-105 binding site from the NEFL 3’UTR reduced the
stabilizing effect it had on the luciferase transcript, it did not completely abolish the effect. This
could indicate that miR-105 regulates the expression of another target that is responsible for
regulating NEFL stability. TDP-43 and RGNEF are two ALS-associated RNA-binding proteins
known to regulate NEFL mRNA stability (Droppelmann et al., 2013; Volkening et al., 2009),
and thus, it would be worth investigating whether the expression of these RNA-binding proteins
are affected by changes to miR-105 levels.
Both miR-9 and miR-105 downregulation in sALS likely contributes to the loss of
intermediate filament stoichiometry, ultimately leading to intermediate filament aggregation and
eventual neuronal death. MiRNAs are ideal therapeutic targets as they are known to regulate
several genes within a network. For example, miR-506 and miR-146a are negative regulators of
several genes involved in cancer metastasis and inflammation, respectively (Sun et al., 2015; Wu
et al., 2015). Thus, rather than targeting individual genes that contribute to the disease, miRNAs
offer an avenue in which we can target multiple genes involved in a disease process (Rupaimoole
and Slack, 2017). Our data suggests that both miR-105 and miR-9 regulate a network of ALSassociated neuronal intermediate filaments, and thus recovery of these miRNAs within sALS
patients could slow disease progression by mitigating the alterations seen to intermediate
filament stoichiometry. Further work within in vivo models is still needed to confirm this
hypothesis.
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3.1 Abstract
Neurofilaments (NFs) are the most abundant cytoskeletal component of vertebrate
myelinated axons. NFs function by determining axonal caliber, promoting axonal growth and
forming a 3-dimensional lattice that supports the organization of cytoplasmic organelles. The
stoichiometry of NF protein subunits (NFL, NFM and NFH) must be tightly controlled to
avoid the formation of NF neuronal cytoplasmic inclusions (NCIs), axonal degeneration and
neuronal death, all pathological hallmarks of amyotrophic lateral sclerosis (ALS). The posttranscriptional control of NF transcripts is critical for regulating normal levels of NF proteins.
Previously, we showed that miRNAs that are dysregulated in ALS spinal cord regulate the
levels of NEFL mRNA. In order to complete the understanding of altered NF expression in
ALS, in this study we have investigated the regulation of NEFM and NEFH mRNA levels by
miRNAs. We observed that a small group of ALS-linked miRNAs that are expressed in
human spinal motor neurons directly regulate NEFM and NEFH transcript levels in a manner
that is associated with an increase in NFM and NFH protein levels in ALS spinal cord
homogenates. In concert with previous observations demonstrating the suppression of NEFL
mRNA steady state levels in ALS, these observations provide support for the hypothesis that
the dysregulation of miRNAs in spinal motor neurons in ALS fundamentally alters the
stoichiometry of NF expression, leading to the formation of pathological NCIs.
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3.2 Introduction
Neurofilaments (NFs) are unique neuron-specific intermediate filaments in
vertebrates. They are highly dynamic structures that determine axonal caliber, promote
axonal growth and organize the cytoplasm to form a stable 3-dimensional lattice that supports
the organization of organelles and cytoplasmic proteins (Szaro and Strong, 2010; Walker et
al., 2001).
NF subunit proteins (low, medium and high molecular weight neurofilaments; NFL,
NFM and NFH, respectively) form homo- and hetero-polymers following a specific
stoichiometry and tight spatiotemporal regulation. Conserving NF stoichiometry by
controlling the levels of expression of individual NF subunits is critical for the maintenance
of healthy neurons. Alterations of NF mRNA steady stoichiometry and the associated
formation of neuronal cytoplasmic inclusions (NCIs) composed of NF proteins are
neuropathological markers of degenerating motor neurons in amyotrophic lateral sclerosis
(ALS), a progressive neurodegenerative disease (Szaro and Strong, 2010; Thyagarajan et al.,
2007; Xiao et al., 2006). Although the exact mechanism by which NF NCIs exert toxicity is
unknown, it has been suggested that they alter the internal structure of axons and disrupt
axonal transport, in addition to impairing NMDA-mediated calcium influx, compromising the
survival of neurons (Sanelli et al., 2004; Thyagarajan et al., 2007).
Post-transcriptional control is crucial for preserving NF subunit expression in
neuronal homeostasis and also during axonal outgrowth in development and regeneration
(Ananthakrishnan et al., 2008; Ananthakrishnan and Szaro, 2009; Schwartz et al., 1994).
MiRNAs are evolutionary conserved non-coding RNAs that control the expression of the
majority of the mammalian transcriptome and have been increasingly linked to
neurodegenerative disorders. We and others have described a profound dysregulation of
miRNAs in spinal cord and motor cortex of ALS patients (Campos-Melo et al., 2013; Emde
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et al., 2015; Figueroa-Romero et al., 2016; Wakabayashi et al., 2014). We previously
demonstrated that a selective group of these miRNAs directly regulate NEFL mRNA stability
(Campos-Melo et al., 2013), and postulated that this dysregulation of miRNA expression
would contribute to the selective suppression of NEFL mRNA levels observed in ventral
lateral spinal cord motor neurons in ALS (Bergeron et al., 1994; Wong et al., 2000). Proper
control of the levels of the NF triplet is critical because the backbone of the NF is mainly
formed by NFL (Leermakers and Zhulina, 2010) and the stoichiometry of NFL/NFM/NFH
(4:2:1) has to be carefully maintained (Scott et al., 1985). The miRNAs responsible for
regulating human NEFM and NEFH mRNA stability are however unknown. In this study we
observed that a limited number of ALS-linked miRNAs that are expressed in spinal motor
neurons directly regulate NEFM and NEFH mRNA levels, in a way that might explain the
increase in NFM and NFH protein levels that we observed in ALS spinal cords and thus
contribute directly to the formation of NF NCIs.
3.3 Materials and Methods
3.3.1 Tissue Collection
Spinal cord samples from sALS patients and age-matched, neurologically intact
control individuals were used. All ALS cases were both clinically and neuropathologically
confirmed using the El Escorial Criteria (World Federation of Neurology Research Group on
Neuromuscular Disease, 1994). Written consent for autopsy was obtained from the next of
kin at the time of death or from the patient antemortem in accordance with the London Health
Sciences Centre consent for autopsy. Cases were genotyped and confirmed to have no known
mutations in SOD1, TARDBP, FUS or expanded repeats in C9ORF72 (Table 3.1).
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Table 3.1. Patient demographics.
Cases

Gender

Control

ALS

Symptom
onset

Age of
death

Cause of Death

F
M
F
M
M
F
F
M

Age of
symptom
onset
-

-

62
74
68
68
75
53
74
67

Heart Attack
Stroke
Unknown
Brain Tumor
Unknown
Pneumonia
Leukemia
Unknown

F

58

60

Unknown

M

69

Unknown
Upper/lower
limbs

72

Unknown

F

40

Bulbar

41

Systemic Failure

M

55

Unknown

61

Pneumonia

M

64

F

69

M

63

Unknown

64

Unknown

F

47

Bulbar

49

Respiratory
Failure

Upper/lower
limbs
Respiratory
Symptoms

67
71

Respiratory
Failure
Respiratory
Failure
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3.3.2 3’RACE PCR, cloning and miRNA target prediction
NEFM and NEFH mRNA 3’UTRs were obtained using 3’RACE PCR. Briefly,
TRIzol reagent (Thermo Fisher Scientific) was used for total RNA extraction from human
spinal cord tissue. 3’RACE PCR was performed using SMARTer RACE 5’/3’ RACE Kit
(Takara Bio. Inc., Clontech) and primers hNEFM_3RACE_F1D:
5’CACTTCACACGCCATAGTAAAGGAAGTCACC3’ and hNEFH_3RACE_F2:
5’GAGAAGGCCACAGAAGACAAGGCCGCCAAG3’ for NEFM and NEFH 3’UTRs,
respectively. 3’UTR isoforms were cloned into pGEMT-Easy vector and sequenced. For
luciferase assays, 3’UTRs were subcloned into pmirGLO vector between NheI and SalI sites
and linked to the firefly luciferase coding region. Mutations in two nucleotides at the 3’end of
each miRNA recognition element (MRE) within the NEFM and NEFH 3’UTRs were made
using QuikChange Site-Directed Mutagenesis Kit II (Agilent) according to the
manufacturer’s instructions. Mutations were carefully designed to ensure no changes were
made in the secondary structures of the transcripts using the RNAFold WebServer
(http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi). Both TargetScan
(http://www.targetscan.org/) and miRanda
(http://www.microrna.org/microrna/getGeneForm.do) software programs were used to
determine miRNAs with predicted MREs in either NEFM or NEFH 3’UTRs.
3.3.3 miRNA extraction and real-time PCR
Total miRNA extraction using the mirVana miRNA isolation kit (Thermo Fisher
Scientific) was performed from human ventral lumbar spinal cord using 5 controls and 8 ALS
tissue samples according to the manufacturer’s instruction. Yield and purity of the miRNA
solution was determined using spectrophotometry while RNA integrity was measured using a
bioanalyzer instrument.
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MiRNA extracts from the spinal cord of ALS patients or controls were reversed
transcribed and then subjected to real-time PCR using the miRCURY LNATM Universal RT
microRNA PCR (Exiqon) and ExiLENT SYBR Green master mix (Exiqon), according to the
manufacturer’s instructions. PCRs were performed using the 7900 HT real-time PCR system.
Relative expression of miRNAs was normalized to miR-16-5p, a miRNA previously
demonstrated to have the same expression in sALS and controls (Campos-Melo et al., 2013).
The analysis of the relative expression of candidate miRNAs between sALS and controls was
done using the 2-ΔΔCT method. All experiments were run in triplicate and significance was
determined using Student’s t-test.
3.3.4 TaqMan real-time PCR
To examine the expression levels of NEFM and NEFH mRNA, total RNA extraction
was performed on ALS patient and control lumbar spinal cord tissue using TRIzol reagent
(Ambion, Life Technologies). RNA samples were subjected to a cDNA synthesis reaction
using the SuperScript IV VILO reverse transcriptase (Invitrogen, Thermo Fisher Scientific) in
accordance to the manufacture’s instructions. Real-time PCR was done on the cDNA
templates using the TaqMan Fast Advanced Master Mix and TaqMan Gene Expression
Assays (Applied Biosystems, Thermo Fisher Scientific) targeting either NEFM or NEFH.
Assays were performed in accordance to the manufacture’s instructions. TaqMan probes that
targeted either NEFM or NEFH were designed with a FAM fluorophore. The expression of
NEFM and NEFH was normalized to the expression of a reference gene (HPRT1), which was
targeted by a TaqMan probe containing a VIC fluorophore. Changes in NEFM and NEFH
mRNA expression between ALS patients and control subjects were determined using the 2ΔΔCT

method. Experiments were run in triplicate and determined to be significantly different

using a Student’s t-test.
3.3.5 Fluorescent in situ hybridization (FISH)
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To ensure that the miRNAs of interest are expressed in human motor neurons,
neuropathologically normal lumbar spinal cord from control subjects was examined for
miRNA expression. Tissue sections were formalin-fixed, paraffin embedded (FFPE) and cut
into 7μm sections. Samples were UV treated overnight to reduce the lipofuscin-induced autofluorescent signal. FISH was performed as described previously (Planell-Sauger et al 2010).
LNA probes were designed with double DIG-labels that targeted the miRNA of interest
(Exiqon). DIG-HRP secondary antibody, and Tyramide Signal Amplification (TSA) Systems
tagged with a Cy3 fluorophore (PerkinElmer) were used to obtain a fluorescent signal of the
miRNA target. Ventral horn of human lumbar spinal cord tissue was examined for positive
staining within motor neurons using the Olympus FV1000 confocal microscope.
3.3.6 Cell culture, luciferase assay and relative quantitative RT-PCR
HEK293T cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM)
containing 10% fetal bovine serum (FBS), at 37oC with 5% CO2. HEK293T cells were plated
on 96-well plates with a density of 10,000 cells/well 24 hours prior to transfection. 100 nM of
miRNA mimics (Thermo Fisher Scientific) and 3.47 fmol of pmirGLO containing NEFM or
NEFH 3’UTR were co-transfected into the cells using Lipofectamine 2000 reagent (Thermo
Fisher Scientific).
Luciferase assays and relative quantitative RT-PCR were performed 24 hours posttransfection as was described previously (Campos-Melo et al., 2014). Data show positive
values as upregulation and negative values as downregulation. All experiments were run in
triplicate, and significance was determined using a Student’s t-test or one-way ANOVA
followed by Turkey’s post hoc test.
3.3.7 Western blot
Total protein extraction from ventral lumbar spinal cord of 3 controls and 7 ALS
patients was performed using NP40 lysis buffer containing proteinase inhibitors. Samples
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were sonicated, resuspended in loading buffer, denatured at 90°C and run on an 8% SDS-gel.
After transfer, the nitrocellulose membrane was probed with either mouse anti-NFM (1:1000;
Boehringer Mannheim, 814-334), mouse anti-NFH (1:1000; Boehringer Mannheim, 814342), or rabbit anti-GAPDH (1:5000; Abcam, ab9485) and later with HRP-secondary
antibody (goat anti-mouse 1:3000, or goat anti-rabbit 1:5000; BioRad and Invitrogen,
respectively). Relative protein expression of NFM and NFH were normalized to GAPDH
expression levels. Student’s t-test was used to determine statistical differences in endogenous
protein expression.
3.4 Results
3.4.1 Only one 3’UTR isoform of either NEFM are NEFH is expressed in human spinal
cord
Considering that 3’UTR polymorphisms have been increasingly reported in the
literature, we determined if 3’UTR variants of NEFM and NEFH mRNAs are expressed in
human spinal cord. A single variant form of NEFM and NEFH 3’UTRs (486 and 583 nt,
respectively) was detected in lumbar spinal cord control tissue (Fig. 3.1). Analysis of ALS
patients showed no difference in the 3’UTR variants of NEFM and NEFH expressed in spinal
cord compared to control samples (data not shown).
3.4.2 Several ALS-linked miRNAs have MREs within the NEFM and NEFH 3’UTRs
Prediction algorithms showed that NEFM and NEFH 3’UTRs have multiple MREs for
different pools of miRNAs. However, for this study we only considered those miRNAs that
we previously observed to be differentially expressed in ALS tissue versus controls using the
TaqMan assay (Campos-Melo et al., 2013). We performed real-time PCR using SYBR green
of 40 miRNAs to validate differential expression of 6 miRNAs that have MREs in NEFM or
NEFH 3’UTRs (Fig. 3.2A). Each miRNA, (miR-92a-3p, miR-125b-5p, miR-9-5p, miR-20b-
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Figure 3.1. Single NEFM and NEFH mRNA 3’UTR variants are expressed in human
spinal cord. 3’RACE-PCR was performed from spinal cord tissue samples of control
individuals using specific primers to amplify NEFM and NEFH 3’UTRs. 3’UTRs were
cloned and sequenced. One 3’UTR variant for each NEFM (486 nt) and NEFH (583 nt)
transcript was observed in human spinal cord. NEFM specific primer anneals to a region 40
nt upstream the stop codon.
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5p and miR-223-3p and miR-519d-3p) showed significant downregulation of expression in
ALS spinal cord versus controls (Fig. 3.2B).
Next, we examined the neuronal expression of the group of miRNAs that potentially
regulate NEFM and NEFH transcripts in human spinal cord motor neurons of control tissue
through FISH. MiR-92a-3p is almost exclusively expressed in motor neurons of the spinal
cord. MiR-125b-5p, miR-9-5p, miR-20b-5p and miR-519d-3p showed higher expression in
motor neurons than in other cell types within the spinal cord. MiR-223-3p showed similar
expression in motor neurons and surrounding cells. MiR-548c-3p was used as a negative
control and miR-124-3p, which is highly expressed in neurons, was used as positive control.
In summary, we observed that the 6 ALS-linked miRNAs that are predicted to regulate
NEFM and NEFH mRNAs are expressed in motor neurons of human spinal cord (Fig. 3.3).
3.4.3 MiRNA candidates interact with NEFM and NEFH 3’UTRs to regulate gene
expression
Functionality assays of these 6 miRNAs showed that miR-92a-3p and miR-125b-5p
downregulate the levels of a luciferase reporter linked to NEFM 3’UTR (Fig. 3.4A). MiR-95p, miR-20b-5p, miR-92a-3p and miR-223-3p downregulate the levels of the luciferase
reporter coupled to NEFH 3’UTR (Fig. 3.4B). We observed that most of these miRNAs also
significantly downregulate mRNA levels of the luciferase reporter bound to either NEFM or
NEFH 3’UTR (Fig. 3.4C and D), which implies that miRNAs are dysregulating the stability
of NEFM and NEFH transcripts. Reporter gene assay using NEFM or NEFH 3’UTR MRE
mutants showed a decrease in the downregulatory effect of each miRNA compared with the
wild type, indicating that miR-9-5p, miR-20b-5p, miR-92a-3p, miR-125b-5p and miR-223-3p
directly regulate NEFM or NEFH 3’UTRs stability (Fig. 3.5).
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3.4.4 NEFM and NEFH mRNA and protein are increased in ALS spinal cord
Finally, considering the reduced expression of this group of 5 miRNAs in ALS spinal
cords and the downregulatory function they showed on NEFM and NEFH, we should expect
an increase of NEFM and NEFH transcript and protein levels in ALS spinal cord tissue
compared to controls. Consistent with this, we observed an increase in both NEFM and
NEFH transcript and protein levels in ALS ventral lumbar spinal cords (Fig. 3.6).
3.5 Discussion
In this study, we have shown that a small group of miRNAs that are dysregulated in
the spinal cord of ALS patients directly regulate NEFM and NEFH mRNA stability and that
this is associated with an increase in NFM and NFH protein levels in ALS spinal cord
homogenates compared to neurological intact control spinal cord homogenates.
The post-transcriptional control of NF transcripts is critical for establishing,
consolidating and maintaining normal levels of NF proteins. The stoichiometry of NF
subunits has to be tightly controlled to promote axonal outgrowth, control axon caliber and
avoid the formation of NF aggregates, axonal degeneration and neuronal death (Julien, 1999;
Thyagarajan et al., 2007). The regulation of NF transcripts expression occurs at multiple
levels. It has been reported that splicing of the last intron of Xenopus NEFM increases
nucleocytoplasmic export of the transcript which allows for robust gene expression (Wang
and Szaro, 2016). Another level of regulation is at the mRNA transport. One study observed
that the mRNAs of each NF subunit are present and translated within intact and regenerating
rat sciatic nerve, demonstrating that NF transcripts are transported through axons (SoteloSilveira et al., 2000). At the final stage of mRNA regulation, it has been shown that the RNAbinding protein HuB increases the translation of NEFM transcript (Antic et al., 1999).
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B
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Figure 3.2. MiRNAs that have MREs in NEFM or NEFH 3’UTRs are downregulated in
the spinal cord of ALS patients. (A) MREs within NEFM and NEFH 3’UTRs of ALSlinked miRNAs. (B) Real-time PCR using SYBR green. Validation of differential expression
in ALS versus control spinal cords of 6 miRNAs that have MREs in NEFM or NEFH mRNA
3’UTRs is shown. Experiments were performed in triplicate. Values below 1 indicate
downregulation. Results are shown as mean (n=3) ± SEM (Student t-test: **** p < 0.0001,
*** p < 0.001, ** p < 0.01, * p < 0.05. MiR-9-5p, p = 0.0229; miR-20b-5p, p = 0.0230; miR92a-3p, p = 0.0234; miR-125b-5p, p = 0.0412; miR-223-3p, p = 0.0215 and miR-519d-3p, p
= 0.0232).
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Figure 3.3. MiRNAs that have MREs within NEFM or NEFH 3’UTRs are expressed in
motor neurons of human spinal cord control tissue. FISH was performed using FFPE
control spinal cord tissue and LNATM-enhanced detection probes 5`-DIG and 3`-DIG labeled
for miRNAs. Amplification was performed using anti-DIG-HRP and TSA Plus Cy3. MiR548c-3p, which is not expressed in human spinal cord, was used as negative control. MiR124-3p, which is known as highly expressed in neurons, was used as positive control.
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Figure 3.4. A group of ALS-linked miRNAs regulate a luciferase reporter linked to
NEFM or NEFH 3’UTRs. HEK293T cells were co-transfected with a reporter plasmid
containing NEFM or NEFH 3’UTRs and miRNA mimics. (A, B) Reporter gene assays were
performed 24 hours after transfection. Data are expressed as relative change and plotted in
logarithmic scale. (C, D) Relative quantitative RT-PCRs were performed after RNA
extraction, 24 hours post-transfection. Data are expressed as relative mRNA level change and
plotted in logarithmic scale. All experiments were performed in triplicate. Results are shown
as mean (n=3) ± SEM (Student t-test: **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p <
0.05, relative to the pmirGLO vector control). Reporter gene assays: miR-92a-3p/NEFM, p <
0.0001; miR-125b-5p/NEFM, p = 0.0005; miR-let-7a/NEFM, p = 0.6015; miR-9-5p/NEFH,
miR-20b-5p/NEFH, miR-92a-3p/NEFH and miR-223-3p/NEFH, p < 0.0001; miR-519d3p/NEFH, p = 0.0723; miR-let-7a/NEFH, p = 0.0893. RT-PCRs: miR-92a-3p/NEFM, p =
0.0052; miR-125b-5p/NEFM, p = 0.0429; miR-9-5p/NEFH, p = 0.0431; miR-20b-5p/NEFH,
p = 0.0518; miR-92a-3p/NEFH, p = 0.0003; miR-223-3p/NEFH, p < 0.001; miR-519d3p/NEFH, p = 0.0903).
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Figure 3.5. MiRNAs directly regulate luciferase transcripts linked to NEFM or NEFH
3’UTRs. HEK293T cells were co-transfected with a reporter plasmid containing mutant
NEFM (A) or NEFH (B) 3’UTRs and miRNA mimics. Reporter gene assays were performed
24h after transfection. Data are expressed as relative change and plotted in logarithmic scale.
All experiments were performed in triplicate. Result are shown as mean (n=3) ± SEM (Oneway ANOVA followed by Tukey’s post hoc test: **** p <0.0001, *** p < 0.001, ** p < 0.01,
* p < 0.05, relative to the pmirGLO vector control). MiR-92a-3p/NEFM, miR-125b5p/NEFM, miR-9-5p/NEFH, miR-20b-5p/NEFH, miR-92a-3p/NEFH and miR-2233p/NEFH, p < 0.0001).
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Figure 3.6. NEFM and NEFH transcript and protein levels are increased in spinal cord
of ALS patients. (A) Real-time PCR using TaqMan and (B) Western blots were performed
using ventral lumbar spinal cord samples of 5 controls and 7 ALS patients. (C) Quantification
by densitometry of Western blots in A. Protein levels were normalized to GAPDH. Data was
expressed as the mean ± SEM (Student t-test: **** p < 0.0001, *** p < 0.001, ** p < 0.01, *
p < 0.05. Real-time PCR: NEFM, p = 0.0027: NEFH, p = 0.0239. Western blot: NFM, p =
0.0238; NFH, p = 0.4762).
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mRNA stability is the regulatory process of NF transcripts most extensively studied in which
multiple trans-acting factors participate. In mice, it has been shown that the RNA-binding
protein p190RhoGEF stabilizes and that glycolytic isoenzymes aldolases A and C directly
destabilize Nefl mRNA (Canete-Soler et al., 2005; Canete-Soler et al., 2001). Our previous
studies have shown that the stability of NEFL is regulated by ALS-associated RNA-binding
proteins. Mutant copper/zinc superoxide dismutase (mtSOD1) and Rho Guanine Nucleotide
Exchange Factor (RGNEF; the human homologue of p190RhoGEF) mediate the
destabilization and TAR DNA binding protein 43 kDa (TDP-43) the stabilization of NEFL
mRNA (Droppelmann et al., 2013; Ge et al., 2005; Strong et al., 2007). In addition, fused in
sarcoma/translocated in liposarcoma (FUS/TLS), another ALS-associated protein, has been
shown to bind to murine Nefl, Nefm and Nefh transcripts (Lagier-Tourenne et al., 2012).
The most prominent mechanism of RNA mediated gene silencing involves the
interaction of miRNAs with their target mRNAs in which most, but not all, interactions
between the miRNA and MREs leads to a degradation of the mRNA. Previously, we and
others have observed a massive downregulation of miRNAs in ALS spinal cord (CamposMelo et al., 2014; Emde et al., 2015; Figueroa-Romero et al., 2016). We also showed that
three miRNAs that are dysregulated in ALS, miR-146a*, miR-524-5p and miR-582-3p,
regulate levels of NEFL mRNA (Campos-Melo et al., 2013). In this paper, we extended our
study to miRNAs responsible for NEFM and NEFH post-transcriptional regulation. We
created a list of miRNAs that are downregulated in ALS spinal cord and that also possess
MREs within NEFM and NEFH 3’UTRs. From the published literature, we observed that two
miRNAs of this group (miR-9 and miR-125b-5p) were confirmed to be reduced in ALS
spinal cord (Emde et al., 2015; Figueroa-Romero et al., 2016). We established that a small
group of ALS-linked miRNAs (miR-9-5p, miR-20b-5p, miR-92a-3p, miR-125b-5p and miR223-3p) directly downregulate human NEFM and NEFH mRNA levels, an effect that is
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translated into a reduction of NFM and NFH protein levels within spinal cord homogenates.
From this group of miRNAs that regulate NEFM and NEFH mRNA levels, only miR-9 has
been reported to have a role in neuronal function. More specifically, by regulating several
targets including OC1, FoxP1, MAP1B, and MCPIP1, miR-9 is critical for motor neuron
development, function and survival (Hawley et al., 2017).
As these group of miRNAs that regulate NEFM and NEFH are reduced in spinal cord
of ALS tissue, we predicted that the net effect would be an increase of NFM and NFH protein
levels in ALS-spinal cords. Several groups have shown that NFL, NFM and/or p-NFH levels
are increased in biological fluids of ALS patients (Feneberg et al., 2018; Ganesalingam et al.,
2013; Haggmark et al., 2014; Rosengren et al., 1996; Xu et al., 2016), but there are no reports
of NFs protein levels in spinal cord tissue. In this study we showed that both NFM and NFH
levels are increased in ventral lumbar spinal cord of ALS patients compared to controls. This
observation is in agreement with the increased in NEFM and NEFH transcripts in ALS
ventral lumbar spinal cord homogenates that we observed here using real-time PCR and
reported previously using RNase protection assay (Strong et al., 2004).
A selective reduction of NEFL steady-state mRNA levels in spinal motor neurons of
ALS patients has been well documented (Bergeron et al., 1994; Menzies et al., 2002; Wong
et al., 2000) a finding that we have proposed is due to alterations in the expression of NEFLlinked miRNAs (Campos-Melo et al., 2013). In concert with the observations of this study,
we hypothesize that in ALS spinal cords the sustained dysregulation in time of the expression
of groups of miRNAs that control NF levels fundamentally alters the expression of all three
NF transcripts in a manner that induces an alteration in the stoichiometry of the individual NF
proteins, favoring the formation of pathological NCIs.
While this hypothesis supports the critical role of the alteration of miRNA expression
in ALS, miRNAs alone are not the sole mediators of RNA stability. Indeed, understanding
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the fundamental relationship between alterations in RNA-binding proteins and how this
interacts with alterations in miRNAs expression will be critical to understanding the process
of perturbed RNA-mediated gene silencing which appears to lie at the core of a majority of
ALS cases.
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4.1 Abstract
Common pathological features of amyotrophic lateral sclerosis (ALS) include
cytoplasmic aggregation of several RNA-binding proteins. Out of these RNA-binding proteins,
TDP-43, FUS and RGNEF have been known to co-aggregate with one another within motor
neurons of sporadic ALS (sALS) patients suggesting there may be a common regulatory network
disrupted. MiRNAs have been a recent focus in ALS research, as they have been identified to be
globally downregulated in the spinal cord of ALS patients. The objective of this study was to
identify if there were miRNA(s) dysregulated in sALS that are responsible for regulating the
TDP-43, FUS and RGNEF network. In this study, we identify miR-194 and miR-b2122 to be
significantly downregulated in sALS patients, and were predicted to regulate TARDBP, FUS and
RGNEF expression. Reporter gene assays and RT-qPCR revealed that miR-b2122 downregulates
the reporter gene through direct interactions with either the TARDBP, FUS, or RGNEF 3’UTR,
while miR-194 downregulates firefly expression when it contained either the TARDBP or FUS
3’UTR. Further, we showed that miR-b2122 regulates endogenous expression of all three of
these genes in a neuron-derived cell line. Also, an ALS-associated mutation in the FUS 3’UTR
ablates the ability of miR-b2122 to regulate a reporter gene linked to the FUS 3’UTR, and sALS
samples which showed a downregulation in miR-b2122 also showed an increase in FUS protein
expression. Overall, we have identified a novel miRNA that is downregulated in sALS that
appears to be a central regulator of disease-related RNA-binding proteins, and thus, its
dysregulation likely contributes to TDP-43, FUS and RGNEF pathogenesis in sALS.
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4.2 Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive motor neurodegenerative disease
resulting in paralysis and death within 2-5 years after diagnosis (Taylor et al., 2016; Zarei et al.,
2015). 5-10% of ALS cases are familial (fALS), while the remaining are sporadic (sALS)
although ~10-12% of these latter cases also have a genetic basis (Al-Chalabi et al., 2017; Chen et
al., 2013; Taylor et al., 2016). While our understanding of ALS pathogenesis has advanced
significantly in recent years, this understanding, and in particular the relationship amongst the
individual genetic defects and the associated formation of pathological intraneuronal inclusions
which are a hallmark of the disease, remains in its early phases (Blokhuis et al., 2013; Keller et
al., 2012; Xiao et al., 2006).
Defects in mRNA metabolism have been suggested to be a major driver in the genesis of
pathological inclusions in ALS (Cestra et al., 2017; Droppelmann et al., 2014; Freibaum et al.,
2010; Hideyama et al., 2012; Tsuiji et al., 2013). Further, it has been shown that miRNAs,
essential regulators of mRNA expression and protein synthesis, are globally downregulated
within the spinal cord tissue of sALS patients (Campos-Melo et al., 2013; Figueroa-Romero et
al., 2016). This downregulation of miRNA expression has been shown to be motor neuron
specific (Emde et al., 2015), contributing to the concept that altered miRNA homeostasis is a
major contributor to the pathogenesis of ALS (Hawley et al., 2017; Rinchetti et al., 2017). The
finding of this global downregulation of miRNAs within sALS patients is intriguing, as TDP-43
and FUS, two proteins often found to be dysregulated in sALS, are known to be essential
components of miRNA biogenesis (Kawahara and Mieda-Sato, 2012; Morlando et al., 2012).
Further, ALS mutations within the FUS 3’ untranslated region (UTR) have been shown to
disrupt a negative feedback network between miR-141/200a and FUS, leading to an
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accumulation of FUS within the cell (Dini Modigliani et al., 2014; Sabatelli et al., 2013). This
suggests that there may be a disruption in the feedback networks between miRNAs and RNAbinding proteins in ALS, including TDP-43 and FUS.
Beyond TDP-43 and FUS, we have described RGNEF, another RNA-binding protein,
that forms pathological aggregates within sALS spinal motor neurons and has mutations
associated with ALS (Droppelmann et al., 2013a; Droppelmann et al., 2013b; Keller et al., 2012;
Ma et al., 2014). Interestingly, we observed that TDP-43, FUS and RGNEF co-aggregate with
each other within the motor neurons of sALS patients, suggesting a co-dysregulation of these
three RNA-binding proteins (Keller et al., 2012). While miRNA biogenesis has been clearly
shown to be affected in sALS, it is unclear the consequence of this mass downregulation, and
how it may contribute to TDP-43, FUS and RGNEF pathogenesis.
In the current study, we describe two miRNAs, miR-194 and miR-b2122, that are
predicted to regulate TDP-43, FUS and RGNEF. The novel miR-b2122 is expressed in human
spinal motor neurons, significantly downregulated in sALS patients, and regulates the expression
of all three of these RNA-binding proteins. Further, an ALS-associated mutation within the FUS
3’UTR located in the miRNA recognition element (MRE) of miR-b2122 disrupts its ability to
suppress gene expression. Overall, our results suggest that the downregulation of miR-b2122 in
sALS could result in altered levels of all three of these RNA-binding proteins, contributing to the
pathological state of TDP-43, FUS and RGNEF observed within motor neurons of sALS
patients.

4.3 Materials and Methods
4.3.1 Tissue samples

151

Spinal cord tissue was obtained from sALS patients and age-matched, neurologically
intact individuals (Table 4.1). All ALS cases were both clinically and neuropathologically
confirmed using the El Escorial Criteria (World Federation of Neurology Research Group on
Neuromuscular Disease, 1994). All research was approved by “The University of Western
Ontario Research Ethics Board for Health Sciences Research Involving Human Subjects
(HSREB)”. Written consent for autopsy was obtained from the next of kin at the time of death or
from the patient antemortem in accordance with the London Health Sciences Centre consent for
autopsy. Cases were genotyped and confirmed to have no known mutations in SOD1, TARDBP,
FUS, RGNEF or expanded repeats in C9orf72.
4.3.2 3’ RACE
Total RNA extraction was performed on SH-SY5Y cells and spinal cord tissue from
neurologically intact humans using TRIzol reagent (Life Technologies Inc., Ambion, Carlsbad,
CA, USA). This was followed by cDNA synthesis and PCR with the SMARTer 5’/3’ RACE Kit
(Takara Bio. Inc., Clontech, USA) to amplify the TARDBP, FUS and RGNEF 3’UTRs according
to the manufactures instructions using the following forward primers: TARDBP 5’-TAG ACA
GTG GGG TTG TGG TTG GTT GGT A-3’, FUS 5’- GCA GGG AGA GGC CGT ATT AAT
TAG CCT-3’ and RGNEF 5’-GCC CCG AGG TAA TGG AAC TTA ATC G-3’. 3’UTRs were
identified using a 1% agarose gel containing a SYBR Safe dye. 3’UTR bands were excised and
extracted from the agarose gel, and then individually cloned into a pGEMT-easy vector
according to manufactures instructions (Promega, Madison, WI, USA). All 3’UTRs were
confirmed using Sanger sequencing.

4.3.3 MiRNA selection
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Table 4.1. Patient demographics.
Cases

Gender

Control

ALS

Symptom
onset

Age of
death

Cause of Death

F
M
F
M
M
F
F
M

Age of
symptom
onset
-

-

62
74
68
68
75
53
74
67

Heart Attack
Stroke
Unknown
Brain Tumor
Unknown
Pneumonia
Leukemia
Unknown

F

58

60

Unknown

M

69

Unknown
Upper/lower
limbs

72

Unknown

F

40

Bulbar

41

Systemic Failure

M

55

Unknown

61

Pneumonia

M

64

F

69

M

63

Unknown

64

Unknown

F

47

Bulbar

49

Respiratory
Failure

Upper/lower
limbs
Respiratory
Symptoms

67
71

Respiratory
Failure
Respiratory
Failure
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MiRNAs predicted to target TARDBP, FUS and RGNEF 3’UTRs were selected using
miRanda software. Further, the sequence of the miRNA had to be perfectly complementary to
the miRNA recognition element (MRE) from +2 to +7. Novel miRNAs currently not found with
the miRanda program were manually checked to see if their seed sequence had an MRE within
the 3’UTR of TARDBP, FUS and RGNEF. We only considered those miRNAs for which we
identified MREs within the 3’UTR isoforms of TARDBP, FUS and RGNEF in the spinal cord
tissue.

4.3.4 Real-time PCR
Total miRNA extractions were performed on ventral lumbar spinal cord tissue using the
mirVana miRNA extraction kit according to manufactures instructions (Life Technologies Inc.,
Ambion, Carlsbad, CA, USA). Yield and purity of the miRNA extracts were measured using
spectrophotometry (Nanodrop, ThermoFisher Scientific, Burlington, ON, Canada), while
integrity was measured using Bioanalyzer (Aligent Technologies Canada Inc., Missasauga, ON,
Canada) analysis. MiRNA extracts were reversed transcribed and then subjected to real-time
PCR using miRCURY LNATM Universal RT microRNA PCR (Exiqon, Woburn, MA, USA) and
ExiLENT SYBR Green master mix (Exiqon, Woburn, MA, USA) kits, respectively, according to
manufacturer’s instructions. To detect novel miRNAs, miRNAs extracts went under reverse
transcription using the Taqman microRNA reverse transcriptase kit (Life Technologies Inc.,
Applied Biosystems, Forest City, CA, USA), and then were pre-amplified using the Taqman
PreAmp Master Mix Kit (Life Technologies Inc., Applied Biosystems, Forest City, CA, USA)
followed by real-time PCR with the TaqMan Universal PCR Master Mix (x2) no AmpErase
UNG (Life Technologies Inc., Applied Biosystems, Roche, Branchburg, NJ, USA). The 7900
HT Real Time PCR system was used to read PCR outputs. Relative expression of miRNAs was
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normalized to an internal control (miR-16-5p), followed by comparison of the relative expression
of candidate miRNAs between ALS cases and a control population using the 2-ΔΔCT method.
Negative values show downregulation and positive values upregulation of the expression.
Statistical significance was determined using Student’s t-test, and samples were considered
significantly different if p<0.05.

4.3.5 Fluorescent in situ hybridization (FISH)
Neuropathologically normal human lumbar spinal cord tissue was formalin-fixed,
paraffin-embedded and cut into 7µm sections. Samples were UV treated overnight prior to the
experiment to reduce lipofuscin-induced autofluorescent signaling. FISH of miRNAs was
performed as described before (de Planell-Saguer et al., 2010). Probes for miRNA detection were
designed with double DIG labels (Exiqon, Woburn, MA, USA), and were targeted by a DIGHRP secondary antibody (1:100; Roche, Indianapolis, IN, USA) and Tyramide Signal
Amplification tagged with a Cy3 fluorophore (PerkinElmer, Waltham, MA, USA). Olympus
FV1000 confocal microscope was used to observe miRNA expression within spinal motor
neurons.

4.3.6 Cell culture and plasmid construction
HEK293T and SH-SY5Y cells were cultured in Dulbecco’s Modified Eagle’s Media
(DMEM) containing 10% Fetal Bovine Serum (FBS). Cells were incubated at 37oC with 5%
CO2.
3’UTR isoforms of RNA-binding proteins identified in the human spinal cord tissue were
individually cloned into the pmirGLO vector in between SalI and NheI restriction enzyme sites
and downstream from the firefly luciferase gene (Promega, Madison, WI, USA). Site-directed
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mutagenesis assays were done by adding a two-nucleotide mutation within the +2 and +3
positions of each miR-194 or miR-b2122 MRE using the Site-Directed Mutagenesis Kit II
(Aligent Technologies Canada Inc., Missasauga, ON, Canada) according to the manufacturer’s
instructions. Mutations were carefully designed to ensure no changes to mRNA secondary
structure using RNAfold WebServer (http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi).

4.3.7 Luciferase assay
HEK293T cells were seeded into 96 well plates (9,000 cells per well) 24 hours prior to
transfection. Cells were co-transfected with 3.5 fmol of pmirGLO plasmid and 100 nM of
miRNA mimics according to the Lipofectamine 2000 protocol (Life Technologies Inc.,
Invitrogen, Burlington, ON, Canada). Luciferase activity was measured 24 hours posttransfection using the Dual-GLO Luciferase Assay System (Promega, Madison, WI, USA).
Firefly activity was normalized to renilla activity. Experimental design and normalization of data
was performed as previously described (Campos-Melo et al., 2014). Data was quantified as
relative difference from the control and expressed as mean ± SEM. Statistical significance was
determined by performing Student’s t-test, and was considered significantly different if p<0.05.

4.3.8 Relative quantitative RT-PCR
To determine the effects of miR-194 and miR-b2122 on the luciferase mRNA expression
when it contained the 3’UTR of TARDBP, FUS or RGNEF, HEK293T cells were seeded into 24
well plates (20,000 cells per well) 48 hours prior to transfection. Cells were co-transfected with
20.6 fmol of pmirGLO plasmid and 100 nM of miRNA mimics according to the Lipofectamine
2000 protocol (Life Technologies Inc., Invitrogen, Burlington, ON, Canada). 24 hours after
transfection, total RNA extraction was performed using TRIzol reagent (Life Technologies Inc.,
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Ambion, Carlsbad, CA, USA) followed by first-strand cDNA synthesis (Life Technologies Inc.,
Invitrogen, Burlington, ON, Canada) and PCR amplification of firefly and renilla cDNA as
previously described (Campos-Melo et al., 2013). Data was quantified as relative difference from
the control and expressed as mean ± SEM. Statistical significance was determined by performing
Student’s t-test and was considered significantly different if p<0.05.
To identify whether miR-194 and miR-b2122 could regulate the endogenous mRNA
expression of these three RNA-binding proteins within a neuronal-derived cell line, SH-SY5Y
cells were seeded into 6-well plates (500,000 cells per well) 24 hours prior to the transfection.
100 nM of miRNA mimics and anti-miRs were then either transfected individually or cotransfected. 24 hours after transfection total RNA extraction was performed using TRIzol reagent
(Life Technologies Inc., Ambion, Carlsbad, CA, USA) followed by cDNA synthesis (Life
Technologies Inc., Invitrogen, Burlington, ON, Canada). Quantitative PCR (qPCR) to determine
the relative change in endogenous mRNA expression of TARDBP, FUS and RGNEF was
performed using following primers: TARDBP for: 5’-CAG GGT GGG TTT GGT AAC GT-3’
rev: 5’-AAA GCC CCC ATT AAA ACC AC-3’; FUS for: 5’-TCG GGA CCA AGG ATC ACG
TC-3’ rev: 5’-ATC TGG TTT AGG GGC CTT ACA CTG-3’; RGNEF for: 5’-AGG AAC GCA
ATA ACT GGA TGA GAC G-3’ rev: 5’-TTC CAC CTT CTC CCC TGC ATC AG-3’; 18S
RNA for: 5’-AGT TGG TGG AGC GAT TTG TC-3’ rev: 5’-TTC CTC GTT CAT GGG GAA
TA-3’. All expression profiles were normalized to 18S RNA levels prior to comparison. Oneway ANOVA followed by a Tukey’s post-hoc was used to determine statistical differences in
endogenous mRNA expression, and samples were significantly different if p<0.05.

4.3.9 Western blot analysis
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SH-SY5Y cells were seeded into 6-well plates (500,000 cells per well) 24 hours prior to
the experiment. 100 nM of miRNA mimics and inhibitors were then either transfected
individually or co-transfected. 48 hours after transfection total protein extraction was performed
using NP40 lysis buffer containing proteinase inhibitors (cOmplete, Roche, Indianapolis, IN,
USA), followed by sonication. Samples were suspended in loading buffer and proteins were
denatured at 90oC for 5 minutes. Samples ran on a 12% SDS-gel and transferred to a
nitrocellulose membrane. To measure endogenous levels of TDP-43, FUS and RGNEF, the
membrane was probed with either anti-TDP-43 (1:2500; Proteintech, 10782-2-AP), anti-FUS
(1:3000; Proteintech, 11570-1-AP), or anti-RGNEF (1:1000; Abcam, ab157095) rabbit
antibodies, respectively. Blots were then probed with an HRP-secondary antibody (goat antirabbit; 1:5000; Life Technologies Inc., Invitrogen, Burlington, ON, Canada). Blots were stripped
using stripping buffer (2% SDS, 62.5 mM Tris-HCl, 100 mM β-mercaptoethanol, pH 6.8) and reprobed for GAPDH using anti-GAPDH rabbit antibody (1:2500; Abcam, ab9485). Relative
protein expression of TDP-43, FUS and RGNEF were normalized to GAPDH expression levels.
One-way ANOVA followed by a Tukey’s post-hoc was used to determine statistical differences
in endogenous protein expression, and samples were significantly different if p<0.05.
4.4 Results
4.4.1 A small group of miRNAs contain MREs within the mRNA 3’UTR of TARDBP, FUS,
and RGNEF.
Spinal cord tissue from neurologically intact individuals was used to determine the
3’UTR isoform(s) of TARDBP, FUS and RGNEF being expressed. TARDBP consistently
showed one 3’UTR isoform across all human samples with a length of 1398bp (BC095435.1)
(Fig. 4.1A) (Ayala et al., 2011). Subject two appeared to have a higher band, but we were unable
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to confirm a longer 3’UTR through sequencing, and for that reason, we focused only on the
transcript that was consistently expressed across all samples.
FUS contained one 3’UTR isoform within three different control cases, which was 150bp
in length (Fig. 4.1A) (NM_004960). While RGNEF appeared to have three 3’UTR isoforms in
each control case, we were only able to confirm the top and bottom bands through sequencing.
The two RGNEF 3’UTR isoforms that were confirmed had a length of 177bp and 981bp, which
we termed RGNEF-short and RGNEF-long, respectively (Fig. 4.1A). Both short and long
3’UTRs of RGNEF have been previously described (NM_001244364.1 and NM_0010804079.2,
respectively).
Subsequently, we identified 5 miRNAs which had MREs within the 3’UTR of all three of
these RNA-binding proteins. However, our previous work has indicated that miR-548d-3p was
not dysregulated in sALS cases, and thus was eliminated from further analysis. We also
previously observed that miR-194 is downregulated in sALS patients (Campos-Melo et al.,
2013), while miR-b2122, miR-sb659 and miR-548x have not been analyzed for dysregulation
within sALS patients (Fig. 4.1B and C). The latter four miRNAs were thus of interest for further
analysis.

4.4.2 MiR-194 and miR-b2122 are downregulated in the spinal cord tissue of sALS
patients.
We characterized the relative expression of miR-194, miR-548x, miR-sb659 and miRb2122 within the spinal cord tissue of sALS patients compared to control subjects. Using realtime PCR, we observed that miR-194 and miR-b2122 were significantly downregulated in sALS
patients (Fig. 4.2). The downregulation of miR-194 is consistent with what we reported
previously using TaqMan Array (Campos-Melo et al., 2013). Using FISH, we confirmed that
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both miR-194 and miR-b2122 were strongly expressed within human spinal motor neurons of
control samples with little to no non-motor neuronal expression, suggesting that the
downregulation of these two miRNAs is likely motor neuron specific (Fig. 4.3).
4.4.3 MiR-b2122 regulates a reporter linked to either TARDBP, FUS, or RGNEF 3’UTR.
A reporter gene assay was used to examine the effect of miR-194 and miR-b2122 on the
regulation of firefly luciferase protein when it contained the 3’UTR of either TARDBP, FUS, or
RGNEF that we identified within the human spinal cord. MiR-b2122 significantly reduced firefly
protein activity when it contained either the TARDBP, FUS, RGNEF-short, or RGNEF-long
3’UTR, whereas miR-194 downregulated firefly protein activity only when it contained either
the TARDBP or FUS 3’UTR, and had no effect when it contained the RGNEF-long 3’UTR (Fig.
4.4A). MiR-194 did not contain an MRE within the RGNEF-short 3’UTR and thus the
interaction between these two components was not examined. Further, to determine if miR-194
and miR-b2122 could also alter luciferase mRNA levels, we performed RT-PCR analysis. The
results in the RT-PCR analysis matched the downregulation seen by these two mRNAs in the
luciferase reporter gene assay, indicating that the effect of these miRNAs involves regulation of
the levels of mRNA species (Fig. 4.4B).
To study if miR-194 and miR-b2122 were regulating firefly luciferase by directly
interacting with the 3’UTR, we mutated two nucleotides within the MRE sites of miR-194 and
miR-b2122. Mutating the miR-b2122 MRE sites within either the TARDBP, FUS, RGNEF-short,
or RGNEF-long 3’UTR significantly abolished the ability of miR-b2122 to reduce firefly
luciferase activity. Similarly, mutating the miR-194 MRE sites within either TARDBP or FUS
ablated miR-194 downregulation of luciferase activity (Fig. 4.5). These findings indicate that
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Figure 4.1. A small group of miRNAs have MREs within the 3’UTRs of TARDBP, FUS,
and RGNEF. (A) 3’RACE PCR identified the 3’UTRs of TARDBP, FUS and RGNEF that are
expressed in the human spinal cord tissue within three different control samples. One isoform of
both TARDBP and FUS were identified with a length of 1,398 and 150 bases, respectively. Two
isoforms of RGNEF, which we have termed RGNEF-short (RGNEF-S) and RGNEF-long
(RGNEF-L) 3’UTRs, were identified in all three subjects running at 177 and 981 bases,
respectively. Bands in figures appear higher than actual 3’UTR size, as primers were designed
upstream from stop codon. (B) Five miRNAs were identified to have binding sites within the
TARDBP, FUS and RGNEF mRNA 3’UTRs. MiR-548d-3p in previous work has shown to have
no dysregulation in sALS, and thus, four miRNAs (outlined in the black box) went under further
study. (C) Schematic of all TARDBP, FUS and RGNEF 3’UTRs identified within human spinal
cord, and location of MREs for miRNA candidates.
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Figure 4.2. Differential expression of candidate miRNAs within the spinal cord of sALS
patients. Candidate miRNA expression was examined in ventral spinal cord tissue of sALS
patients (n=8) and control subjects (n=5). MiR-194 and miR-b2122 were significantly
downregulated in sALS patients, while miR-sb659 showed no difference and miR-548x was not
expressed in the spinal cord tissue. Data was expressed as log10 (fold-change) ± SEM, and
significance was determined using Students t-test (**=p<0.01, *p<0.05, NS=p>0.05).
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Figure 4.3. MiR-194 and miR-b2122 are expressed in human spinal motor neurons. Ventral
lumbar human spinal cord of control tissue (n=1) was analyzed using FISH to determine the
expression of miR-194 and miR-b2122 within motor neurons. Both miRNAs showed strong
positive staining within motor neurons. MiR-124 and miR-548c were used as positive and
negative controls, respectively. Scale bar represents 10µm.
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Figure 4.4. MiR-b2122 reduces firefly luciferase activity when it contains either the
TARDBP, FUS or RGNEF 3’UTR. HEK293T cells were transfected with a pmirGLO plasmid
containing the 3’UTR of one of the RNA-binding proteins of interest either with or without miR194 or miR-b2122. PmirGLO plasmid without any 3’UTRs were also transfected with or without
miRNAs of interest to determine the miRNAs effect on the plasmid itself. (A) Reporter gene
assay revealed miR-b2122 reduced firefly activity when it contained either the TARDBP, FUS,
or RGNEF-short/long 3’UTR, whereas miR-194 downregulated firefly levels when it contained
either TARDBP, FUS, but not RGNEF-long. MiR-194 has no MRE in RGNEF-short, and thus,
the interaction between the two was not examined. (B) RT-qPCR results showed similar
suppression of mRNA levels as observed in the reporter gene assay. Let-7a was used as a
negative control for these experiments. Firefly was normalized to renilla luciferase, and then
further normalized to account for the effect of each miRNA on the pmirGLO vector to determine
the exact effect that each miRNA has on each 3’UTR. Each miRNA was compared to its own
individual control based on the normalization of the data. Data is expressed as sample mean
(n=3) ± SEM, and significance was determined using a Student’s t-test (***=p<0.001,
**=p<0.01, *=p<0.05, NS=p>0.05).
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Figure 4.5. MiR-b2122 and miR-194 directly interact with their 3’UTR targets. HEK293T
cells were co-transfected with either the pmirGLO plasmid containing the wild-type 3’UTR, or
the 3’UTR mutant, and either with or without the miRNA of interest. Mutations within the MRE
of miR-b2122 in the TARDBP, FUS, and RGNEF 3’UTRs, and the MRE of miR-194 in the
TARDBP and FUS 3’UTRs abolished each miRNAs ability to reduce firefly activity. Firefly was
normalized to renilla, and then further normalized to the effect of each miRNA on the pmirGLO
vector to determine the miRNAs exact effect on the 3’UTR. Data is expressed as sample mean
(n=3) ± SEM, and significance was determined using a student’s t-test (***=p<0.001,
**=p<0.01, *=p<0.05).
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both miR-194 and miR-b2122 directly interact with their 3’UTR targets to regulate gene
expression.

4.4.4 MiR-b2122 regulates endogenous TDP-43, FUS and RGNEF within a human
neuronal cell line.
Next, we decided to determine if miR-b2122 and miR-194 regulate the endogenous
mRNA expression of TARDBP, FUS and RGNEF within a human neuronal-derived cell line –
SH-SY5Y cells. SH-SY5Y cells express the TARDBP, FUS and RGNEF 3’UTR isoforms we
identified with in the spinal cord. SH-SY5Y cells showed multiple bands in the TARDBP lane,
but we were not able to confirm the top two bands through sequencing, only the 1398 b 3’UTR
isoform identified in spinal cord, which also appears to be dominantly expressed in SH-SY5Y
cells (Fig. 4.6A). Also, endogenous expression of miR-b2122 and miR-194 in SH-SY5Y cells
was confirmed through real-time PCR (Fig. 4.6B).
Transfection of miR-b2122 lead to a significant downregulation in TARBDP, FUS and
RGNEF mRNA levels. Further, co-transfection of miR-b2122 with its anti-miR abrogates the
downregulation of these transcripts via miR-b2122. Transfection of the anti-miR of miR-b2122
alone lead to an upregulation in mRNA levels of all three genes (Fig. 4.7A). The upregulation
observed with the addition of the anti-miR, suggests that miR-b2122 does regulate these RNAbinding proteins endogenously within this neuronal cell line. Let-7a was used as negative
control, as we showed it has no effect on the endogenous mRNA levels of these three genes (Fig.
4.8).
Further, we also transfected miR-194 and/or its anti-miR into SH-SY5Y cells. Similar to
the reporter gene assays, miR-194 only reduced TARDBP and FUS endogenous mRNA levels
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with no effect on RGNEF mRNA levels, which was abolished when co-transfecting miR-194
with its anti-miR (Fig. 4.7B). Also, only adding the anti-miR of miR-194 caused a strong trend
towards upregulation of TARDBP mRNA expression, but no change in the FUS transcript levels,
suggesting miR-194 might play a role in regulating TARDBP gene expression within SH-SY5Y
cells. Overall, these results suggest that miR-b2122 is the central regulator of TARDBP, FUS and
RGNEF mRNA expression.
To determine whether the alteration in mRNA levels was associated with alterations in
protein expression, we examined protein levels of TDP-43, FUS and RGNEF post-transfection of
miR-b2122 (Fig. 4.9A). MiR-b2122 alone had no significant effect on the protein levels of TDP43 within the cell, but when the anti-miR alone was added, there was a strong trend towards
upregulation of TDP-43. This upregulation was significantly different from when miR-b2122
was transfected alone, suggesting that endogenous miR-b2122 is likely participating keeping
TDP-43 protein at steady-state levels, but loss of this miRNA leads to an increase in TDP-43
protein output (Fig. 4.9B). Transfection of miR-b2122 alone showed a strong trend towards the
downregulation in FUS protein levels, which was abrogated when the anti-miR was cotransfected with miR-b2122. The transfection of the anti-miR of miR-b2122 alone did lead to a
significant upregulation of FUS protein levels, indicating miR-b2122 regulates protein synthesis
of FUS endogenously (Fig. 4.9B).
Interestingly, miR-b2122 had the reverse effect on the protein levels of RGNEF as
compared to the changes observed at the mRNA level (Fig. 4.9B). Transfection of miR-b2122
alone lead to increased RGNEF protein levels, which was reduced to the control levels when
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Figure 4.6. 3’UTR isoforms of RNA-binding proteins, and miR-194 and miR-b2122 are
expressed in SH-SY5Y cells. (A) 3’RACE PCR showing TARDBP, FUS and RGNEF 3’UTR
isoforms expressed in SH-SY5Y cells. FUS and RGNEF isoforms match those expressed in
human spinal cord. TARDBP showed multiple isoforms, but only the 1398bp isoform identified
in spinal cord could be confirmed by sequencing. (B) Real-time PCR indicating the expression of
miR-194 and miR-b2122 in SH-SY5Y cells (n=3).
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Figure 4.7. MiR-b2122 regulates mRNA expression of TARDBP, FUS and RGNEF in a
human-derived neuronal cell line. SH-SY5Y cells were transfected individually with miR-194
or miR-b2122, or co-transfected with miR-194 or miR-b2122, and their anti-miRs. Transfection
of let-7a was used as a negative control. (A) Transfection of miR-b2122 significantly
downregulates the mRNA levels of TARDBP, FUS and RGNEF, while co-transfection of miRb2122 with its anti-miR led to a recovery in the mRNA levels. Transfection of the anti-miR
alone led to increased mRNA expression of all three RNA-binding proteins (B) Transfection of
miR-194 alone resulted in reduction of TARDBP and FUS, which was abolished when it was cotransfected with its anti-miR. No effect was observed on RGNEF when miR-194 and/or its antimiR were transfected. Data was expressed as the mean (n=3) ± SEM, and significance was
determined using a one-way ANOVA followed by a Tukey’s post-hoc.
(***=p<0.001, **=p<0.01 *=p<0.05).

176

177

Figure 4.8. Let-7a has no effect on mRNA levels of TARDBP, FUS, or RGNEF within SHSY5Y cells. Let-7a was transfected into SH-SY5Y cells to determine if it changed the basal
mRNA levels of TARDBP, FUS or RGNEF, and was compared to a non-transfected control. The
data indicated no significant change in the transcript levels of either TARDBP (p=0.64), FUS
(p=0.51), or RGNEF (p=0.74) between the two conditions. Data is expressed as sample mean
(n=3) ± SEM, and significance was determined using a Student’s t-test.
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Figure 4.9. MiR-b2122 alters protein levels of TDP-43, FUS and RGNEF within a humanderived neuronal cell line. Changes in protein levels of TDP-43, FUS and RGNEF were studied
when SH-SY5Y cells were transfected with either miR-b2122, miR-b2122 plus its anti-miR, or
the anti-miR alone. Transfection of let-7a was used as a negative control. (A) Western blot
showing expression of TDP-43, FUS, RGNEF, and GAPDH (B) Quantification of Western blots
for TDP-43, FUS and RGNEF protein levels. TDP-43 and FUS show small reductions in protein
levels when transfected with miR-b2122 alone, while their protein levels increased when the
anti-miR is added. Differences in protein levels when miR-b2122 or the anti-miR are added
alone are significantly different for both TDP-43 and FUS. RGNEF has increased and decreased
protein levels when either miR-b2122 or its anti-miR are added alone, respectively, and these
differences are significantly different from one another. Protein levels were normalized to
GAPDH. Data was expressed as the mean (n=3) ± SEM, and significance was determined using
a one-way ANOVA followed by a Tukey’s post-hoc (**=p<0.01, *=p<0.05).
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miR-b2122 was co-transfected with its anti-miR. Transfection of the anti-miR alone led to
reduced levels of RGNEF compared with let-7a. While these results were not significantly
different from the negative control, there was a significant difference in RGNEF protein levels
between when either miR-b2122 or the anti-miR were transfected alone. All data was compared
to let-7a (negative control), as we showed it, has no effect on the protein levels of these three
genes (Fig. 4.10). Overall, these results indicate that miR-b2122 can regulate FUS protein
expression, while having minor changes on TDP-43 and RGNEF protein levels.
4.4.5 An ALS-associated mutation in FUS 3’UTR is located in miR-b2122 MRE.
Previously, mutations within the FUS 3’UTR were found within ALS patients, all of
which lead to the overexpression and increased cytoplasmic mislocalization of FUS protein
(Sabatelli et al., 2013). Interestingly, one of these mutations (*c.108C>T) is located in the +2
position of the MRE for miR-b2122 (Fig. 4.11A), suggesting this would critically affect the
ability of miR-b2122 to bind and reduce FUS expression. We sought to investigate whether this
mutation would affect the ability to regulate firefly expression when the firefly gene was linked
to the FUS 3’UTR that contained the *c.108C>T mutation. Indeed, this mutation significantly
abolished the ability for miR-b2122 to reduce the firefly expression, compared to when the
firefly gene contained the wild-type FUS 3’UTR (Fig. 4.11B). This result implies that FUS
would be overexpressed without proper regulation of miR-b2122 via direct interaction with the
3’UTR.
Based on the previous result, we decided to examine if sALS cases that showed a
downregulation in miR-b2122 would have an increase in FUS expression. In sALS cases that
showed a downregulation of miR-b2122 there was a 3-fold increase in FUS protein expression
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(Fig. 4.11C and D), suggesting a relationship between reduced levels of miR-b2122 and increase
FUS expression.
4.5 Discussion
In this study, we identified miR-b2122 to be a central regulator of ALS-linked RNAbinding proteins TDP-43, FUS and RGNEF. We showed that miR-b2122 was significantly
downregulated within the spinal cord tissue of sALS patients, and specifically expressed within
motor neurons. MiR-194, which was also found be downregulated in sALS patients, regulates
the mRNA expression of TARDBP and FUS, but not RGNEF. Together, our data introduces a
novel miRNA (miR-b2122) to sALS pathology and indicates that the downregulation of this
miRNA in sALS could affect a regulatory network of RNA-binding proteins within motor
neurons, contributing to the disease pathology.
The 3’UTRs for TARDBP, FUS, and RGNEF identified in spinal cord match those that
have been previously described; however, for TARDBP we were only able to describe one
3’UTR isoform, while previous authors have described multiple. The TARDBP 3’UTR isoform
we described matches the pA1 transcript isoform (Ayala et al., 2011). Whether this is the only
isoform expressed in spinal cord, or a limitation of our technique, the pA1 isoform is known to
be the dominant transcript expressed in steady-state conditions, and has been shown to be the
main isoform for TDP-43 protein synthesis (Avendano-Vazquez et al., 2012; Bembich et al.,
2014; Koyama et al., 2016). Further, it has been hypothesized that the pA1 isoform is the one
overexpressed in ALS (Koyama et al., 2016), providing another reason why we decided to focus
on the pA1 isoform and its interactions with miR-194 and miR-b2122. MiR-194 is a well-known
tumor suppressor, and reduced levels of miR-194 has been linked to both cancer and diabetes
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Figure 4.10. Let-7a has no effect on protein levels of TDP-43, FUS, or RGNEF within SHSY5Y cells. Let-7a was transfected into SH-SY5Y cells to determine if it changed the basal
protein levels of TDP-43, FUS or RGNEF, and was compared to a non-transfected control. The
data indicated no significant change in the protein levels of either TDP-43 (p=0.71), FUS
(p=0.28), or RGNEF (p=0.87) between the two conditions. Data is expressed as sample mean
(n=3) ± SEM, and significance was determined using a Student’s t-test.
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Figure 4.11. ALS-associated mutation within FUS 3’UTR inhibits the ability for miR-b2122
to reduce firefly activity. HEK293T cells were co-transfected with either the pmirGLO plasmid
containing the wild-type FUS 3’UTR, or the mutated form, and either with or without miRb2122. (A) ALS-associated mutation (*c.108 C>T) affects the +2 binding site of the miR-b2122
MRE. (B) ALS-associated mutation within the FUS 3’UTR inhibits miR-b2122 from reducing
firefly activity. Firefly expression was normalized to renilla expression, and then further
normalized to account for the effect miR-b2122 on the pmirGLO vector itself to determine the
miRNAs exact effect on the 3’UTR (n=3). (C) Western blot of FUS protein expression in the
spinal cord of 7 sALS cases versus 5 control subjects. (D) Quantification of western blot. Data is
expressed as sample mean ± SEM, and significance was determined using a Student’s t-test
(**=p<0.01; *=p<0.05).
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(Bao et al., 2015; Dong et al., 2011; Latouche et al., 2016; Song et al., 2012; Zhang et al., 2016;
Zhou et al., 2016). Interestingly, the dysfunctional pathways identified within both of these
diseases relate to those described in ALS (Bao et al., 2015; Latouche et al., 2016). For example,
miR-194 expression has been shown to be switched off by NF-kB - a proinflammatory
transcription factor that has been associated with ALS progression via increase activation in
astrocytes and microglia (Bao et al., 2015; Frakes et al., 2014; Swarup et al., 2011). Further,
overexpression of TDP-43 has been related to an increase in NF-kB activation (Swarup et al.,
2011). In this study, reduction of miR-194 leads to increased levels of TARDBP mRNA, and
thus, through its regulation of TDP-43, miR-194 may be part of an inflammatory regulatory
network that contributes to ALS progression.
Since miR-b2122 was a novel miRNA identified by our group previously [Ishtiaq et al.,
2014], this is the first pathway in which this miRNA has been implicated. Our data would
suggest that the downregulation of miR-b2122 would lead to a significant increase in TARDBP,
FUS and RGNEF mRNA levels in sALS patients. This is consistent with the increase of
TARDBP mRNA and protein levels observed in sALS patients (Swarup et al., 2011). Further,
rodent models overexpressing wild-type human FUS and TDP-43 do develop age-related motor
deficiencies and cytoplasmic protein aggregation in motor neurons similar to that seen in ALS
cases (Janssens et al., 2013; Mitchell et al., 2013; Wils et al., 2010; Xu et al., 2010). However,
the latter models look at the overexpression of a single gene, when it is the dysregulation of both
expression and localization of multiple RNA-binding proteins which contributes to the disease
progression. This makes miR-b2122 an intriguing miRNA, as its downregulation in sALS would
contribute to the overexpression and dysregulation of multiple RNA-binding proteins involved in
the pathogenesis of ALS.
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While TDP-43, FUS and RGNEF protein levels showed discrete changes when compared
to the negative control, there were significant changes between when miR-b2122 and its antimiR were transfected alone, suggesting that either overexpression, or reduced activity of miRb2122, does in fact alter protein levels. These noticeable changes to the TDP-43, FUS and
RGNEF protein levels when miR-b2122 levels are increased or decreased, suggests that chronic
changes to miR-b2122 activity might have more drastic effects on protein levels within the cell
over-time.
Interestingly, RGNEF protein levels went in the opposite direction of the mRNA levels
within our study. While rare to see inverse correlations between mRNA and protein levels of a
single gene, it is not unprecedented (Marinova et al., 2015; Xiu et al., 2014). This could imply
that when miR-b2122 binds to the RGNEF 3’UTR, its role is to maintain low levels of mRNA
while keeping the transcript in a translationally stable state, and thus, loss of its binding stabilizes
the mRNA molecule, but leaves the transcript in a translationally silent state. The latter
phenomenon is a common one seen within stress and transport granules within neurons
(Anderson and Kedersha, 2008; Buchan, 2014; Panas et al., 2016). However, this would suggest
that there is competition between miR-b2122 and another miRNA, or RNA-binding protein at
the RGNEF 3’UTR which would need further investigation.
We sought to determine whether an ALS mutation located in the MRE of miR-b2122
within the FUS 3’UTR affected the ability of miR-b2122 to reduce gene expression. Clinically,
the patient identified with this FUS 3’UTR mutation (*c.108C>T) had limb onset ALS with
severe limb weakness and respiratory difficulties. Previously, fibroblast cells cultured from the
ALS patient with this mutation showed an overexpression of FUS mRNA and protein and an
increase in cytoplasmic localization – two factors believed to contribute to ALS development
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(Sabatelli et al., 2013). Despite identifying these phenotypes there was no clear mechanism to
why this may happen. In this study, we showed that loss of direct interaction between miRb2122 and the FUS 3’UTR may play a critical role in FUS overexpression. Further, we were able
to show that reduce levels of miR-b2122 in sALS spinal cord seems to be related to an increase
in FUS protein expression. In addition, reduction of the levels of miR-b2122 in a neuronal cell
line (SH-SY5Y) using anti-b2122 hindered the ability for miR-b2122 to reduce endogenous FUS
leading to an overall increase in both mRNA and protein levels.
In this study, we have not only provided an explanation of the significance for reduced
levels of miR-b2122 in sALS, but provide a molecular link showing the importance of the
interaction between miR-b2122 and the FUS 3’UTR. Thus, dysregulation of miR-b2122 either
through reduce levels or mutations within the MRE could be a major contributing factor to FUS
dysregulation and pathogenesis in ALS. In a different study, a group examined another ALSrelated mutation within the FUS 3’UTR, which lead to an overexpression of FUS. This aberrant
expression of FUS was attributed to the loss of its interaction with miR-141/200a due to the
3’UTR mutation (Dini Modigliani et al., 2014). These findings emphasize the importance of
examining mutations outside of the coding regions, as alterations within the 3’UTR can have
drastic effects on both protein expression and localization (Berkovits and Mayr, 2015; Mayr,
2016).
While it is interesting to note the relationship between the dysregulation of RNA-binding
proteins and miRNAs, it is still unclear how miRNAs, like miR-b2122 and miR-194, become
reduced in sALS. However, there is strong evidence suggesting that the miRNA biogenesis
pathway is disrupted in sALS, as both TDP-43 and FUS are crucial parts of miRNA production
(Kawahara and Mieda-Sato, 2012; Morlando et al., 2012). More specifically, it appears that the
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dysregulation in miRNA biogenesis happens at the level of DICER, as it is the mature miRNA
form and not the pre-miRNA form showing a global downregulation in sALS (Emde et al.,
2015). Also, ALS-linked mutations in TDP-43 and FUS affects miRNA biogenesis specifically
at the level DICER (Emde et al., 2015). Thus, it is plausible that TDP-43 and/or FUS could
regulate the biogenesis of miR-b2122 and miR-194, suggesting a negative feedback loop
between RNA-binding proteins and miRNAs exists and it is the loss of this negative feedback
loop that drives, at least in part, sALS disease progression.
It has been previously shown that the pathogenesis of sALS patients likely does not rely
on the dysregulation of a single RNA-binding protein, but a combination of TDP-43, FUS and
RGNEF, as they co-aggregate with each other in motor neurons of sALS patients (Keller et al.,
2012). In the current study, we have identified a single miRNA that regulates all three of these
RNA-binding proteins. The observation that miR-b2122 is downregulated in sALS suggests that
this miRNA may play an essential role in the pathogenic mechanism of sALS. As we further
look at those miRNAs related to ALS, we start developing an understanding of a miRNA
network critical for motor neuron function which we have previously termed MotomiRs (Hawley
et al., 2017). Further, it would be intriguing to know whether these miRNAs play a role in
closely related neurodegenerative diseases, including primary lateral sclerosis (PLS), spinal
muscular atrophy (SMA), or frontotemporal dementia (FTD). Based on the current study, miRb2122 should be added to the already established list of MotomiRs, as it regulates a network of
RNA-binding proteins essential for motor neuron function, and its regulation could potentially
contribute to motor neuron degeneration in ALS.
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5.1 Abstract
TAR DNA-binding protein 43 (TDP-43) and Fused in sarcoma (FUS) are DNA/RNAbinding proteins that are integral to RNA processing. Among these functions, both play a critical
role in microRNA (miRNA) biogenesis through interactions with either the DROSHA and/or
DICER complexes. It has been previously shown that there is a global reduction in miRNA
levels within the spinal cord and spinal motor neurons of amyotrophic lateral sclerosis (ALS)
patients. The most common pathological feature of TDP-43 and FUS in ALS is a re-distribution
from the nucleus to the cytoplasm in motor neurons where they form cytoplasmic inclusions.
Among miRNAs dysregulated in ALS, several are known to regulate TDP-43 and FUS
expression. In this study, we demonstrate that TDP-43 is in a regulatory negative feedback
network with two miRNAs—miR-27b-3p and miR-181c-5p—that is dependent on its nuclear
localization within HEK293T cells; however, we are unable to show FUS is in an similar
network with the miRNAs it regulates. Further, we show that cellular stress which induces a
redistribution of TDP-43 from the nucleus to the cytoplasm correlates with the reduced
production of miR-27b-3p and miR-181c-5p. This suggests that reduced nuclear TDP-43 disrupts
a negative feedback network between itself and miRNAs. These findings provide a further
understanding of altered miRNA biogenesis as a key pathogenic process in ALS.
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5.2 Introduction
TAR DNA-binding protein 43 (TDP-43) and Fused in Sarcoma (FUS) are primarily
nuclear DNA/RNA-binding proteins that are ubiquitously expressed in every cell, and both share
a diverse set of functions which include: mRNA transcription, mRNA splicing, mRNA transport,
microRNA (miRNA) and long non-coding RNA (lncRNA) processing, mRNA translation, and
stress granule formation (Ratti and Buratti, 2016; Svetoni et al., 2016). Several of these functions
have been identified as dysregulated within motor neurons of patients with amyotrophic lateral
sclerosis (ALS) where both TDP-43 and FUS have been shown to re-locate from the nucleus to
the cytoplasm resulting in the subsequent formation of pathological aggregates. In particular,
TDP-43 pathology occurs in 97% of all ALS cases, while FUS pathology is only observed in 1%
of cases (Campos-Melo et al., 2013; Fratta et al., 2018; Ling et al., 2013; Weskamp and
Barmada, 2018).
Cellular stress can induce the re-localization of TDP-43 and FUS from the nucleus to the
cytoplasm, where they can partition into stress granule structures (Baradaran-Heravi et al., 2020;
Khalfallah et al., 2018; McDonald et al., 2011; Moisse et al., 2009). Accumulation of proteins
with low-complexity domains (LCD’s), like TDP-43 and FUS, have been shown to phase
separate into liquid droplets. However, if left to accumulate, LCD-containing proteins can form
irreversible insoluble fibrils which is believed to cause the pathology of these proteins in ALS
motor neurons (Kato et al., 2012; Molliex et al., 2015; Murakami et al., 2015). Evidence that
stress granules may act as a seed for pathological cytoplasmic aggregates in ALS is that TIA-1—
an essential stress granule component—co-localizes with TDP-43 aggregates in ALS motor
neurons (Liu-Yesucevitz et al., 2010; Volkening et al., 2009). Further, increased mRNA and
protein levels of TDP-43 have been observed within both the spinal cord and motor neurons of
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patients with ALS (Koyama et al., 2016; Swarup et al., 2011), suggesting that TDP-43 levels are
being aberrantly regulated which may contribute to its accumulation into cytoplasmic aggregates.
Further, overexpression of FUS in in vitro or in vivo models is associated with cytoplasmic
inclusion formation similar to what is observed in ALS motor neurons (Mitchell et al., 2013;
Patel et al., 2015). Interestingly, both TDP-43 and FUS have been observed to co-aggregate with
each other in ALS motor neurons (Keller et al., 2012).
Our lab, and others, have shown that a large pool of miRNAs—small RNA molecules
(20-22 nucleotides) that are generally responsible for post-transcriptional gene suppression
(Bartel, 2018)—have reduced levels within ALS spinal cord and motor neurons (Campos-Melo
et al., 2013; Emde et al., 2015). Further, we have shown that ALS-linked miRNAs suppress
TDP-43 and FUS expression suggesting that loss of miRNA function could result in increased
levels of TDP-43 and FUS in ALS motor neurons (Hawley et al., 2017). Given the observation
that TDP-43 and FUS are involved in the miRNA biogenesis pathway through interactions with
either DROSHA and/or DICER complexes (Kawahara and Mieda-Sato, 2012; Morlando et al.,
2012), we postulated that TDP-43 and FUS regulates the production of miRNAs that in turn will
suppress their expression. We further hypothesize that TDP-43 and FUS are in a negative
feedback loop with a specific group of miRNAs and that this function is dependent on their
nuclear localization. FUS has been shown to be in a negative feedback loop with ALS-linked
miRNAs (miR-141/200a) previously (Dini Modigliani et al., 2014), and therefore, we sought to
determine whether there are other miRNAs involved with this negative feedback loop.
In this chapter, we explore the negative feedback network between TDP-43 and two
ALS-related miRNAs, miR-27b-3p and miR-181c-5p, in HEK293T cells, and we show that this
regulation is dependent on TDP-43 nuclear localization. Further, we show that TDP-43 regulates
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the processing of these two miRNAs at different levels within the miRNA biogenesis pathway.
In contrast, while we were able to determine two miRNAs (miR-2110 and miR-6804-5p) with
MREs in the FUS 3’UTR whose expression was promoted by FUS, we were unable to show
these miRNAs were in a negative feedback loop.
5.3 Methods and Materials
5.3.1 Plasmid Constructs
SiRNA resistant plasmids (siRES) were either pC32-FLAG-TDP-43 wild-type or pC32FLAG-TDP-43 ∆NLS and were resistant to an siRNA that targets endogenous TARDBP (siTDP
#2) (Deshaies et al., 2018).
TARDBP and FUS 3’UTRs that are expressed in human spinal cord were linked to the
firefly luciferase gene within the pmirGLO plasmid (Promega Cat. # E1330) as described
previously (Hawley et al., 2017). Mutations were put into the +2 and +3 position of the miRNA
recognition element (MRE) of either miR-27b-3p or miR-181c-5p of the TARDBP 3’UTR using
the QuikChange Site-Directed Mutagenesis Kit (Agilent Cat. # 210219). Cloned sequences and
mutants were confirmed using Sanger sequencing.
5.3.2 Cell culture and transfection
HEK293T cells were maintained in Dulbecco’s Modified Eagles Media (DMEM; Gibco
Cat. # 11965084) which contained 10% fetal bovine serum (FBS) at 37oC with 5% CO2. Sorbitol
was added to cell media at a concentration of 400 mM to induce an osmotic stress. Media with
sorbitol was then added to HEK293T cells with an 80% confluency. The osmotic stress was
maintained for five hours prior to experimentation.
HEK293T cells were seeded into a 6-well plate (150,000 cells/well) and incubated for 48
hours. Cells were then either transfected with 100 nM of SCR (Sigma-Aldrich Cat. # SIC001) or
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a custom siRNA targeting endogenous TARDBP (siTDP #2; Dharmacon) but not exogenous
TARDBP cloned into siRNA resistant (siRES) plasmids as previously described (Deshaies et al.,
2018). 24 hours post-transfection of siTDP #2, cells were transfected again with 2.5μg of either
pcDNA 3.1 (negative control), pC32-FLAG-TDP-43 wild-type or pC32-FLAG-TDP-43 ∆NLS
siRES plasmids. Mature miRNA levels were examined 24 hours post-transfection of plasmids.
Transfections were done using the Lipofectamine 2000 Reagent (Invitrogen Cat. # 11668019)
protocol following the manufacturer’s instructions.

5.3.3 Microarray analysis
HEK293T cells were seeded into a 6-well plate (150,000 cells/well) and incubated for 48
hours. Cells were either transfected with an 100nM of siRNA SMARTpool targeting TARDBP
(siTDP #1; Dharmacon Cat. # L-012394-00-0005), siRNA SMARTpool targeting FUS (siFUS;
Dharmacon Cat. # L-009497-00-0005), or a scramble negative control (SCR; Sigma-Aldrich Cat.
# SIC001) at a 60% confluency using the Lipofectamine 2000 Reagent (Invitrogen Cat. #
11668019) protocol. Total RNA extraction was then performed 48 hours post-transfection using
the RNeasy Mini Kit (Qiagen Cat. # 74106). RNA samples were tested for integrity using
bioanalyzer analysis. Total RNA extracts were sent to the Center of Applied Genomics – TCAG
Facilities at the University of Toronto for microarray analysis using the GeneChip miRNA 4.0
Array (Applied Biosystems Cat. # 902412). Quality control and experimental data from the
microarray was analyzed using the Transcriptome Analysis Console Software (ThermoFisher
Scientific).

5.3.4 Real-time PCR
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Samples from HEK293T cells underwent a small RNA extraction using the mirVana
miRNA Isolation Kit (Invitrogen Cat. # AM1560) to obtain RNA molecules <200nts which
allowed us to separate pri-miRNAs (>200nts) from pre-miRNAs (<200nts). Yield and purity of
small RNAs was determined using spectrophotometry. When measuring mature miRNA levels,
small RNA extracts went under cDNA synthesis using the TaqMan Advanced cDNA Synthesis
Kit (Applied Biosystems Cat. # A28007), but when measuring the levels of pre-miRNAs, small
RNA extracts went under cDNA synthesis using the SuperScript IV VILO Master Mix with
DNease Enzyme (Invitrogen Cat. # 11766050) protocol. All cDNA synthesis protocols were
done according to the manufacturers’ instructions. Real-time PCR for mature miRNAs and premiRNAs was done either using the TaqMan Advanced miRNA Assay (Applied Biosystems Cat.
# A25576) or the TaqMan Pre-miRNA Assay (Applied Biosystems Cat. # 4331182),
respectively, and the Fast TaqMan Advanced Master Mix (Applied Biosystems Cat. # 4444965)
in accordance to the manufactures protocol. Since microarray was normalized to an exogenous
control, confirmation of changes to miRNA levels was done using an endogenous control (miR1296-5p) which showed no change in expression following TDP-43 knockdown. Candidate
miRNA expression for the rest of the experiments was normalized to an RNA spike-in (cel-miR39b-5p). All real-time PCR data was quantified according to the 2^-∆∆CT method.

5.3.5 Reverse transcriptase relative quantitative PCR (RT-qPCR)
HEK293T cells were either transfected with a SCR (Sigma-Aldrich Cat. # SIC001), miR27b-3p, miR-181c-5p, miR-2110 or miR-6804-5p human miRNA mimics (Invitrogen Cat. #
4464066) to measure changes to either endogenous TARDBP or FUS mRNA levels, or cells were
transfected with either SCR (Sigma-Aldrich Cat. # SIC001) or siTDP #1 (Dharmacon Cat. # L012394-00-0005) to measure changes in pri-miRNA levels using the Lipofectamine 2000
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Reagent (Invitrogen Cat. # 11668019) protocol. Total RNA extraction using the RNeasy Mini
Kit (Qiagen Cat. # 74106) was performed 48 hours post-transfection. Yield and purity of RNA
was determined using spectrophotometry. RNA extracts went under cDNA synthesis using the
SuperScript II Reverse Transcriptase (Invitrogen Cat. # 18064014) in accordance with the
manufactures instructions which was followed by quantitative PCR using the Platinum Taq DNA
Polymerase (Invitrogen Cat. # 10966018) protocol for amplification via primers outlined in
Table 5.1. Expression levels were normalized to 18S rRNA levels prior to comparison.

5.3.6 Luciferase assay
HEK293T cells were co-transfected with either SCR (Sigma-Aldrich Cat. # SIC001), or
human miRNA mimics (miR-27b-3p or miR-181c-5p; Invitrogen Cat. # 4464066) and either an
empty pmirGLO plasmid or a pmirGLO plasmid containing the 3’UTR of TARDBP using the
Lipofectamine 2000 Reagent (Invitrogen Cat. # 11668019) protocol. Luciferase activity was
measured 24 hours post-transfection using the Dual-GLO Luciferase Assay System (Promega
Cat. # E2920). Firefly luciferase levels were normalized to renilla luciferase levels, and data was
further normalized to account for the effect the miRNAs have on the plasmid itself prior to
comparison as previously described (Campos-Melo et al., 2014).

5.3.7 Western blot
All protein extractions were done from HEK293T cells using the NP40 lysis buffer with
proteinase inhibitors followed by sonication. Protein lysates were resuspended in loading buffer
containing 5% β-mercaptoethanol and denatured at 90oC for 5 minutes. Samples ran on an 10%
SDS-page gel and then were transferred onto a nitrocellulose membrane. Blots were probed with
either rabbit anti-TDP-43 (1:5000; Proteintech Cat. # 10782-2-AP), rabbit anti-FUS (1:5000;
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Table 5.1. Primer Design for RT-qPCR and site-directed mutagenesis assays.
Primer Name
pri-miR-27b
forward
pri-miR-27b
reverse
pri-miR-181c
forward
pri-miR-181c
reverse
miR-27b
mutant forward
miR-27b
mutant reverse
miR-181c
mutant forward
miR-181c
mutant reverse

Sequence
5’ AGGGATTACCACGCAACCACGACCTTG 3’
5’ CCTTCTCTTCAGGTGCAGAACTTAG 3’
5’ GGTTTGGGGGAACATTCAACCTGTCG 3’
5’ GAATGTTGATTGTGACCTCGGCTGTGG 3’
5’ CCCTTTGTCAACTGCTGTGTTTGCTGTATGGTGTGTGTTC 3’
5’ GAACACACACCATACAGCAAACACAGCAGTTGACAAAGGG 3’
5’ GATAACCCACATTAGATGAATCCGTTAAGTGAAATGATACTTG 3’
5’CAAGTATCATTTCACTTAACGGATTCATCTAATGTGGGTTATC 3’
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Proteintech Cat. # 11570-1-AP), mouse anti-FLAG (1:2500; Cedarlane Cat. # CLANT146-2),
rabbit anti-DROSHA (1:1000; abcam Cat. # ab12286), rabbit anti-DCGR8 (1:1000; abcam Cat.
# ab191875), mouse anti-XPO5 (1:1000; abcam Cat. # ab57491), mouse anti-DICER (1:1000;
abcam Cat. # ab14601), mouse anti-AGO2 (1:1000; abcam Cat. # ab57113), rabbit anti-TRBP
(1:1000; Proteintech Cat. # 15753-1-AP), or rabbit anti-GAPDH (1:5000; abcam Cat. # ab9485)
and later with an HRP secondary antibody (goat anti-mouse 1:3000; Biorad Cat. # STAR207P,
or goat anti-rabbit 1:5000; Invitrogen Cat. # 65-6120). Data was quantified using densitometry
measured by ImageJ software. Relative protein levels were normalized to GAPDH expression
prior to comparison.

5.3.8 Fluorescent in situ hybridization (FISH)
Neuropathologically intact human spinal cord tissue was used to examine whether
candidate miRNAs were expressed in human spinal motor neurons. Tissue was cut into 7μm
sections. FISH was done as previously described (Hawley et al., 2019). MiRCURY LNA
miRNA Detection Probes that targeted miRNA candidates contained 5’ and 3’ DIG labels
(Qiagen Cat. # 339111), which were further targeted by an HRP secondary antibody (SigmaAldrich Ca. # 11633716001) and a Tyramide Signal Amplification tagged with a Cy3
fluorophore (PerkinElmer Cat. # NEL744001KT). Spinal cord samples were examined for
positive expression of candidate miRNAs using the Leica TSC SP8 confocal microscope.

5.3.9 Immunocytochemistry
Cells were fixed using 4% paraformaldehyde (PFA) and blocked with 8% Bovine Serum
Albumin (BSA). Proteins of interest were targeted by either rabbit anti-TDP-43 (1:250;
Proteintech Cat. # 10782-2-AP), goat anti-TIA-1 (1:100; Santa Cruz Cat. # sc-166247), or rabbit

205

anti-FLAG (1:100; abcam Cat. # ab49763) primary antibodies, which were targeted by Alexa
488 goat anti-rabbit, Alexa 555 donkey anti-goat, and Alexa 488 goat anti-mouse, respectively,
secondary antibodies (1:200; Life Technologies Cat. # A32721, A21432, and A32721,
respectively). Samples were imaged using the Leica TSC SP8 confocal microscope.

5.3.10 Fractionation
Nuclear and cytosolic protein and RNA fractionations was performed using the PARIS
kit (Invitrogen Cat. # AM1921) in accordance to the manufacturer’s instructions. 100 U/ml of
SUPERase IN RNase Inhibitor (Invitrogen Cat. # AM2694) was added to the cell fractionation
buffer and cell disruption buffer within the PARIS kit to prevent RNA degradation.

5.3.11 Statistics
Significance was determined either using a Students t-test when comparing two
conditions, or one-way ANOVA followed by a Tukey’s post-hoc when comparing multiple
conditions. Data was considered significant if p<0.05.
5.4 Results
5.4.1 Knockdown of either TDP-43 or FUS alters small RNA profile in HEK293T cells
Knockdown of either TDP-43 or FUS in HEK293T cells was accomplished using siRNA
pools targeting either TARDBP (siTDP #1) or FUS (siFUS) mRNA, respectively (Fig. 5.1A &
5.1E). MiRNA expression was then analyzed by microarray. The results showed that more than
370 and 300 small RNAs (scaRNAs, snoRNAs, and miRNAs) were significantly dysregulated
following knockdown of either TDP-43 or FUS, respectively, most of which were miRNAs (Fig.
5.1B & 5.1F; list of small RNAs can be found in Appendix A). Interestingly, several miRNAs
that were downregulated following knockdown of TDP-43 also contained a miRNA recognition
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element (MRE) within the 3’untranslated region (UTR) of TARDBP (Fig. 5.1C) according to
miRanda software. Further, we confirm reduction of miR-141-3p and miR-200a-3p following
knockdown of FUS, but also identified two other miRNAs (miR-2110 and miR-6804-5p)
downregulated with MREs in the FUS 3’UTR (Fig. 5.1G) according to miRanda software.
However, we could not identify any upregulated miRNAs that had MREs in the TARDBP or
FUS 3’UTRs. We selected five miRNA candidates with MREs in the TARDBP 3’UTR that had
the greatest reduced fold-change following knockdown of TDP-43, and confirmed with real-time
PCR that four of the five selected miRNAs (miR-27b-3p, miR-30a-5p, miR-181c-5p and miR425-3p) were significantly downregulated after knockdown of TDP-43, while miR-1260b
showed a non-significant reduction (Fig. 5.1D).
Since miR-141-3p and miR-200a-3p have already been shown to be in a negative
feedback loop with FUS which is dependent on FUS nuclear localization (Dini Modigliani et al.,
2014), we decided to look at miR-2110 and miR-6804-5p to see if we could expand on this
network. We confirmed reduced levels of miR-2110 and miR-6804-5p following knockdown of
FUS via real-time PCR (Fig. 5.1H).
In previous work, we had shown that out of the 4 miRNA candidates that we identified
for TDP-43, miR-27b-3p, miR-181c-5p and miR-425-3p, but not miR-30a-5p, were significantly
reduced in ALS spinal cord (Campos-Melo et al., 2013). Further, TargetScan 7.2 showed that
only miR-27b-3p and miR-181c-5p had conserved MREs in the TARDBP 3’UTR giving them a
high probability that they would affect TDP-43 expression, and therefore, we further examined
these two miRNAs. However, miR-2110 and miR-6804-5p are not known to be affected in ALS
and they do not have conserved MREs in the FUS 3’UTR. Despite this information we decided
to further explore miR-2110 and miR-6804-5p to determine if there was a potential negative
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feedback loop between these miRNAs and FUS. All four miRNA candidates (miR-27b-3p, miR181c-5p, miR-2110 and miR-6804-5p) were found to be expressed in human spinal motor
neurons according to fluorescent in situ hybridization analysis (Fig. 5.2), and therefore, we
decided to explore these miRNAs and their relation to either TDP-43 or FUS expression.
5.4.2 MiR-27b-3p and miR-181c-5p reduce TDP-43 expression
To determine whether miRNA candidates regulated either TDP-43 or FUS expression,
miRNA mimics of miR-27b-3p, miR-181c-5p, miR-2110 and miR-6804-5p were individually
transfected into HEK293T cells. Transfection of either miR-27b-3p or miR-181c-5p led to a
reduction of both endogenous TDP-43 protein and mRNA levels 48 hours after transfection (Fig.
5.3A-C). However, transfection of either miR-2110 or miR-6804-5p had no effect on FUS
protein/mRNA levels (Fig. 5.3E-G), indicating these two miRNAs were not in a negative
feedback loop with FUS.
Since miRNAs regulate gene expression generally by interacting with the 3’UTR of
mRNA, we wanted to determine whether miR-27b-3p and miR-181c-5p regulated TARDBP
expression via the 3’UTR. Reporter gene assays indicated that when TARDBP 3’UTR is linked
to a firefly luciferase gene that this leads to a reduction in luciferase activity when in the
presence of either exogenous miR-27b-3p or miR-181c-5p (Fig. 5.3D). Using the same assay, we
examined whether miR-2110 or miR-6804-5p could regulate luciferase expression in the
presence of the FUS 3’UTR. They had no effect (Fig.5.3H). Therefore, we decided to only
continue to explore the relationship between TDP-43 and miR-27b-3p/miR-181c-5p.
Next, we determined whether miR-27b-3p and miR-181c-5p regulated TARDBP
expression through direct interactions with its 3’UTR. Wild-type TARDBP 3’UTR, or TARDBP
3’UTR containing mutations in the +2 and +3 position of either the miR-27b-3p or miR-181c-5p

208

B
A

C
MiRNAs downregulated and have
binding sites in TDP-43 3’UTR
•
•
•
•
•
•

miR-27b-3p
miR-23b-3p
miR-181c-5p
miR-181b-5p
miR-107
miR-373-5p

•
•
•
•
•
•

D

miR-26a-5p
miR-30a-3p
miR-30a-5p
miR-361-5p
miR-425-3p
miR-1260b

F

E

H
G

MiRNAs downregulated and have
binding sites in FUS 3’UTR
•
miR-141-3p†
•
miR-200a-3p†
•
miR-2110
•
miR-6804-5p

209

Figure 5.1. Global change in miRNA expression following knockdown of either TDP-43 or
FUS in HEK293T cells using siRNAs. (A)Western blot showing knockdown of TDP-43 via
siRNA (siTDP #1). (B) Volcano plot indicating change in small RNA expression following
knockdown of TDP-43 (n=3). Green and red represent downregulated and upregulated RNAs,
respectively. (C) List of miRNAs that are downregulated following knockdown of TDP-43 and
have binding sites within the TARDBP 3’UTR. (D) Real-time PCR was used to confirm the
change in candidate miRNA expression following TDP-43 knockdown (n=3). (E) Western blot
showing knockdown of FUS via siRNA (siFUS). (F) Volcano plot indicating change in global
small RNA expression following knockdown of FUS (n=3). Green and red represent
downregulated and upregulated RNAs, respectively. (G) List of miRNAs downregulated
following FUS knockdown and have binding sites within the FUS 3’UTR. (H) Real-time PCR
was used to confirm the change in candidate miRNA expression following FUS knockdown
(n=3). Real-time PCR data was normalized to an endogenous control (miR-1296-5p). Bars
represent mean (n=3) fold-change (2^-∆∆CT) ± SEM in real-time PCR analyses. Student’s t-test
was used to determine significance in microarray and real-time analyses (*p<0.05, **p<0.01,
***p<0.001).
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Figure 5.2. MiR-27b-3p, miR-181c-5p, miR-2110 and miR-6804-5p are expressed in human
spinal motor neurons. A lumbar spinal cord from a neuropathologically intact individual (n=1)
was used for fluorescent in situ hybridization (FISH) analysis in order to determine whether
miRNA candidates were expressed in human spinal motor neurons. Red puncta indicate positive
staining for miRNAs. MiR-548c was used as a negative control. Scale bar represents 25μm.
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MREs were linked to a firefly luciferase gene (Fig. 5.4A). Reporter gene assays revealed that
when the firefly gene contains the TARDBP 3’UTR with mutations in either the miR-27b-3p or
or miR-181c-5p MREs, miR-27b-3p and miR-181c-5p are no longer able to effect luciferase
activity, respectively (Fig. 5.4B). This indicates that both miR-27b-3p and miR-181c-5p must
interact with the 3’UTR of TARDBP in order to reduce gene expression.

5.4.3 Nuclear localization of TDP-43 is required to regulate miR-27b-3p and miR-181c-5p
expression
Since cellular stress is known to alter TDP-43 localization from the nucleus to the
cytoplasm, we wanted to determine whether stress would lead to a reduction in the levels of
miR-27b-3p and miR-181c-5p similar to that observed following knockdown of TDP-43. After
an induced cellular stress, levels of both miR-27b-3p and miR-181c-5p were significantly
reduced concomitant with the expected reduction of nuclear localization of TDP-43 (Fig. 5.5).
Based on this information, we next determined if the nuclear localization of TDP-43 is a
requirement for the regulation of miR-27b-3p and miR-181c-5p expression. To do this, we used
siRNA plasmids (siRES) resistant to a specific siRNA (siTDP #2) which contained either FLAGtagged wild-type TDP-43 (siRES pC32-FLAG-TDP-43 WT) or FLAG-tagged TDP-43 without
its nuclear localization signal (siRES pC32-FLAG-TDP-43 ∆NLS), as previously described
(Deshaies et al., 2018). Both plasmids had a transfection efficiency of ~70% (Fig. 5.6A-B).
SiTDP #2 was able to knockdown endogenous TDP-43 (Fig. 5.7A) without affecting the
expression of the siRES plasmids (Fig. 5.6C-E). The siRES pC32-FLAG-TDP-43 WT plasmid
was primarily nuclear, while siRES pC32-FLAG-TDP-43 ∆NLS was primarily cytoplasmic (Fig.
5.7B) as expected. 24 hours after transfection of either SCR (negative control) or siTDP #2,
either pcDNA 3.1 (negative control), siRES pC32-FLAG-TDP-43 WT, or siRES pC32-FLAG-
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TDP-43 ∆NLS were transfected into HEK293T cells. Recovery of both miR-27b-3p and miR181c-5p to normal levels 48 hours post-knockdown of TDP-43 was seen only when cells were
transfected with siRES pC32-FLAG-TDP-43 WT and not when either pcDNA 3.1 or siRES
pC32-FLAG-TDP-43 ∆NLS plasmids were transfected (Fig. 5.7C), indicating that TDP-43
nuclear localization is necessary for the expression of miR-27b-3p and miR-181c-5p.
5.4.4 Knockdown of TDP-43 or cellular stress affect primary miRNA processing
Based on the reduction of mature miRNA levels of miR-27b-3p and miR-181c-5p
following knockdown of TDP-43, we wanted to determine at what level in the biogenesis
pathway of these two miRNAs TDP-43 was acting. When examining primary miRNA (primiRNA) levels following knockdown of TDP-43, we observed that there was a significant
increase in the amount of pri-miR-181c, while there was no change pri-miR-27b levels (Fig.
5.8A) indicating that TDP-43 only regulates the levels of pri-miR-181c.
We next examined whether cellular stress would have a similar effect on the pri-miRNAs
as observed with knockdown of TDP-43. We observed that there was a significant increase in
pri-miR-27b and pri-miR-181c following a cellular stress (Fig. 5.8B). Taken together, the data
suggest that reduced levels of mature miRNA levels either by knockdown of TDP-43 or cellular
stress is not due to reduced pri-miRNA levels, but rather, later reduced processing of miRNAs.
Given this, we next further investigated precursor structures of miR-27b and miR-181c.
5.4.5 Knockdown of TDP-43 and cellular stress affects precursor miRNA processing
Knockdown of TDP-43 showed no change in the overall levels of pre-miR-27b or premiR-181c (Fig. 5.9A), while cellular stress led to a significant increase in pre-miR-27b but had
no effect on pre-miR-181c levels (Fig. 5.9B). Since precursor miRNA molecules are present in
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Figure 5.3. Transfection of miR-27b-3p and miR-181c-5p decreased protein and mRNA
expression of TDP-43, while transfection of miR-2110 and miR-6804-5p had no effect on
FUS expression within HEK293T cells. (A) Western blot showing TDP-43 and GAPDH
protein levels following transfection of either scramble control (SCR), miR-27b-3p and miR181c-5p. (B) Quantification of relative TDP-43 protein expression when normalized to GAPDH
(n=3). (C) Change in mRNA expression of TARDBP when normalized to 18S rRNA following
transfection of either SCR, miR-27b-3p, or miR-181c-5p (n=3). (D) Plasmids containing a
reporter gene linked to the TARDBP 3’UTR were co-transfected in HEK293T cells with either
SCR (control), miR-27b-3p, or miR-181c-5p to determine changes in reporter gene expression in
the presence of either miR-27b-3p or miR-181c-5p. Data was normalized to renilla expression
prior to comparison (n=3). (E) Western blot showing FUS and GAPDH protein levels following
transfection of either scramble control (SCR), miR-2110 and miR-6804-5p. (F) Quantification of
relative FUS protein expression when normalized to GAPDH (n=3). (G) Change in mRNA
expression of FUS when normalized to 18S rRNA following transfection of either SCR, miR2110, or miR-6804-5p (n=3). (H) Plasmids containing a reporter gene linked to the FUS 3’UTR
were co-transfected in HEK293T cells with either SCR (control), miR-2110, or miR-6804-5p to
determine changes in reporter gene expression in the presence of either miR-2110 or miR-68045p. Data was normalized to renilla expression prior to comparison (n=3). Bars represent mean ±
SEM. Significance was determined using a one-way ANOVA followed by a Tukey’s post-hoc
for multiple comparisons (B, C, F, and G) and a Student’s t-test was used to determine
significance between two groups (D and H) (NSp>0.05, *p<0.05, **p<0.01, ***p<0.001).
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Figure 5.4 MiR-27b-3p and miR-181c-5p interact with the TARDBP 3’UTR to regulate
gene expression. (A) Mutations were put in the +2 and +3 position of the miR-27b-3p or miR181c-5p MRE within the TARDBP 3’UTR. (B) Reporter gene assays showing the change in
expression of the reporter gene when its linked to the either the wild-type (TDP WT) or mutated
(TDP Mut.) TARDBP 3’UTR when in the presence of either miR-27b-3p or miR-181c-5p. Data
was normalized to renilla prior to comparison. Bars represent mean (n=3) ± SEM. Significance
was determined using a one-way ANOVA followed by a Tukey’s post-hoc for multiple
comparisons (NSp>0.05, ***p<0.001)
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Figure 5.5. Reduced expression of miR-27b-3p and miR-181c-5p that is concomitant with
reduced nuclear TDP-43 levels five hours post osmotic stress. (A) HEK293T cells were either
not treated (control) or treated with 400 mM of sorbitol to induce an osmotic stress. Cells were
fixed and stained for TDP-43 (red) and TIA-1 (green) immunofluorescence. (B) MiR-27b-3p and
miR-181c-5p expression between non-stressed and stressed cells was measured via real-time
PCR. Expression levels were normalized to an exogenous control (cel-miR-39b-5p) prior to
comparison. Bar represents mean (n=5) fold-change (2^-∆∆CT) ± SEM. Student’s t-test was
used to determine significance (*p<0.05, **p<0.01).
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Figure 5.6. SiRES plasmids have an ~70% transfection efficiency and are resistant to a
specific TDP-43 siRNA (siTDP #2). (A) Immunofluorescence showing the expression of either
pC32-FLAG-TDP-43 wild-type (TDP WT) or pC32-FLAG-TDP-43 ∆NLS (TDP ∆NLS) siRES
plasmids following transfection within HEK293T cells. (B) Quantification of percentage of cells
positive for either siRES TDP WT or TDP ∆NLS plasmids following transfection within
HEK293T cells (n=3). (C) Western blot showing expression of endogenous GAPDH, TDP-43
and siRES TDP WT after cells were transfected with either SCR (control) or siTDP #2. (D-E)
Quantification of (D) siRES TDP WT or (E) endogenous TDP-43 expression when cells were
transfected with either SCR or siTDP #2 (n=3). Expression levels were normalized to GAPDH
prior to comparison. Bar represents mean ± SEM. Significance was determined using a Student’s
t-test (NSp>0.05, ***p<0.001).
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Figure 5.7. Nuclear localization signal of TDP-43 is required for the regulation of miR-27b3p and miR-181c-5p expression. (A) Western blot showing knockdown of TDP-43 following
transfection of siRNA (siTDP #2). (B) Immunofluorescence showing localization of either pC32FLAG-TDP-43 wild-type (TDP WT) or pC32-FLAG-TDP-43 ∆NLS (TDP ∆NLS) siRES
plasmids. (C) HEK293T cells were transfected with either SCR (control) or siTDP #2, and then
transfected again 24 hours later with either pcDNA (control), TDP WT or TDP ∆NLS plasmids.
MiR-27b-3p and miR-181c-5p levels were measured 24 hours after transfection of plasmids.
Expression levels were normalized to an exogenous control (cel-miR-39b-5p) prior to
comparison. Bar represents mean (n=3) fold-change (2^-∆∆CT) ± SEM. SCR+pcDNA samples
were negative controls in which the bar representing their expression levels was set at one for
comparison purposes. Significance was determined using a one-way ANOVA followed by a
Tukey’s post-hoc for multiple comparisons (NSp>0.05, **p<0.01).

224

A

B

225

Figure 5.8. Knockdown of TDP-43 increases levels of pri-miR-181c, while cellular stress
increases levels of the pri-miR-27b and pri-miR-181c. RT-qPCR of pri-miR-27b and pri-miR181c following (A) knockdown of TDP-43, or (B) an osmotic stress. Expression levels were
measured using densitometry and were normalized to 18S rRNA prior to comparison. Bars
represent mean (n=4) ± SEM. Significance was determined using a Student’s t-test (NSp>0.05,
*p<0.05, **p<0.01).
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the nucleus and cytoplasm, we wanted to determine the levels of pre-miR-27b and pre-miR-181c
within both cellular compartments.
We successfully fractionated samples into nuclear and cytosolic fractions (Fig. 5.10).
Both knockdown of TDP-43 and an induced cellular stress caused a significant reduction in
cytosolic pre-miR-181c, but no significant change in its nuclear levels, whereas there was no
significant change in nuclear or cytosolic levels of pre-miR-27b in both conditions (Fig. 5.11).
This suggests that the knockdown of TDP-43 and cellular stress can affect the levels of certain
pre-miRNA molecules within the cytosolic compartment, specifically pre-miR-181c, while
having no effect on other pre-miRNA molecules, such as pre-miR-27b.
Despite showing that knocking down TDP-43 causes deficits at several levels of miRNA
processing, there was no effect on the expression of the major proteins involved in the miRNA
biogenesis pathway at the time we see changes to miRNA levels (Fig. 5.12). This suggests that,
in this time frame, TDP-43 plays a critical role in the function of proteins within the miRNA
biogenesis pathway when processing miR-27b-3p and miR-181c-5p.

5.5 Discussion
We have provided evidence of a negative feedback regulatory loop in which TDP-43,
miR-27b-3p and miR-181c-5p interact in a manner that is dependent on the nuclear localization
of TDP-43. We show that TDP-43 regulates these two miRNAs differently within the miRNA
biogenesis pathway, and that cellular stress that reduces TDP-43 nuclear localization had similar,
but not the exact same effects on the processing of these two miRNAs as reduced TDP-43 levels.
In our experiments, we were unable to identify miRNAs in a negative feedback network
with FUS. Although miR-2110 and miR-6804-5p contained MREs in the FUS 3’UTR, there was
no evidence to suggest that these two miRNAs regulated FUS expression. Interestingly, two
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miRNAs (miR-141-3p and miR-200a-3p) that had been previously shown to be in a negative
feedback loop with FUS (Dini Modigliani et al., 2014), were significantly downregulated in our
microarray analysis. Thus, while we were unable to expand on the potential miRNAs involved in
a negative feedback network with FUS, we still believe that loss of the negative feedback loop
between FUS and miR-141/200a could be a major driver of the disease pathogenesis, as both
miR-141/200a have been shown to be reduced in ALS spinal cord (Campos-Melo et al., 2013).
TDP-43 has previously been shown to be involved in pri-miRNA and pre-miRNA
processing within the DROSHA and DICER complex, respectively (Kawahara and Mieda-Sato,
2012). Interestingly, TDP-43 regulates miRNAs in different ways, including selectively
promoting the processing of certain pri-miRNAs, or promoting or preventing the processing of
certain pre-miRNAs (Kawahara and Mieda-Sato, 2012; King et al., 2014). However, the
molecular reason for this selectivity is still unclear. In line with previous work, our data showed
this diverse role of TDP-43 within miRNA biogenesis, where knockdown of TDP-43 led to
reduced levels of cytoplasmic pre-miR-181c and mature miR-181c-5p levels but increases in primiR-181c levels. Low levels of TDP-43 function likely reduce DROSHA processing, which
could explain the accumulation of pri-miR-181c. The reduction of cytoplasmic pre-miR-181c
either means that reduced TDP-43 levels impede pre-miR-181c transport or that it promotes the
degradation of this pre-miRNA molecule in the cytoplasm. Regardless, it is clear that TDP-43
promotes the production of miR-181c-5p at several levels within the miRNA biogenesis
pathway. Further, knockdown of TDP-43 only caused a reduction of mature miR-27b-3p with no
effect on the pri and pre-miRNAs, indicating that TDP-43 likely promotes DICER processing of
pre-miR-27b. Since TDP-43 interacts with DROSHA and DICER in both an RNA-dependent
and independent manner (Kawahara and Mieda-Sato, 2012), it is difficult to know
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Figure 5.9. Knockdown of TDP-43 has no effect on overall pre-miR-27b or pre-miR-181c
levels, while cellular stress increases levels of pre-miR-27b. Real time PCR of pre-miR-27b
and pre-miR-181c following (A) knockdown of TDP-43, or (B) an osmotic stress. Expression
levels were normalized to an exogenous control (cel-miR-39b-5p) prior to comparison. Bar
represents mean (n=3) fold-change (2^-∆∆CT) ± SEM. Significance was determined using a
Student’s t-test (NSp>0.05, *p<0.05, **p<0.01).
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Figure 5.10. Fractionation protocol successfully separates protein and RNA nuclear and
cytosolic fractions. (A) Western blot showing protein expression of Lamin A/C (nuclear
protein) and GAPDH (primarily cytosolic protein) from nuclear and cytosolic protein extracts
(n=3). (B) Agarose gel showing PCR amplicons of pri-miR-27b (a nuclear RNA species)
expression in nucleus, but not cytosolic RNA extracts (n=3). Total RNA from whole cell extracts
was used as a positive control.

232

A

B

233

Figure 5.11. Nuclear/cytosolic fractionation indicated reduced cytoplasmic levels of premiR-181c following knockdown of TDP-43 or cellular stress. Real-time PCR showing levels
of nuclear and cytosolic pre-miRNA levels of either miR-27b or miR-181c following (A)
knockdown of TDP-43, or (B) osmotic stress. Expression levels were normalized to an
exogenous control (cel-miR-39b-5p) prior to comparison. Bar represents mean (n=3) fold-change
(2^-∆∆CT) ± SEM. Significance was determined using a Student’s t-test (NSp>0.05, *p<0.05).
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Figure 5.12. Knockdown of TDP-43 has no effect on the levels of proteins associated with
the miRNA biogenesis pathway. (A) Western blots showing the protein expression of TDP-43,
DROSHA, DCGR8, XPO5, DICER, AGO2, TRBP and GAPDH within HEK293T cells when
either transfected with SCR (control) or siTDP #1. (B) Quantification of DROSHA, DCGR8,
XPO5, DICER, AGO2 and TRBP protein levels when cells were either transfected with SCR or
siTDP #1. Expression levels were normalized to GAPDH prior to comparison. Bar represents
mean (n=3) ± SEM. Significance was determined using a Student’s t-test (NSp>0.05).
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whether TDP-43 needs to bind directly to either pri- and/or pre-miRNAs, DROSHA and/or
DICER complexes, or both to assist in the processing of these two miRNAs, and therefore,
warrants further investigation.
While TDP-43 has been shown to regulate several different miRNAs in multiple cell
lines, this is the first study, to our knowledge, that shows TDP-43 in a negative feedback network
with miRNAs. Similar networks have been identified between other RNA-binding proteins and
miRNAs, such as FUS and miR-141/200a, and hnRNPA1 and miR-18a (Dini Modigliani et al.,
2014; Fujiya et al., 2014; Guil and Caceres, 2007). These negative feedback networks are likely
critical biological mechanisms that regulate homeostatic levels of RNA-binding proteins and
miRNAs.
Our data suggests that the regulation of miR-27b-3p and miR-181c-5p, and hence the
negative feedback network, are dependent on the nuclear localization of TDP-43 providing
relevance for several neurodegenerative diseases that show accumulation of TDP-43 in neuronal
cytoplasmic inclusions including ALS, FTD and Alzheimer’s Disease (Amador-Ortiz et al.,
2007; Arai et al., 2006; Tan et al., 2007). In some cases, TDP-43 has been known to form
intranuclear inclusions in FTD-ALS, FTD and Alzheimer’s Disease (Amador-Ortiz et al., 2007;
Neumann et al., 2006), and in this case, it still likely that TDP-43 cannot perform its function in
the miRNA biogenesis pathway due to it being trapped in these inclusions. Thus, both the loss of
nuclear localization and the formation of TDP-43 inclusions likely results in miRNA
dysregulation.
Both miR-27b-3p and miR-181c-5p have been shown to be reduced in the spinal cord of
patients with ALS (Campos-Melo et al., 2013). We show here that these miRNAs are expressed
in motor neurons (Fig. 5.2), providing a correlation between TDP-43 cytoplasmic re-localization
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and the dysregulation of these two miRNAs within ALS. MiR-181c-5p has been shown to be
reduced within the anterior temporal cortex and parietal lobe cortex of patients with Alzheimer’s
Disease, and in cultures of primary hippocampal neurons from Alzheimer mouse models,
indicating that miR-181c-5p may be critical for overall central nervous system and neuronal
function (Schonrock et al., 2012; Schonrock et al., 2010). Previous work has already shown that
TDP-43 regulates the mature levels of miR-27b-3p and miR-181c-5p, and other members of the
miR-181 family (miR-181a-d) in several cell lines (Chen et al., 2018; Di Carlo et al., 2013;
Kawahara and Mieda-Sato, 2012). Thus, TDP-43 regulation on the biogenesis of miR-27b-3p
and the miR-181a-d family likely represents a broad phenomenon rather than a cell-specific one.
Further, we showed that an induced cellular stress which causes reduced TDP-43 nuclear
localization alters miRNA processing leading to a reduction in miR-27b-3p and miR-181c-5p,
similar to what was seen after knockdown of TDP-43. This is a critical finding as cellular stress
has been shown to drive TDP-43 from the nucleus to the cytoplasm in both in vitro and in vivo
neuronal models (Khalfallah et al., 2018; McDonald et al., 2011; Moisse et al., 2009), indicating
that cellular stress, while not the only effect, results in the reduction of nuclear TDP-43 levels to
regulate miRNA biogenesis. This may be a major component to the pathogenesis of ALS where
an extensive reduction in miRNA levels in spinal cord and motor neurons is observed (CamposMelo et al., 2013; Emde et al., 2015).
In conclusion, we propose a biological mechanism by which under normal conditions
TDP-43 is in a negative feedback network with miRNAs (i.e. miR-27b-3p and miR-181c-5p),
and that this is perturbed during cell stress due to reduced TDP-43 nuclear localization. Thus,
reduction of nuclear TDP-43 reduces miRNAs levels resulting in a de-repression of the TARDBP
transcript, and ultimately, increased TDP-43 cytoplasmic levels. This biological mechanism
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could have important implications for the pathogenesis of neurodegenerative diseases, such as
ALS, where the reduction of miRNA levels coincides with the upregulation and mis-localization
of TDP-43 (Campos-Melo et al., 2013; Emde et al., 2015; Koyama et al., 2016; Swarup et al.,
2011; Tan et al., 2007). Further, enhancement of miRNA processing at the level of DICER has
been shown to improve motor function of rodent models who carry ALS-related mutations in
TDP-43 (Emde et al., 2015). Since we and others have shown that TDP-43 affects miRNA
processing at multiple levels within the miRNA biogenesis pathway (Kawahara and Mieda-Sato,
2012), an enhancement of both the DROSHA and DICER complexes may be necessary to have
the greatest impact to slow ALS disease progression.
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Chapter 6
Discussion and Conclusion
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6.1 Summary of Results
In this dissertation, I aimed to elucidate the potential consequences of reduced miRNA
levels as seen in ALS, and to understand the mechanism by which miRNAs may become
dysregulated in the first place. Data presented showed that reduced miRNA expression may
contribute to both RNA-binding protein and intermediate filament pathogenesis as many ALSlinked miRNAs regulate these two protein groups as shown within in vitro cell models. Further, I
identified a novel negative feedback network between TDP-43 and miRNAs in HEK293T cells
which may provide insight into how miRNA levels become reduced in ALS motor neurons.
Chapters 2-3 highlighted several ALS-associated miRNAs that may contribute to the loss
of intermediate filament stoichiometry in ALS. Previous work had shown that ALS-associated
miRNAs could contribute to the suppression of NEFL mRNA—a common phenomenon
observed in motor neurons of patients with ALS (Bergeron et al., 1994; Campos-Melo et al.,
2013; Wong et al., 2000). However, in mature motor neurons there are 5 main intermediate
filaments expressed (NFL, NFM, NFH, PRPH and INA), and it is the overall loss of
stoichiometry between these 5 intermediate filaments that drives intermediate filament pathology
(Szaro and Strong, 2010). Therefore, I sought to determine the ALS-linked miRNAs that are
involved in regulating overall intermediate filament stoichiometry. I identified two miRNAs
(miR-105-5p and miR-9-5p) that showed reduced expression in ALS, that are expressed in motor
neurons and that regulate the mRNA levels of NEFL, PRPH and INA. MiR-105-5p enhanced the
expression of NEFL and PRPH but suppressed INA expression while miR-9-5p suppressed the
expression of all three intermediate filaments of interest in the human neuronal-derived cell line
IMR-32 (Hawley et al., 2019).
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In chapter 3, a series of motor neuron expressing miRNAs that are reduced in ALS were
identified to suppress the levels of a reporter gene when interacting with the 3’UTR of either
NEFM (miR-92a-3p and miR-125b-5p) or NEFH (miR-9-5p, miR-20b-5p, miR-92a-3p, miR223-3p) providing more examples of miRNAs responsible for regulating intermediate filament
stoichiometry (Campos-Melo et al., 2018). All this suggests that several miRNAs are responsible
for the tight regulation of intermediate filament stoichiometry, and loss of these miRNAs, as seen
in ALS, could contribute to intermediate filament pathogenesis.
Chapter 4 focused on ALS-linked miRNAs that are responsible for the regulation of three
RNA-binding proteins—TDP-43, FUS and RGNEF—that are known to co-aggregate together in
ALS motor neurons (Keller et al., 2012). I identified miR-b2122 to be a central regulator of
TDP-43, FUS and RGNEF expression in SH-SY5Y cells—a human neuronal-derived cell line—
and further, provided evidence that miR-194-5p may be responsible for TDP-43 and FUS gene
silencing. Further, I described an ALS-associated mutation in the FUS 3’UTR that was located in
the MRE of miR-b2122. This mutation disrupted the ability of miR-b2122 to bind to the 3’UTR
of FUS to regulate gene expression, providing a genetic link between miRNA regulation and
ALS (Hawley et al., 2017b). Since TDP-43 has been shown to be overexpressed in ALS spinal
cord and motor neurons and FUS overexpression has been known to cause ALS-like phenotypes
within in vitro and in vivo models, it is clear that the loss of homeostatic levels of these proteins
contributes to the disease pathogenesis (Koyama et al., 2016; Mitchell et al., 2013; Sabatelli et
al., 2013; Swarup et al., 2011). Thus, the loss of miR-194-5p and miR-b2122 in ALS motor
neurons could be a major contributor to the disease progression.
Finally, in Chapter 5, a negative feedback loop between TDP-43 and two ALS-linked
miRNAs (miR-27b-3p and miR-181c-5p) that is dependent on TDP-43 nuclear localization was
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identified in HEK293T cells, thus providing a biological mechanism that may be disrupted in
ALS (Hawley et al., 2020). While I looked at both TDP-43 and FUS, I did not identify a negative
feedback loop between FUS and miRNAs. However, previous work has shown that FUS is in a
negative feedback loop with two other ALS-linked miRNAs (miR-141-3p and miR-200a-3p;
Dini Modigliani et al., 2014), indicating that this biological mechanism does exist for FUS.
Further, TDP-43 regulated the expression of miR-27b-3p and miR-181c-5p at different levels in
the miRNA biogenesis pathway, as reduced TDP-43 levels led to increased pri-miR-181c and
reduced cytoplasmic pre-miR-181c, while lowering mature miR-27b-3p levels with no changes
to either miR-27b primary or precursor levels. This suggested that TDP-43 regulates miRNAs at
several levels in the biogenesis pathway, consistent with what has been seen previously
(Kawahara and Mieda-Sato, 2012).
Overall, the data presented in this dissertation demonstrates that reduced miRNA levels
in motor neurons of patients with ALS likely contributes to both intermediate filament and RNAbinding protein pathogenesis in ALS. Further, I have provided a biological mechanism that
provides evidence that loss of TDP-43 nuclear localization, as seen in ALS, may contribute to
the reduction of miRNAs seen in ALS motor neurons.

6.2 Implications
6.2.1 MiRNA network that regulates intermediate filament stoichiometry
Proper intermediate filament stoichiometry is considered necessary for the formation and
maintenance of cytoskeleton structures in neuronal cells (Szaro and Strong, 2010). Alterations to
this stoichiometry have been associated with the formation of intermediate filament aggregates
that are observed in ALS motor neurons (Beaulieu and Julien, 2003; Beaulieu et al., 1999; Kriz
et al., 2000; Lee et al., 1994; Wong et al., 2000; Zhu et al., 1997). Previous work has indicated
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two ALS-related RNA-binding proteins (TDP-43 and RGNEF) and miRNAs play essential roles
in regulating the levels of NEFL mRNA (Campos-Melo et al., 2013; Volkening et al., 2010;
Volkening et al., 2009). The work presented here identified 8 miRNAs, in addition to the five
miRNAs previously shown to regulate NEFL (Campos-Melo et al., 2013; Ishtiaq et al., 2014),
that are responsible for regulating the transcript levels of the five main intermediate filaments
(NEFL, NEFM, NEFH, PRPH and INA) expressed in mature neurons (Campos-Melo et al., 2018;
Hawley et al., 2019).
Identification of these interactions between miRNAs and intermediate filaments
highlights the complex network of trans-acting regulatory elements that are required to maintain
the appropriate spatiotemporal stoichiometry of these proteins. This fact paired with the evidence
that these miRNAs are reduced in ALS shows that a highly sophisticated regulatory network
between miRNAs and intermediate filaments is likely to be disrupted in ALS, thus contributing
to the formation of intermediate filament cytoplasmic aggregates. Beyond miRNAs, we know
that RNA-binding proteins play an integral role in post-transcriptionally regulating neurofilament
stoichiometry, including TDP-43, RGNEF, hnRNPK, ALDOA, ALDOC, HuB, 14-3-3 and
hnRNPE1/E2 (Antic et al., 1999; Canete-Soler et al., 2005; Droppelmann et al., 2013; Ge et al.,
2007; Stefanizzi and Canete-Soler, 2007; Thyagarajan and Szaro, 2004, 2008; Volkening et al.,
2010; Volkening et al., 2009). Amongst these proteins, TDP-43, RGNEF and 14-3-3 have been
associated with ALS pathology, indicating that the dysregulation of these proteins could also
contribute to loss of intermediate filament stoichiometry (Keller et al., 2012). It is still unclear
how miRNAs and RNA-binding proteins work together to finely regulate intermediate
stoichiometry and how their co-dysregulation in ALS contributes to overall intermediate filament
pathology.
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Further, there is evidence that long non-coding RNAs (lncRNAs), small nucleolar RNAs
(snoRNAs), and circular RNAs (circRNAs) are increasingly associated with ALS (Dolinar et al.,
2019; Errichelli et al., 2017; Nishimoto et al., 2013; Riva et al., 2016; Salvatori et al., 2020). This
provides even further complexity, as miRNAs, lncRNAs, snoRNAs, circRNAs and RNA-binding
proteins work together to tightly regulate gene expression both transcriptionally and posttranscriptionally (Salvatori et al., 2020). While it is still unclear how lncRNAs, snoRNAs and
circRNAs contribute to ALS pathogenesis, it will be interesting to determine if these non-coding
RNA molecules play an essential role in regulating neuronal intermediate stoichiometry and how
that may be affected in ALS. However, the understanding of the role of ALS-linked miRNAs in
neuronal intermediate filament post-transcriptional regulation has allowed us to develop a deeper
knowledge of the potential pathogenesis of these proteins in ALS. This has provided a
foundation to further explore these networks in neuron models to determine how these miRNAs
work with RNA-binding proteins, and potentially other non-coding RNA species, to regulate
neuronal intermediate filament stoichiometry, and how this system may be manipulated to
prevent the loss of intermediate filament stoichiometry in ALS motor neurons (Wong et al.,
2000).

6.2.2 Potential contributions of miRNAs in RNA-binding protein pathogenesis
An overwhelming amount of evidence has shown that the simple accumulation of LCDcontaining proteins, like the RNA-binding proteins observed in ALS, can cause them to phase
separate into irreversible insoluble aggregates (Conicella et al., 2016; Kato et al., 2012;
Murakami et al., 2015; Murray et al., 2017). Thus, several research groups have searched for
ways to prevent the toxic cytoplasmic accumulation of these proteins as potential therapeutics
(Barmada et al., 2010; Tamaki et al., 2018; Tradewell et al., 2012). The work presented in this
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dissertation provides a unique perspective in the potential use of miRNAs as a therapeutic target
to prevent the accumulation of these proteins into cytoplasmic aggregates.
The data provided in this dissertation indicates that reduced miRNA levels, as seen in
ALS, could contribute to the overexpression, and potentially the formation of cytoplasmic
aggregates by RNA-binding proteins. MiR-b2122 was identified to silence the mRNA expression
of three RNA-binding proteins (TDP-43, FUS and RGNEF) that co-aggregate with each other in
ALS motor neurons (Hawley et al., 2017b; Keller et al., 2012). Overexpression of TDP-43 and
FUS have both been shown to result in the formation of cytoplasmic aggregates in both in vitro
and in vivo models, and further, both have been shown to have increased levels in the spinal cord
of ALS patients (Dini Modigliani et al., 2014; Hawley et al., 2017b; Koyama et al., 2016;
Mitchell et al., 2013; Swarup et al., 2011; Xu et al., 2010). In our work, we had identified a
relationship between reduced levels of miR-b2122 and increased levels of FUS in the spinal cord
of sALS patients, and an ALS-associated genetic variant in the FUS mRNA 3’UTR that prevents
miR-b2122 from binding to the FUS 3’UTR to regulate gene expression (Hawley et al., 2017b).
All this put together, suggests miR-b2122 may be a potential therapeutic target to reduce the
RNA-binding protein expression via gene silencing and prevent the aggregation of all three of
these proteins.

6.2.3 Identification of novel negative feedback network
A novel negative feedback network between TDP-43 and miRNAs was identified
providing further insight biological mechanisms that may be affected in ALS motor neurons. The
identification of this network not only has major implications for our understanding ALS disease
progression, but as well our understanding of basic biological networks.
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Negative feedback networks are classic self-regulating biological systems designed to
maintain homeostasis (Tsang et al., 2007). Since miRNAs have been described as the “master
regulators”, it is not surprising that miRNAs are involved in several negative and positive
feedback networks. Further, in a panel of over 70 pre-miRNA baits, researchers were able to
pulldown over 180 RNA-binding proteins that preferentially bound to specific miRNA groups
which demonstrated the vast network of RNA-binding proteins that participate in the biogenesis
of a small subset of miRNAs (Treiber et al., 2017). Several RNA-binding proteins have been
shown to be in negative, positive and double negative feedback networks with miRNAs
indicating the importance of these two groups to work together to maintain homeostasis (Tsang
et al., 2007).
Under physiological stress conditions, several RNA-binding proteins leave the nucleus
and enter the cytoplasm to form stress granule structures, including TDP-43 (Protter and Parker,
2016). Further, cellular stress has generally shown to cause a reduction in miRNA processing
(Emde et al., 2015), as I showed with miR-27b-3p and miR-181c-5p. Therefore, one hypothesis
may be that reduced miRNA processing during stress allows for de-repression of RNA-binding
proteins needed for stress granule formation, but overaccumulation of LCD-containing RNAbinding proteins—which are prone to aggregate—either through chronic or repeated stresses
may induce the formation of insoluble cytoplasmic aggregates. Thus, while reduced miRNA
processing may be beneficial for a rapid stress response, repeated or chronic stresses increase the
risk of developing cytoplasmic aggregates that are toxic to the cell.
The identification of a negative feedback network between TDP-43 and miRNAs is the
second negative feedback network that has been identified between ALS-related miRNAs and
RNA-binding proteins. The first was identified between FUS and two miRNAs—miR-141/200a-
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3p (Dini Modigliani et al., 2014). Beyond TDP-43 and FUS, other ALS-related RNA-binding
proteins have been implicated in the miRNA biogenesis pathway including TAF15, EWSR1,
hnRNPA1, hnRNPA2B1, MATR3, TIA-1 and ATXN2 (Alarcon et al., 2015; Ballarino et al.,
2013; Guil and Caceres, 2007; Kapeli et al., 2016; Kooshapur et al., 2018; Ouyang et al., 2017;
Sanchez-Jimenez et al., 2013; Weiss et al., 2019). Therefore, several regulatory networks
between miRNAs and RNA-binding proteins may be disrupted in ALS. Identification of these
regulatory networks, how they are disrupted in ALS, there contribution to ALS pathogenesis, and
how to restore these networks will assist in our understanding of ALS development and potential
therapeutic targets.
Further, TDP-43 forms cytoplasmic aggregates in 97% of all cases regardless of genetic
background (Ling et al., 2013). Therefore, identification for pathways that may explain the
accumulation of TDP-43 in the cytoplasm has become critical. Loss of a negative feedback
between TDP-43 and miRNA due to loss of nuclear localization, as shown in Chapter 5, may
contribute to the formation of TDP-43 cytoplasmic aggregates in ALS. Therefore, if we are able
to identify this negative feedback loop in motor neuron models, and further, show it is disrupted
in ALS motor neuron models, it will be necessary to target this pathway to see if we can restore
homeostatic levels of miR-27b-3p and miR-181c-5p to lower levels of TDP-43 to hopefully
alleviate ALS-like phenotypes.
6.2.4 Development of therapeutics targeting miRNA pathways
In this dissertation, I have identified 10 ALS-linked miRNAs that could contribute to
intermediate filament and RNA-binding protein pathogenesis. This is likely an
underrepresentation of the total amount of miRNAs that are involved in in the disease
pathogenesis. This data highlights that there is not a single miRNA that will ameliorate the
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dysfunctional physiology observed in ALS motor neurons, but rather a whole host of miRNAs,
each individually contributing to the disease process. This is critical to understand if we are
going to develop therapeutics that target miRNA pathways.
Targeting individual miRNAs in ALS likely will have minimal effects in terms of a
therapeutic. Rather we need to focus on developing drugs that are able to reboot the miRNA
biogenesis pathway. In chapter 5 of this thesis, I showed that reduced nuclear TDP-43, as seen in
97% of all ALS cases, can inhibit efficient processing of miRNAs at multiple levels in the
biogenesis pathway. Thus, rather than targeting specific miRNAs, developing therapeutics that
increase the efficiency of DROSHA and DICER to process pri- and pre-miRNAs, respectively,
may be a better approach. Enoxacin is a drug that can enhance miRNA biogenesis by interacting
with TRBP to enhance DICER pre-miRNA processing (Shan et al., 2008). In ALS transgenic
mouse models containing ALS-causing mutations in either SOD1 or TDP-43, enoxacin has been
proven to delay motor deficiencies that are developed in these models, thus providing some
evidence that enhancement of the miRNA biogenesis pathway could be an effective therapeutic
approach (Emde et al., 2015). However, many of the RNA-binding proteins that are involved in
ALS also interact with DROSHA to promote miRNA biogenesis. Thus, a better therapeutic may
be one that improves the efficiency of both DROSHA and DICER processing.
Two acetylase inhibitors—trichostatin A and nicotinamide—have been shown to increase
levels of DROSHA and enhance miRNA processing (Tang et al., 2013). In particular,
nicotinamide is derivative form of vitamin B3 which has been implicated as potential therapeutic
for several neurodegenerative diseases, including ALS (Fricker et al., 2018; Naia et al., 2017;
Schondorf et al., 2018; Xie et al., 2019; Zhou et al., 2020). Nicotinamide is a critical metabolite
involved in converting NADH to NAD+, an important process for the production of ATP

253

(Poddar et al., 2019). Low levels of NAD+ has been seen in animal models of Alzheimer’s
Disease, Parkinson’s Disease, Huntingtion’s Disease and ALS, suggesting that oxidation of
NADH may be a deficient process in neurodegeneration (Fricker et al., 2018; Zhou et al., 2020).
Further, nicotinamide has been shown to prevent DNA damage, apoptosis, maintain cell
membrane structure and reduce oxidative stress, all of which has been associated with several
neurodegenerative diseases (Surjana et al., 2010; Turunc Bayrakdar et al., 2014). Recent work in
ALS SOD1 mouse models has shown that nicotinamide may be a potential for therapeutic for
ALS patients who contain SOD1 mutations (Zhou et al., 2020). Therefore, while nicotinamide is
already being considered for an ALS therapeutic, understanding whether these beneficial affects
occur in part by restoring miRNA homeostasis will be essential to understand its therapeutic
effect and whether it can be used for non-mtSOD1 ALS patients.
While further work in iPSC-derived motor neuronal cell lines and in vivo models still
need to be done, restoring miRNA production may be a potential therapeutic avenue by
combining nicotinamide and enoxacin to increase both DROSHA and DICER activity,
respectively, and in turn, overall miRNA processing.

6.3 Caveats
The data presented in this dissertation has identified critical ALS-linked miRNAs
responsible for regulating intermediate filaments and RNA-binding proteins related to the
disease, and a negative feedback network, that if lost, may contribute to driving the disease
pathogenesis. Despite the significance of this work in developing our understanding of the
biological networks that connect ALS-associated miRNAs, intermediate filaments and RNAbinding proteins, there are some caveats that should be taken into consideration.
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First, the cell models in which these interactions were characterized limit our ability to
determine how significant these interactions are to ALS. As previously mentioned, miRNA
expression, regulation and function can be highly dependent on cell type, cell environment, and
altered cell physiology (Berezikov, 2011; Hawley et al., 2017a). Therefore, if we really want to
understand these networks of miRNAs that are associated with ALS, we need to study these
interactions in motor neuron models. Research using human iPSC-derived motor neuron models
has proven to be effective in understanding specific aspects of motor neuron biology that would
otherwise be missed if looking in other cell models. For example, the regulation of TDP-43 on
STMN2 expression and its significance to ALS was discovered only because researchers used
human iPSC-derived motor neuron models. This would have not been identified looking in other
non-neuronal models, as STMN2 has neuronal specific expression, and further, the addition of
the cryptic exon, as seen in STMN2 when TDP-43 expression is suppressed, is a human specific
affect (Klim et al., 2019; Melamed et al., 2019). All this indicates using the appropriate models
are important when discussing disease. A major experiment in our work was the FISH analyses
to ensure that the miRNAs we were studying in our models were also expressed in motor
neurons, and hence, provide an increased likelihood that the biological pathways identified in our
models also exist in motor neurons. However, while our models allowed us to find several
pathways that are likely related to the disease, we need to move into more complex models, and
start understanding the specific relationship between miRNAs, intermediate filaments and RNAbinding proteins within motor neurons.
Second, while we have shown several miRNAs that likely contribute to the pathology of
the disease, at this point we have no data to support that loss of miRNA expression can induce
the formation of cytoplasmic aggregates similar to those seen in ALS motor neurons. Mutations
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in the 3’UTR of FUS that disrupt miRNA binding and gene silencing can induce cytoplasmic
aggregates of FUS protein (Dini Modigliani et al., 2014; Morlando et al., 2012). However, it is
still unclear whether the resulting pathology from those mutations is caused from loss of miRNA
regulation or other factors. Further, while several lines of work have shown loss of intermediate
filament stoichiometry induces the formation of intermediate filament aggregates (Robertson et
al., 2002), does loss of miRNA regulators that alter the stoichiometry enough to induce
intermediate filament pathology is still in question.
Finally, our assays where miRNA expression was either overexpressed or inhibited could
have technical experimental issues. This is because when you transfect a miRNA mimic, the
amount of miRNA that is present within the cellular system could easily out compete other
trans-acting molecules that would normally regulate your gene of interest, even if your miRNA
candidate does not regulate it normally. Further, ablating miRNA function in a cell via an
inhibitor does not necessarily represent the changes seen in ALS spinal cord where we generally
see reduced levels and not complete loss of the miRNA. Thus, we need to determine the
threshold in which the change of expression in our miRNA candidates results in a change in the
expression of our genes of interest, and determine if that is representative of what is seen in ALS
spinal cord and motor neurons.
Studying how reduced expression of specific ALS-related miRNAs using in vitro and in
vivo motor neuron models will be necessary to understand the contribution of miRNAs to disease
pathology and whether loss of miRNA regulation alone can drive ALS-like proteinopathies and
motor neuron death. These are critical caveats to consider when interpreting the data, and further
experiments will need to be done in motor neuron models to more accurately understand
MotomiR biology and how loss of these miRNAs may contribute to the pathology of the disease.
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6.4 Future Directions
As mentioned in the previous section, a major future direction for this work is to
determine whether the loss of miRNA function can induce intermediate filament and/or RNAbinding protein ALS-like proteinopathies. For example, does reduction or loss of miR-105-5p or
miR-9-5p—two miRNAs know to regulate NEFL, PRPH and INA mRNA expression—result in
intermediate filament aggregation? Does loss of miR-b2122 lead to cytoplasmic aggregates of
TDP-43, FUS and RGNEF? The answer to these questions will be necessary to understand the
contribution these miRNAs have in the progression of the disease. Some evidence has shown
that knocking out Dicer in mouse motor neurons can recapitulate loss of intermediate filament
stoichiometry and induce motor neuron death (Haramati et al., 2010). However, knockout of
Dicer would cause a global downregulation of miRNAs in motor neurons and does not provide
any information on specific miRNAs. Therefore, further analyzing the miRNAs identified in this
dissertation and whether loss of these miRNAs via knockdown or knockout models could
contribute to both intermediate filament and RNA-binding protein dysregulation, ALS-like
pathologies and motor neuron death will help us to understand their contribution to disease
pathogenesis.
Another important factor to consider is that miRNAs are promiscuous molecules where
one miRNA can have many targets, as seen in the work presented in this dissertation. While I
focused on the affect miRNA candidates would have on RNA-binding proteins and intermediate
filaments, there could be other pathways affected due to the loss of the miRNAs I studied. For
example, miR-105-5p and miR-9-5p, two miRNAs shown to regulate intermediate filament
expression in this dissertation (Hawley et al., 2019), have also been shown to suppress the
expression of several cell-cycle genes to promote cell-cycle arrest (Zhang et al., 2017; Zhang et
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al., 2019). One theory in ALS is that many of these cell-cycle genes that are normally suppressed
in post-mitotic motor neurons are activated in ALS motor neurons, putting cells in a S phase
rather than a G0 phase (Ranganathan and Bowser, 2003; Ranganathan and Bowser, 2010; Sharma
et al., 2017). The re-entry of post-mitotic neurons into the cell-cycle has been shown to lead to
activation of apoptotic pathways and subsequent neuron death (Sharma et al., 2017). Thus,
reduced levels of miR-105-5p and miR-9-5p, as seen in ALS, may contribute to the re-entry of
ALS motor neurons into the cell-cycle, triggering apoptotic pathways, rather than disrupting
intermediate filament stoichiometry, or the loss of these miRNAs could be contributing to both.
Moving forward it will be necessary to determine all the pathways in which these miRNAs are
contributing to in motor neurons to understand the full impact of the loss of these miRNAs in
ALS.
In chapters 2 and 4, miRNAs that were predicted to regulate all our intermediate
filaments or RNA-binding proteins of interest but were previously shown to have no change in
expression in ALS spinal cord were not considered for our study (Fig. 2.1 & 4.1). This does not
mean these miRNAs are not important. This is because if they are unchanged, they may become
the dominant regulators of our genes of interest when the other miRNAs are reduced. Therefore,
it will be crucial to not only determine how miRNAs that have altered levels in ALS affect the
expression of our genes of interest, but as well as those miRNAs that are unchanging in ALS
spinal cord and motor neurons.
Genetic association studies focusing on miRNA encoding regions could have a massive
impact on our understanding of the relevance of miRNAs in ALS pathogenesis. As previously
mentioned, mutations within the FUS 3’UTR located in two MREs—miR-141/200a-3p and miRb2122—cause overexpression and cytoplasmic aggregates of FUS protein, like the pathology
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seen in ALS motor neurons (Dini Modigliani et al., 2014; Hawley et al., 2017b; Morlando et al.,
2012). This gives us an indication that loss of miRNA regulation on critical genes could
contribute to the disease pathogenesis, giving significance to the mass downregulation of
miRNAs seen in the spinal motor neurons of ALS patient groups. More recently, several rare
mutations were identified in the miR-218 gene of patients with ALS (Reichenstein et al., 2019).
These are the first genetic variants to date that have been identified in miRNA regions of the
genome that are associated with ALS. Mutations in miR-218 reduced its processing by DICER,
and further, less of this miRNA led to reduce motor neuron activity (Reichenstein et al., 2019).
More genetic studies like these could identify miRNAs critical to motor neuron function and
disease, better enabling us to find therapeutic targets. Historically, genetic studies have focused
on coding regions of the genome with little work done outside those regions. However, now
knowing non-coding regions of the genome contain critical genetic information to regulate cell
physiology, expanding our efforts to look at miRNA genetic material may further drive our
understanding of miRNAs role in disease pathogenesis and which miRNAs are the most critical
to disease development.
6.5 Conclusion
The research presented in this dissertation provided a foundational understanding of the
potential consequence and cause of miRNA dysregulation in ALS. With the use of in vitro
models, several miRNAs were identified to be critical for the regulation of RNA-binding protein
expression and intermediate filament stoichiometry, and thus, loss of these miRNAs, as seen in
ALS, may contribute to the pathogenesis of these two protein groups (Fig. 6.1). Finally, a novel
negative feedback network between TDP-43 and miRNAs was identified in HEK293T cell
models which could have major implications in our understanding of not only ALS development,
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but other neurodegenerative diseases that have TDP-43 proteinopathies. Knowing that reduced
miRNAs may play a major role in ALS pathogenesis, it is now time to move forward into in
vitro and in vivo motor neuron models, which is a critical step if we are to develop potential
therapeutics that target these miRNA regulatory networks.
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Figure 6.1. Hypothesis of miRNA contribution to ALS pathogenesis. (A) Healthy motor
neuron. TDP-43 contributes to miRNA biogenesis by assisting in pri- and pre-miRNA
processing with DROSHA and DICER complexes, respectively. Further, we provided evidence
that TDP-43 potentially assists in pre-miRNA export. FUS also assists in pri-miRNA processing.
Certain miRNAs, as identified in this thesis, target RNA-binding protein transcripts to suppress
and limit their expression. We showed this creates a negative feedback loop between TDP-43
and miR-27b-3p/miR-181c-5p and suggests that these regulatory networks are essential in
maintaining homeostatic levels of RNA-binding proteins and miRNAs. Further, we showed that
certain ALS-linked miRNAs target neuronal intermediate filament transcripts to promote or
suppress their expression, which is essential in maintaining stochiometric levels of intermediate
filament proteins (NFL [L], NFM [M], NFH [H], PRPH [P], or INA [A]) . This allows for proper
cytoskeleton formation, which is necessary to maintain axonal integrity, and in turn, overall
neuronal transport and function. (B) Diseased motor neuron. Due to the loss of TDP-43 and FUS
nuclear (purple) localization and their formation into cytoplasmic (yellow) inclusions, reduced
miRNA processing is observed. Lower miRNA levels result in de-repression of ALS-linked
RNA-binding proteins such as TDP-43, FUS and RGNEF. This rise in production of RNAbinding proteins results in increased formation of toxic cytoplasmic inclusions through phase
separation. Further, lower miRNA levels will cause loss of intermediate filament stoichiometry
due to either degradation or overexpression of intermediate filament transcripts. This results in
intermediate filament cytoplasmic inclusions and loss of cytoskeleton formation, and
subsequentially, loss of axonal integrity. Overall, I hypothesize that reduced miRNAs levels, as
seen in ALS, results in the increased formation of toxic cytoplasmic inclusions and a loss of
proper cytoskeleton formation leading to motor neuron death.
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Appendix A
Tables indicating significant changes to small RNA expression following TDP-43 or FUS
knockdown in HEK293T cells

Data was collected using a microarray (GeneChip miRNA 4.0 Array) and analyzed using the
Transcriptome Analysis Console. See Methods & Materials in Chapter 5 for further details.

Table A.1. Small RNAs significantly altered following TDP-43 Knockdown.
ID
Transcript ID(Array
P-val
Fold Change
siTDP Avg (log2) SCR Avg (log2) FDR PDesign)
val
20518879 hsa-miR-4485
0.000000134
3.74
8.81
6.9
0.0009
20524036 hsa-miR-6126
0.0000171
1.92
8.24
7.29
0.0531
20525395 hsa-miR-6723-5p
0.000024
4.26
5.97
3.88
0.0531
20518834 hsa-miR-4454
0.0000491
-3.55
6.53
8.36
0.0795
20535460 hsa-mir-1298
0.0000697
-1.4
1.58
2.07
0.0795
20528733 hsa-miR-7704
0.000072
1.77
9.78
8.96
0.0795
20534812 hsa-mir-29c
0.0001
1.42
1.88
1.37
0.1139
20537518 hsa-mir-6775
0.0001
-2.69
1.4
2.83
0.107
20509224 hsa-miR-1908-5p
0.0002
1.64
6.74
6.03
0.1518
20518933 hsa-miR-4532
0.0004
1.98
7.02
6.04
0.2686
20536775 hsa-mir-4500
0.0004
-1.84
1.21
2.09
0.2627
20518892 hsa-miR-4497
0.0005
1.52
9.21
8.61
0.2724
20532932 ENSG00000202449
0.0005
1.43
1.33
0.81
0.2724
20504413 hsa-miR-663a
0.0006
1.84
6.84
5.96
0.2741
20518431 hsa-miR-3910
0.0006
1.66
1.72
0.99
0.2741
20504433 hsa-miR-421
0.0007
-1.73
5.99
6.78
0.2805
20517942 hsa-miR-3682-5p
0.0007
1.59
1.66
0.99
0.2805
20533897 ENSG00000252190
0.0008
1.5
1.89
1.31
0.2995
20536814 hsa-mir-4534
0.001
1.39
1.82
1.35
0.3166
20536889 hsa-mir-4664
0.001
-1.58
1.4
2.06
0.3166
20537456 hsa-mir-6715b
0.001
1.43
2.23
1.72
0.3166
20504408 hsa-miR-652-3p
0.0011
-1.35
6.84
7.27
0.3166
20507742 hsa-miR-1469
0.0011
1.63
7.05
6.34
0.3166
20501197 hsa-miR-361-5p
0.0012
-1.47
8.8
9.36
0.3166
20538223 U68
0.0012
1.24
6.54
6.24
0.3166
20538181 U43
0.0015
1.29
10.23
9.87
0.3694
20536568 hsa-mir-3664
0.0016
1.63
1.75
1.05
0.3694

Chromosome
chr11
chr16
chr1
chr4
chrX
chr2
chr1
chr16
chr11
chr20
chr13
chr12
chr4
chr20
chr9
chrX
chr2
chr1
chr22
chr8
chr10
chrX
chr15
chrX
chr19
chr22
chr11
270

Table A.1. Small RNAs significantly altered following TDP-43 Knockdown.
ID
Transcript ID(Array
P-val
Fold Change
siTDP Avg (log2) SCR Avg (log2) FDR PDesign)
val
20537538 hsa-mir-6795
0.0016
1.59
1.78
1.11
0.3694
20525526 hsa-miR-6782-3p
0.0017
-1.42
1.21
1.71
0.3779
20533168 ENSG00000221633
0.0019
1.63
1.91
1.21
0.4082
20533189 ENSG00000223027
0.0019
-1.5
1.23
1.82
0.4082
20518816 hsa-miR-4441
0.0021
-1.3
1.08
1.46
0.4174
20533677 ENSG00000239033
0.0021
-1.32
0.91
1.31
0.4174
20534818 hsa-mir-219a-2
0.0021
-1.45
1.35
1.89
0.4174
20500170 hsa-miR-92a-1-5p
0.0023
2.69
3.1
1.67
0.4247
20536757 hsa-mir-4485
0.0023
1.4
3.54
3.05
0.4247
20538180 U43
0.0028
1.2
10.63
10.37
0.5084
20536760 hsa-mir-4487
0.0029
1.74
2.08
1.28
0.5135
20500489 hsa-miR-224-5p
0.0036
1.39
1.57
1.09
0.5519
20515595 hsa-miR-3170
0.0036
-1.29
1.08
1.45
0.5519
20500742 hsa-miR-137
0.0037
1.3
1.08
0.7
0.5519
20518878 hsa-miR-4484
0.0039
1.42
8.13
7.63
0.5519
20533980 ENSG00000252526
0.0039
-1.38
1.34
1.81
0.5519
20538048 hsa-mir-8088
0.0039
-1.45
1.33
1.87
0.5519
20525416 hsa-miR-6727-5p
0.004
1.38
7.92
7.45
0.5519
20519441 hsa-miR-4656
0.0041
2.37
3.53
2.29
0.5519
20515551 hsa-miR-3142
0.0042
1.23
1.35
1.05
0.5519
20500137 hsa-miR-19b-3p
0.0044
-5.02
3.6
5.93
0.5519
20525554 hsa-miR-6796-3p
0.0045
1.5
2.08
1.49
0.5519
20500721 hsa-miR-23b-3p
0.0046
-1.13
9.32
9.49
0.5519
20504552 hsa-miR-671-5p
0.0047
-1.44
5.07
5.59
0.5519
20500148 hsa-miR-24-3p
0.0048
-1.51
7.33
7.92
0.5519
20500465 hsa-miR-210-3p
0.0048
-2.36
3.71
4.95
0.5519
20536929 hsa-mir-4698
0.0048
2.08
2.53
1.48
0.5519

Chromosome
chr19
chr17
chr3
chr10
chr2
chr12
chr9
chr13
chr11
chr22
chr11
chrX
chr13
chr1
chr10
chr16
chrX
chr1
chr7
chr5
chr13
chr19
chr9
chr7
chr19
chr11
chr12
271

Table A.1. Small RNAs significantly altered following TDP-43 Knockdown.
ID
Transcript ID(Array
P-val
Fold Change
siTDP Avg (log2) SCR Avg (log2) FDR PDesign)
val
20506005 hsa-miR-936
0.005
-1.53
1.33
1.94
0.5519
20519570 hsa-miR-4728-5p
0.005
2.38
4.65
3.4
0.5519
20525633 hsa-miR-6780b-5p
0.005
1.79
6.13
5.29
0.5519
20534879 hsa-mir-151a
0.005
-1.75
1.47
2.27
0.5519
20536902 hsa-mir-4676
0.005
1.38
1.93
1.47
0.5519
20504342 hsa-miR-602
0.0051
-1.6
2.03
2.7
0.5519
20525668 hsa-miR-6853-3p
0.0051
1.39
1.63
1.15
0.5519
20533715 ENSG00000239084
0.0053
1.36
1.42
0.98
0.5674
20506878 hsa-miR-548p
0.0054
1.47
1.58
1.02
0.5674
20501293 hsa-miR-331-3p
0.0057
-2.17
3.74
4.86
0.5674
20536769 hsa-mir-4495
0.0057
1.24
1.5
1.19
0.5674
20523019 hsa-miR-6087
0.0058
1.37
10.47
10.02
0.5674
20532926 ENSG00000202374
0.0059
-1.59
1.44
2.1
0.5674
20536497 hsa-mir-4277
0.0059
-1.71
1.85
2.63
0.5674
20536870 hsa-mir-4650-1
0.006
1.34
1.65
1.23
0.5674
20536871 hsa-mir-4650-2
0.006
1.34
1.65
1.23
0.5674
20533228 ENSG00000238339
0.0065
1.31
1.98
1.59
0.6054
20532651 ACA32
0.0066
1.63
2.66
1.95
0.6104
20505608 hsa-miR-675-5p
0.0069
1.51
2.05
1.46
0.6264
20533161 ENSG00000221398
0.007
-1.58
1.39
2.05
0.6264
20525421 hsa-miR-6729-3p
0.0072
1.32
1.4
1
0.6264
20532748 ENSG00000199666
0.0072
-1.48
1.24
1.8
0.6264
20515591 hsa-miR-1260b
0.0073
-2.96
3.74
5.31
0.6264
20501280 hsa-miR-342-3p
0.0075
-1.18
8.62
8.86
0.6379
20536560 hsa-mir-3656
0.008
-2.07
1.66
2.71
0.6726
20533973 ENSG00000252495
0.0083
1.25
1.64
1.31
0.6775
20537204 hsa-mir-5692c-2
0.0083
1.43
1.79
1.27
0.6775

Chromosome
chr10
chr17
chr6
chr8
chr10
chr9
chr9
chr5
chr5
chr12
chr12
chrX
chr4
chr5
chr7
chr7
chr2
chr11
chr11
chr21
chr1
chr1
chr11
chr14
chr11
chr1
chr7
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Table A.1. Small RNAs significantly altered following TDP-43 Knockdown.
ID
Transcript ID(Array
P-val
Fold Change
siTDP Avg (log2) SCR Avg (log2) FDR PDesign)
val
20536728 hsa-mir-4468
0.0084
-1.5
1.34
1.92
0.6775
20500448 hsa-miR-181c-5p
0.0091
-1.46
1.42
1.97
0.7253
20500456 hsa-miR-196a-3p
0.0094
-1.52
1.56
2.16
0.7344
20522039 hsa-miR-5703
0.0094
-1.88
1.22
2.13
0.7344
20506898 hsa-miR-1306-5p
0.0097
-1.55
1.21
1.85
0.7474
20537467 hsa-mir-892c
0.0099
1.86
2.22
1.33
0.7528
20500191 hsa-miR-103a-3p
0.0102
-1.31
10.45
10.83
0.7542
20533078 ENSG00000212391
0.0102
1.41
2.2
1.7
0.7542
20533463 ENSG00000238696
0.0103
1.24
1.36
1.05
0.7542
20533676 ENSG00000239033
0.0105
-1.26
0.94
1.28
0.7542
20536313 hsa-mir-3194
0.0105
-1.33
1.39
1.8
0.7542
20504582 hsa-miR-766-5p
0.0106
-1.75
1.6
2.4
0.7576
20534302 HBII-85-11
0.0111
1.2
1.58
1.32
0.7791
20500791 hsa-miR-188-5p
0.0112
-2.19
1.71
2.85
0.7791
20512262 hsa-miR-2277-3p
0.0113
1.76
2.42
1.61
0.7791
20504583 hsa-miR-766-3p
0.0116
-1.41
3.5
4
0.7791
20537158 hsa-mir-5583-2
0.0116
-1.38
1.43
1.89
0.7791
20534534 hsa-mir-217
0.0118
1.27
1.59
1.25
0.7791
20533843 ENSG00000251974
0.012
1.15
1.07
0.87
0.7791
20500194 hsa-miR-106a-5p
0.0121
-1.67
10.35
11.09
0.7791
20501176 hsa-miR-99b-5p
0.0122
-1.26
7.57
7.9
0.7791
20501312 hsa-miR-345-5p
0.0122
-1.88
4.28
5.18
0.7791
20534858 hsa-mir-380
0.0122
-1.37
1.33
1.78
0.7791
20537157 hsa-mir-5583-2
0.0128
-1.36
1.44
1.89
0.7791
20505746 hsa-miR-874-3p
0.0129
-1.95
2.62
3.59
0.7791
20518627 hsa-miR-548y
0.0131
-1.28
0.98
1.34
0.7791
20500144 hsa-miR-22-3p
0.0132
-2.31
1.68
2.89
0.7791

Chromosome
chr7
chr19
chr12
chr2
chr22
chrX
chr20
chr2
chr2
chr12
chr20
chrX
chr15
chrX
chr5
chrX
chr18
chr2
chr2
chrX
chr19
chr14
chr14
chr18
chr5
chr14
chr17
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Table A.1. Small RNAs significantly altered following TDP-43 Knockdown.
ID
Transcript ID(Array
P-val
Fold Change
siTDP Avg (log2) SCR Avg (log2) FDR PDesign)
val
20518852 hsa-miR-4467
0.0133
1.51
4.79
4.2
0.7791
20500196 hsa-miR-107
0.0136
-1.26
10.08
10.42
0.7791
20517834 hsa-miR-3620-3p
0.0136
1.65
3.04
2.32
0.7791
20519670 hsa-miR-4783-3p
0.0137
-1.61
1.32
2.01
0.7791
20515607 hsa-miR-3178
0.0138
1.37
7.99
7.53
0.7791
20534830 hsa-mir-361
0.0138
-1.22
7.2
7.5
0.7791
20535688 hsa-mir-937
0.014
-1.61
1.57
2.26
0.7791
20538244 U73a
0.0141
1.39
8.76
8.29
0.7791
20500419 hsa-miR-129-1-3p
0.0142
1.36
1.31
0.87
0.7791
20504310 hsa-miR-582-3p
0.0142
-1.17
1.09
1.32
0.7791
20534042 ENSG00000252787
0.0142
-1.31
1.69
2.08
0.7791
20500162 hsa-miR-30a-5p
0.0143
-2.17
1.99
3.11
0.7791
20504374 hsa-miR-626
0.0143
-1.44
0.79
1.31
0.7791
20535102 hsa-mir-450a-1
0.0143
1.58
1.54
0.89
0.7791
20500454 hsa-miR-187-5p
0.0145
-1.46
2.03
2.57
0.7803
20525731 hsa-miR-6885-5p
0.0146
-2.28
1.68
2.87
0.7803
20534315 HBII-85-22
0.0149
-1.28
1.13
1.49
0.7857
20533699 ENSG00000239063
0.0153
-1.24
1.08
1.39
0.7857
20500182 hsa-miR-99a-3p
0.0154
1.36
1.52
1.08
0.7857
20522031 hsa-miR-5696
0.0154
-1.5
1.12
1.7
0.7857
20506886 hsa-miR-1288-3p
0.0156
-1.81
1.3
2.15
0.7857
20537429 hsa-mir-548ay
0.0157
-1.34
1.2
1.62
0.7857
20525479 hsa-miR-6759-5p
0.0158
-1.24
1.24
1.56
0.7857
20503808 hsa-miR-193b-3p
0.016
-1.48
7.5
8.07
0.7857
20533957 ENSG00000252433
0.0163
1.16
1.18
0.96
0.7857
20529782 hsa-miR-8072
0.0165
1.47
7.11
6.56
0.7857
20533570 ENSG00000238863
0.0165
1.21
1.16
0.88
0.7857

Chromosome
chr7
chr10
chr1
chr2
chr16
chrX
chr8
chr4
chr7
chr5
chr3
chr6
chr15
chrX
chr18
chr19
chr15
chr1
chr21
chr2
chr17
chr3
chr12
chr16
chr1
chr12
chr18
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Table A.1. Small RNAs significantly altered following TDP-43 Knockdown.
ID
Transcript ID(Array
P-val
Fold Change
siTDP Avg (log2) SCR Avg (log2) FDR PDesign)
val
20519468 hsa-miR-4670-5p
0.0168
1.22
1.75
1.46
0.7857
20535131 hsa-mir-376b
0.0168
-1.61
0.85
1.54
0.7857
20536884 hsa-mir-4662a
0.0168
1.46
1.66
1.12
0.7857
20519591 hsa-miR-4740-3p
0.0169
-1.92
1.55
2.49
0.7857
20535101 hsa-mir-450a-1
0.0169
1.21
1.18
0.91
0.7857
20535879 hsa-mir-1263
0.017
-1.78
2.08
2.91
0.7857
20532658 ACA35
0.0172
-1.23
1.38
1.68
0.7857
20500723 hsa-miR-27b-3p
0.0173
-2
4.11
5.12
0.7857
20532645 ACA2b
0.0174
1.43
1.31
0.79
0.7857
20534091 ENSG00000253013
0.0175
-1.45
1.78
2.31
0.7857
20537086 hsa-mir-5094
0.0176
1.47
2.5
1.94
0.7857
20533733 ENSG00000239123
0.0177
-1.45
1.57
2.11
0.7857
20506844 hsa-miR-1251-5p
0.0178
1.37
1.52
1.07
0.7857
20519459 hsa-miR-4666a-5p
0.0178
-1.21
1.56
1.83
0.7857
20534234 HBII-240
0.0178
1.28
1.31
0.96
0.7857
20533793 ENSG00000251775
0.018
1.19
1.53
1.27
0.7863
20536614 hsa-mir-3915
0.0182
-1.25
1.09
1.41
0.7863
20501772 hsa-miR-196b-3p
0.0183
-2.06
2.98
4.02
0.7863
20535671 hsa-mir-873
0.0183
1.53
1.65
1.04
0.7863
20522537 hsa-miR-5787
0.0184
1.38
7.77
7.3
0.7863
20518782 hsa-miR-1268b
0.0186
1.44
5.82
5.3
0.7921
20533113 ENSG00000212558
0.0189
1.57
1.86
1.21
0.7967
20500163 hsa-miR-30a-3p
0.0191
-1.86
2.64
3.53
0.8027
20537639 hsa-mir-6893
0.0196
-1.49
1.63
2.21
0.8148
20520195 hsa-miR-4999-3p
0.0199
-1.45
1
1.54
0.8148
20533553 ENSG00000238841
0.0199
1.48
1.76
1.2
0.8148
20536792 hsa-mir-4514
0.02
-1.28
1.29
1.65
0.8148

Chromosome
chr9
chr14
chr8
chr17
chrX
chr3
chr1
chr9
chr12
chr4
chr15
chr7
chr12
chr1
chr5
chr2
chrX
chr7
chr9
chr3
chr17
chr2
chr6
chr8
chr19
chr7
chr15
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Table A.1. Small RNAs significantly altered following TDP-43 Knockdown.
ID
Transcript ID(Array
P-val
Fold Change
siTDP Avg (log2) SCR Avg (log2) FDR PDesign)
val
20500130 hsa-miR-17-5p
0.0202
-1.62
10.53
11.23
0.8148
20509227 hsa-miR-1909-3p
0.0204
2.06
3.17
2.12
0.8148
20533041 ENSG00000212211
0.0204
1.39
1.67
1.2
0.8148
20534125 ENSG00000262620
0.0204
1.39
1.67
1.2
0.8148
20506837 hsa-miR-1246
0.0205
2.18
7.14
6.01
0.8157
20500132 hsa-miR-18a-5p
0.0207
-1.81
7.22
8.07
0.8181
20500779 hsa-miR-146a-3p
0.021
-1.3
1.44
1.82
0.8181
20535199 hsa-mir-516a-1
0.0211
1.29
1.36
1
0.8181
20535200 hsa-mir-516a-2
0.0211
1.29
1.36
1
0.8181
20525423 hsa-miR-6730-3p
0.0215
-1.17
1.59
1.81
0.8235
20535457 hsa-mir-762
0.0217
1.52
2.08
1.47
0.8235
20538108 SNORA84
0.0218
-1.13
1.76
1.94
0.8235
20537161 hsa-mir-5586
0.0219
-1.15
1.05
1.26
0.8235
20536218 hsa-mir-3132
0.022
-1.33
1.48
1.88
0.8235
20536616 hsa-mir-3914-2
0.022
1.42
1.47
0.96
0.8235
20538300 mgh28S-2411
0.0221
1.13
8.7
8.52
0.8235
20533286 ENSG00000238436
0.023
1.75
2.13
1.32
0.8278
20500787 hsa-miR-185-5p
0.0233
-1.78
6.52
7.36
0.8278
20537253 hsa-mir-6080
0.0234
-1.67
1.68
2.42
0.8278
20535146 hsa-mir-493
0.0235
-1.84
1.57
2.45
0.8278
20525515 hsa-miR-6777-5p
0.0236
1.62
3.26
2.56
0.8278
20500142 hsa-miR-21-3p
0.0237
-1.19
1.5
1.75
0.8278
20500446 hsa-miR-181b-5p
0.0239
-1.31
5.88
6.27
0.8278
20515644 hsa-miR-3200-5p
0.0239
-1.57
1.17
1.82
0.8278
20532737 ENSG00000199411
0.0239
-1.24
1.52
1.83
0.8278
20517917 hsa-miR-3664-5p
0.024
1.13
1.35
1.17
0.8278
20506787 hsa-miR-1237-5p
0.0243
1.4
7.38
6.89
0.8278

Chromosome
chr13
chr19
chr3
chrHG1091_PATCH
chr2
chr13
chr5
chr19
chr19
chr1
chr16
chr9
chr14
chr2
chr7
chr11
chr12
chr22
chr17
chr14
chr17
chr17
chr1
chr22
chr9
chr11
chr11
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Table A.1. Small RNAs significantly altered following TDP-43 Knockdown.
ID
Transcript ID(Array
P-val
Fold Change
siTDP Avg (log2) SCR Avg (log2) FDR PDesign)
val
20533253 ENSG00000238375
0.0243
-1.18
1.4
1.63
0.8278
20538319 hsa-mir-4466
0.0243
1.38
2.67
2.2
0.8278
20517909 hsa-miR-3658
0.0244
1.16
0.96
0.75
0.8278
20533389 ENSG00000238581
0.0244
-1.69
2.48
3.23
0.8278
20536546 hsa-mir-3620
0.0244
-1.79
1.37
2.21
0.8278
20538019 hsa-mir-8061
0.0248
-1.53
1.16
1.77
0.8278
20529568 hsa-miR-7977
0.0249
1.44
5.78
5.25
0.8278
20536885 hsa-mir-4659b
0.0249
1.53
1.6
0.99
0.8278
20534270 HBII-52-26
0.025
1.13
1.32
1.13
0.8278
20535432 hsa-mir-758
0.0251
-1.52
1.71
2.31
0.8278
20536865 hsa-mir-4645
0.0251
-1.51
1.5
2.09
0.8278
20517955 hsa-miR-3691-3p
0.0252
-1.62
1.66
2.36
0.8278
20519604 hsa-miR-4747-5p
0.0255
-1.4
1.24
1.73
0.8278
20532859 ENSG00000201410
0.0255
-1.51
1.09
1.68
0.8278
20536493 hsa-mir-4276
0.0256
-1.49
1.28
1.85
0.8278
20518897 hsa-miR-4501
0.0257
-1.52
1.02
1.63
0.8278
20515523 hsa-miR-3125
0.0262
-1.15
0.98
1.18
0.8278
20537984 hsa-mir-4433b
0.0262
-1.11
1.14
1.29
0.8278
20533462 ENSG00000238696
0.0265
1.37
1.45
0.99
0.8278
20535899 hsa-mir-1277
0.0265
-1.19
0.93
1.17
0.8278
20533115 ENSG00000212565
0.0266
1.23
1.25
0.95
0.8278
20536766 hsa-mir-4492
0.0266
-1.46
1.67
2.22
0.8278
20533756 ENSG00000239153
0.0268
1.42
1.92
1.42
0.8278
20533606 ENSG00000238922
0.027
-1.8
1.09
1.94
0.8278
20505747 hsa-miR-890
0.0272
-1.42
0.98
1.49
0.8278
20517821 hsa-miR-3613-3p
0.0273
1.56
6.92
6.27
0.8278
20518843 hsa-miR-3135b
0.0273
1.57
5.43
4.79
0.8278

Chromosome
chr6
chr6
chr1
chr21
chr1
chr19
chr3
chr8
chr15
chr14
chr6
chr6
chr19
chr3
chr4
chr13
chr2
chr2
chr2
chrX
chr17
chr11
chr11
chr7
chrX
chr13
chr6
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Table A.1. Small RNAs significantly altered following TDP-43 Knockdown.
ID
Transcript ID(Array
P-val
Fold Change
siTDP Avg (log2) SCR Avg (log2) FDR PDesign)
val
20534622 hsa-mir-138-1
0.0274
-1.19
1.59
1.84
0.8278
20533190 ENSG00000223111
0.0275
-1.4
1.33
1.82
0.8278
20533191 ENSG00000223182
0.0275
-1.4
1.33
1.82
0.8278
20534172 ENSG00000265733
0.0275
-1.4
1.33
1.82
0.8278
20535888 hsa-mir-1272
0.0276
1.61
1.68
1
0.8278
20519517 hsa-miR-4701-5p
0.0279
1.56
2.26
1.62
0.8284
20534238 HBII-295
0.0281
-1.39
1.52
1.99
0.8284
20538489 gi:555853
0.0281
-1.14
13.45
13.63
0.8284
20525026 hsa-miR-6512-3p
0.0283
-1.29
1.2
1.57
0.8284
20538262 U85
0.0284
-1.92
1.38
2.32
0.8284
20536900 hsa-mir-4674
0.0286
1.58
2.37
1.71
0.8284
20533047 ENSG00000212229
0.0289
-1.15
1.41
1.62
0.8284
20536970 hsa-mir-4734
0.0289
1.4
2.43
1.94
0.8284
20521782 hsa-miR-4524b-3p
0.029
-1.27
1.22
1.56
0.8284
20525453 hsa-miR-6746-5p
0.029
1.94
3.47
2.51
0.8284
20525706 hsa-miR-6872-3p
0.029
-1.87
1.82
2.72
0.8284
20501233 hsa-miR-373-5p
0.0291
-1.22
1.06
1.34
0.8284
20535918 hsa-mir-1255b-2
0.0294
-1.41
1
1.5
0.8324
20506788 hsa-miR-1237-3p
0.0297
-1.64
1.51
2.23
0.8331
20535387 hsa-mir-638
0.0297
1.12
1.86
1.69
0.8331
20536635 hsa-mir-676
0.0298
-1.35
1.28
1.71
0.8331
20519611 hsa-miR-4751
0.0299
1.35
1.76
1.33
0.8331
20521839 hsa-miR-5590-3p
0.0301
-1.22
0.89
1.18
0.8338
20533114 ENSG00000212558
0.0302
1.52
1.87
1.27
0.8353
20536437 hsa-mir-4293
0.0306
-1.86
1.49
2.39
0.8415
20533384 ENSG00000238575
0.0307
-1.09
1.19
1.32
0.8415
20538016 hsa-mir-8058
0.0309
1.49
1.9
1.32
0.8427

Chromosome
chr3
chr10
chr10
chrHG1211_PATCH
chr15
chr12
chr9
chr2
chr12
chr9
chr6
chr17
chr17
chr11
chr3
chr19
chr1
chr11
chr19
chrX
chr19
chr2
chr2
chr10
chr18
chr16
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Table A.1. Small RNAs significantly altered following TDP-43 Knockdown.
ID
Transcript ID(Array
P-val
Fold Change
siTDP Avg (log2) SCR Avg (log2) FDR PChromosome
Design)
val
20500751 hsa-miR-143-5p
0.0314
-1.55
1.83
2.46
0.8492 chr5
20535453 hsa-mir-766
0.0315
1.33
1.7
1.28
0.8492 chrX
20518803 hsa-miR-548ad
0.0316
-1.29
0.89
1.26
0.8492 chr2
20533729 ENSG00000239111
0.0316
-1.26
1.42
1.75
0.8492 chr1
20537586 hsa-mir-6841
0.0318
1.21
1.43
1.15
0.85 chr8
20536796 hsa-mir-4518
0.0321
-1.29
1.68
2.05
0.8541 chr16
20506869 hsa-miR-1273a
0.0324
-1.56
1.33
1.98
0.855 chr8
20519679 hsa-miR-4787-5p
0.0324
1.29
9.22
8.85
0.855 chr3
20502122 hsa-miR-422a
0.0326
-1.22
6.64
6.93
0.855 chr15
20536615 hsa-mir-3914-2
0.0326
1.46
1.52
0.97
0.855 chr7
20533707 ENSG00000239072
0.0332
1.43
1.95
1.44
0.8557 chr2
20534829 hsa-mir-26a-2
0.0333
-1.25
1.38
1.7
0.8557 chr12
20532669 ACA40
0.0334
-1.72
2.02
2.8
0.8557 chr11
20532862 ENSG00000201465
0.0334
-1.19
1.17
1.42
0.8557 chr7
20500469 hsa-miR-212-3p
0.0335
1.84
3.6
2.72
0.8557 chr17
20535218 hsa-mir-509-1
0.0337
-1.43
1.15
1.67
0.8557 chrX
20535638 hsa-mir-509-2
0.0337
-1.43
1.15
1.67
0.8557 chrX
20535683 hsa-mir-509-3
0.0337
-1.43
1.15
1.67
0.8557 chrX
20533559 ENSG00000238852
0.0339
-1.22
1.45
1.74
0.8573 chr2
20536652 hsa-mir-374c
0.0343
1.13
1.74
1.56
0.8636 chrX
20538460 spike_in-control-17
0.035
1.2
1.68
1.42
0.8659
20533092 ENSG00000212445
0.0354
-1.56
1.59
2.23
0.8659 chr16
20515564 hsa-miR-3150a-5p
0.0356
-1.45
1.58
2.12
0.8659 chr8
20532765 ENSG00000199934
0.0358
-1.34
0.94
1.36
0.8659 chr1
20534526 hsa-mir-210
0.0359
-1.59
1.82
2.5
0.8659 chr11
20518882 hsa-miR-4488
0.0364
1.27
7.51
7.16
0.8659 chr11
20506012 hsa-miR-941
0.0365
-1.61
4.5
5.2
0.8659 chr20
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Table A.1. Small RNAs significantly altered following TDP-43 Knockdown.
ID
Transcript ID(Array
P-val
Fold Change
siTDP Avg (log2) SCR Avg (log2) FDR PDesign)
val
20518628 hsa-miR-3939
0.0367
-1.31
1.42
1.81
0.8659
20538044 hsa-mir-8084
0.0367
1.23
1.28
0.98
0.8659
20517712 hsa-miR-4254
0.0369
1.79
2.44
1.6
0.8659
20536805 hsa-mir-4525
0.037
-2.04
1.46
2.49
0.8659
20536907 hsa-mir-4679-1
0.037
1.17
1.1
0.87
0.8659
20532994 ENSG00000207130
0.0371
1.21
1.7
1.42
0.8659
20536318 hsa-mir-3198-1
0.0374
-1.66
1.58
2.31
0.8659
20536933 hsa-mir-3198-2
0.0374
-1.66
1.58
2.31
0.8659
20500450 hsa-miR-182-5p
0.0375
-1.55
7.51
8.14
0.8659
20500728 hsa-miR-124-5p
0.0375
1.33
2.22
1.81
0.8659
20525690 hsa-miR-6864-3p
0.0376
1.22
1.48
1.2
0.8659
20529133 hsa-miR-1273h-3p
0.0377
1.23
1.88
1.59
0.8659
20538303 snR38C
0.0379
1.3
8.43
8.05
0.8659
20533280 ENSG00000238428
0.0383
-2.4
1.17
2.43
0.8659
20535144 hsa-mir-202
0.0383
1.33
1.61
1.2
0.8659
20535822 hsa-mir-1285-2
0.0384
-1.18
1.14
1.37
0.8659
20537608 hsa-mir-6862-1
0.0385
-1.53
1.27
1.89
0.8659
20538092 hsa-mir-6862-2
0.0385
-1.53
1.27
1.89
0.8659
20525466 hsa-miR-6752-3p
0.039
-1.4
0.86
1.35
0.8659
20533988 ENSG00000252557
0.0394
1.11
1.17
1.02
0.8659
20537594 hsa-mir-6849
0.0398
1.63
2.18
1.48
0.8659
20535143 hsa-mir-146b
0.0399
-1.4
1.38
1.86
0.8659
20504553 hsa-miR-671-3p
0.04
-1.57
2.19
2.84
0.8659
20518856 hsa-miR-4471
0.04
1.21
1.46
1.18
0.8659
20534845 hsa-mir-376c
0.0403
1.32
1.52
1.11
0.8659
20533749 ENSG00000239141
0.0404
1.22
1.42
1.14
0.8659
20536576 hsa-mir-3672
0.0404
-1.19
1.21
1.46
0.8659

Chromosome
chr6
chr8
chr1
chr17
chr10
chr3
chr22
chr12
chr7
chr20
chr17
chr16
chr17
chr2
chr10
chr2
chr16
chr16
chr11
chr7
chr8
chr10
chr7
chr8
chr14
chr3
chrX
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Table A.1. Small RNAs significantly altered following TDP-43 Knockdown.
ID
Transcript ID(Array
P-val
Fold Change
siTDP Avg (log2) SCR Avg (log2) FDR PDesign)
val
20536718 hsa-mir-4461
0.0404
1.41
1.96
1.47
0.8659
20537236 hsa-mir-5739
0.0404
-1.13
1.14
1.31
0.8659
20504328 hsa-miR-591
0.0405
-1.19
0.98
1.23
0.8659
20518000 hsa-miR-3714
0.0407
-2.06
1.26
2.31
0.8659
20536641 hsa-mir-3936
0.0408
1.47
1.89
1.34
0.8659
20532585 14qII-17
0.0409
1.16
1.3
1.09
0.8659
20533179 ENSG00000222185
0.0409
1.28
1.23
0.87
0.8659
20536873 hsa-mir-4652
0.041
-1.34
1.16
1.59
0.8659
20536028 hsa-mir-2116
0.0411
-1.25
1.39
1.71
0.8659
20534577 hsa-mir-124-1
0.0414
1.27
1.31
0.97
0.8659
20501155 hsa-miR-194-3p
0.0418
-1.89
1.32
2.23
0.8659
20538236 U71a
0.0418
-1.22
2.21
2.5
0.8659
20533593 ENSG00000238899
0.042
-1.53
1.15
1.76
0.8659
20537563 hsa-mir-6819
0.042
1.43
2.46
1.95
0.8659
20536695 hsa-mir-4441
0.0421
-1.37
1.3
1.75
0.8659
20506004 hsa-miR-935
0.0422
-1.37
6.38
6.84
0.8659
20515638 hsa-miR-3196
0.0422
1.79
9.31
8.47
0.8659
20536509 hsa-mir-4289
0.0424
-1.24
1.61
1.92
0.8659
20534362 hsa-mir-22
0.0426
-1.17
1.5
1.73
0.8659
20519409 hsa-miR-4634
0.043
1.61
1.98
1.3
0.8659
20533323 ENSG00000238494
0.0431
1.27
1.68
1.33
0.8659
20533349 ENSG00000238535
0.0431
1.27
1.68
1.33
0.8659
20500486 hsa-miR-222-3p
0.0432
-1.26
11.72
12.04
0.8659
20533061 ENSG00000212309
0.0433
1.24
1.47
1.16
0.8659
20519473 hsa-miR-4673
0.0434
-1.56
1.91
2.55
0.8659
20500780 hsa-miR-149-5p
0.0435
-1.23
5.69
5.98
0.8659
20506873 hsa-miR-1276
0.0435
1.39
1.3
0.82
0.8659

Chromosome
chr5
chr22
chr7
chr3
chr5
chr14
chr14
chr7
chr15
chr8
chr11
chr20
chr5
chr22
chr2
chr19
chr20
chr9
chr17
chr5
chr15
chr15
chrX
chr2
chr9
chr2
chr15
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Table A.1. Small RNAs significantly altered following TDP-43 Knockdown.
ID
Transcript ID(Array
P-val
Fold Change
siTDP Avg (log2) SCR Avg (log2) FDR PDesign)
val
20537227 hsa-mir-5704
0.0437
1.23
1.53
1.23
0.8659
20525544 hsa-miR-6791-3p
0.0441
1.35
1.75
1.31
0.8659
20532879 ENSG00000201701
0.0441
1.47
1.51
0.96
0.8659
20533390 ENSG00000238582
0.0441
-1.4
1.14
1.63
0.8659
20517938 hsa-miR-3680-5p
0.0442
1.51
1.79
1.19
0.8659
20538307 ENSG00000199552
0.0443
-1.4
1.35
1.84
0.8659
20536557 hsa-mir-3653
0.0444
-1.41
1.96
2.46
0.8659
20538115 SNORD125
0.0444
-1.41
1.96
2.46
0.8659
20537439 hsa-mir-6508
0.0445
1.49
1.77
1.19
0.8659
20500399 hsa-miR-199a-5p
0.0447
-1.3
1.59
1.97
0.8659
20532847 ENSG00000201316
0.0449
1.2
1.69
1.43
0.8659
20534374 hsa-mir-28
0.0449
-1.12
1.6
1.77
0.8659
20536552 hsa-mir-3648
0.0449
1.64
3
2.29
0.8659
20507744 hsa-miR-1471
0.045
-1.52
1.37
1.97
0.8659
20501157 hsa-miR-106b-5p
0.0451
-1.77
7.43
8.25
0.8659
20536555 hsa-mir-3651
0.0451
1.24
3.15
2.84
0.8659
20538106 SNORA84
0.0451
1.24
3.15
2.84
0.8659
20537597 hsa-mir-6852
0.0452
1.53
2.05
1.44
0.8659
20502452 hsa-miR-452-3p
0.0453
1.37
1.54
1.08
0.8659
20519587 hsa-miR-4738-5p
0.046
1.22
1.55
1.26
0.8659
20501201 hsa-miR-362-5p
0.0461
-2.41
3.84
5.11
0.8659
20536268 hsa-mir-3161
0.0462
1.33
1.4
0.98
0.8659
20536464 hsa-mir-4323
0.0464
-1.32
2.4
2.8
0.8659
20533219 ENSG00000238328
0.0466
1.2
1.31
1.05
0.8659
20535414 hsa-mir-656
0.0467
-1.12
1.34
1.51
0.8659
20520197 hsa-miR-5000-3p
0.0469
1.4
1.43
0.95
0.8659
20535306 hsa-mir-568
0.0469
1.24
1.37
1.06
0.8659

Chromosome
chr3
chr19
chr3
chr2
chr16
chr5
chr22
chr22
chr21
chr1
chr8
chr3
chr21
chr2
chr7
chr9
chr9
chr9
chrX
chr17
chrX
chr11
chr19
chr2
chr14
chr2
chr3
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Table A.1. Small RNAs significantly altered following TDP-43 Knockdown.
ID
Transcript ID(Array
P-val
Fold Change
siTDP Avg (log2) SCR Avg (log2) FDR PDesign)
val
20538000 hsa-mir-548ba
0.047
1.25
1.21
0.89
0.8659
20536435 hsa-mir-4297
0.0473
-1.47
2.57
3.13
0.8659
20533067 ENSG00000212347
0.0474
1.35
1.2
0.77
0.8659
20534199 ENSG00000268513
0.0474
1.35
1.2
0.77
0.8659
20525420 hsa-miR-6729-5p
0.0475
1.23
8.67
8.38
0.8659
20535180 hsa-mir-517a
0.0479
-1.18
1.13
1.37
0.8659
20506811 hsa-miR-548j-3p
0.048
-1.54
1.16
1.78
0.8659
20525525 hsa-miR-6782-5p
0.048
2.12
3.13
2.05
0.8659
20533794 ENSG00000251778
0.048
-1.51
1.25
1.85
0.8659
20533967 ENSG00000252458
0.048
-1.14
1.36
1.55
0.8659
20537632 hsa-mir-6886
0.0481
-1.43
2.8
3.32
0.8659
20538270 U90
0.0482
-1.35
1.85
2.28
0.8659
20519410 hsa-miR-4635
0.0485
-1.44
3.96
4.48
0.8659
20502130 hsa-miR-425-3p
0.0488
-2.24
2.64
3.8
0.8659
20518790 hsa-miR-4421
0.0488
1.36
1.55
1.11
0.8659
20536504 hsa-mir-4284
0.0488
1.27
1.91
1.56
0.8659
20536541 hsa-mir-3616
0.0488
1.32
2.1
1.69
0.8659
20538045 hsa-mir-8085
0.0492
-1.49
1.54
2.12
0.8659
20533700 ENSG00000239063
0.0496
-1.35
1.21
1.65
0.8659
20500152 hsa-miR-26a-5p
0.0497
-1.43
8.25
8.77
0.8659
20502237 hsa-miR-20b-5p
0.0498
-1.59
6.18
6.85
0.8659
20504550 hsa-miR-758-3p
0.0498
-1.59
1.18
1.84
0.8659
20500139 hsa-miR-20a-5p
0.0499
-1.55
9.45
10.08
0.8659
20536578 hsa-mir-3674
0.05
-1.19
1.07
1.32
0.8659

Chromosome
chr2
chr10
chrX
chrHG1435_PATCH
chr1
chr19
chr22
chr17
chr21
chr5
chr19
chr3
chr5
chr3
chr1
chr7
chr20
chr19
chr1
chr12
chrX
chr14
chr13
chr8
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Table A.2. Small RNAs significantly altered following FUS Knockdown.
ID
Transcript ID(Array P-val
Fold Change
siFUS Avg (log2)
SCR Avg (log2) FDR PDesign)
val
20537518 hsa-mir-6775
0.0002
-2.34
1.61
2.83
0.8811
20534818 hsa-mir-219a-2
0.0003
-1.49
1.31
1.89
0.8811
20518818 hsa-miR-4443
0.0005
-1.46
6.5
7.04
0.8811
20535460 hsa-mir-1298
0.0005
-1.3
1.68
2.07
0.8811
20537592 hsa-mir-6847
0.0009
1.66
2.24
1.51
0.9953
20536775 hsa-mir-4500
0.001
-1.69
1.33
2.09
0.9953
20506005 hsa-miR-936
0.0011
-1.56
1.29
1.94
0.9953
20535879 hsa-mir-1263
0.0017
-2.15
1.81
2.91
0.9953
20522017 hsa-miR-548ax
0.0023
-1.63
0.95
1.66
0.9953
20520348 hsa-miR-5095
0.0025
-1.49
1.31
1.88
0.9953
20517909 hsa-miR-3658
0.0028
1.29
1.11
0.75
0.9953
20529568 hsa-miR-7977
0.0029
1.9
6.18
5.25
0.9953
20536752 hsa-mir-4480
0.003
-1.3
1.23
1.6
0.9953
20533957 ENSG00000252433
0.003
1.29
1.33
0.96
0.9953
20537586 hsa-mir-6841
0.0031
1.3
1.53
1.15
0.9953
20532591 14qII-20
0.0032
1.28
1.53
1.18
0.9953
20525669 hsa-miR-6854-5p
0.0033
1.5
1.58
1
0.9953
20504582 hsa-miR-766-5p
0.0033
-1.91
1.47
2.4
0.9953
20525546 hsa-miR-6792-3p
0.0039
1.51
1.59
0.99
0.9953
20536018 hsa-mir-1976
0.0039
-1.9
1.51
2.44
0.9953
20534091 ENSG00000253013
0.004
-1.82
1.44
2.31
0.9953
20537456 hsa-mir-6715b
0.0041
1.36
2.16
1.72
0.9953
20517821 hsa-miR-3613-3p
0.0052
1.81
7.13
6.27
0.9953
20532932 ENSG00000202449
0.0053
1.32
1.22
0.81
0.9953
20525569 hsa-miR-6804-5p
0.0054
-1.85
1.25
2.14
0.9953
20518879 hsa-miR-4485
0.0054
1.5
7.49
6.9
0.9953
20536268 hsa-mir-3161
0.0054
1.6
1.66
0.98
0.9953
20535402 hsa-mir-652
0.0055
-1.48
1.49
2.06
0.9953

Chromosome
chr16
chr9
chr3
chrX
chr8
chr13
chr10
chr3
chrX
chr1
chr1
chr3
chr10
chr1
chr8
chr14
chr9
chrX
chr19
chr1
chr4
chr10
chr13
chr4
chr19
chr11
chr11
chrX
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Table A.2. Small RNAs significantly altered following FUS Knockdown.
ID
Transcript ID(Array P-val
Fold Change
siFUS Avg (log2)
SCR Avg (log2) FDR PDesign)
val
20533069 ENSG00000212363
0.0057
1.3
1.3
0.91
0.9953
20536889 hsa-mir-4664
0.0059
-1.51
1.47
2.06
0.9953
20518816 hsa-miR-4441
0.0071
-1.23
1.17
1.46
0.9953
20537988 hsa-mir-7845
0.0073
-1.88
1.54
2.45
0.9953
20536920 hsa-mir-4689
0.0075
-1.85
1.68
2.57
0.9953
20536297 hsa-mir-3181
0.0076
1.48
1.88
1.31
0.9953
20536025 hsa-mir-2110
0.0076
1.27
1.93
1.58
0.9953
20525027 hsa-miR-6513-5p
0.0078
-1.59
1.41
2.08
0.9953
20536800 hsa-mir-4521
0.0078
1.57
2.25
1.6
0.9953
20500741 hsa-miR-135a-3p
0.008
-1.64
1.15
1.86
0.9953
20532570 14qI-5
0.0082
1.4
1.46
0.97
0.9953
20520197 hsa-miR-5000-3p
0.0083
1.53
1.56
0.95
0.9953
20533763 ENSG00000239159
0.0084
-1.33
0.99
1.41
0.9953
20537563 hsa-mir-6819
0.0085
1.57
2.6
1.95
0.9953
20519451 hsa-miR-4659b-5p
0.0086
1.3
1.18
0.8
0.9953
20518929 hsa-miR-4529-5p
0.0087
1.5
1.78
1.2
0.9953
20534238 HBII-295
0.0088
-1.48
1.42
1.99
0.9953
20535842 hsa-mir-1302-5
0.0092
-1.38
0.91
1.38
0.9953
20500462 hsa-miR-205-5p
0.0094
1.44
1.57
1.04
0.9953
20535432 hsa-mir-758
0.0094
-1.6
1.63
2.31
0.9953
20536497 hsa-mir-4277
0.0106
-1.86
1.73
2.63
0.9953
20537026 hsa-mir-4776-1
0.0107
1.59
2.13
1.46
0.9953
20533253 ENSG00000238375
0.011
-1.27
1.29
1.63
0.9953
20518834 hsa-miR-4454
0.0111
-1.51
7.76
8.36
0.9953
20533431 ENSG00000238656
0.0112
1.11
1.02
0.87
0.9953
20525731 hsa-miR-6885-5p
0.0114
-2.33
1.65
2.87
0.9953
20535446 hsa-mir-1271
0.0114
1.4
2.05
1.57
0.9953
20521804 hsa-miR-548ar-5p
0.0116
1.37
1.55
1.1
0.9953

Chromosome
chr5
chr8
chr2
chr2
chr1
chr16
chr10
chr2
chr17
chr3
chr14
chr2
chr5
chr22
chr8
chr18
chr9
chr20
chr1
chr14
chr5
chr2
chr6
chr4
chr8
chr19
chr5
chr13
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Table A.2. Small RNAs significantly altered following FUS Knockdown.
ID
Transcript ID(Array P-val
Fold Change
siFUS Avg (log2)
SCR Avg (log2) FDR PDesign)
val
20510800 hsa-miR-1973
0.0121
-2.27
1.89
3.07
0.9953
20536628 hsa-mir-3910-2
0.0122
1.52
1.99
1.39
0.9953
20532626 ACA16
0.0125
1.68
2.58
1.83
0.9953
20537565 hsa-mir-6821
0.0126
1.47
1.83
1.27
0.9953
20533128 ENSG00000212604
0.0126
-1.61
1.17
1.86
0.9953
20520565 hsa-miR-5187-5p
0.013
-1.63
0.92
1.62
0.9953
20506771 hsa-miR-1227-5p
0.013
-1.77
2.91
3.74
0.9953
20518893 hsa-miR-4498
0.0131
-1.31
2.24
2.63
0.9953
20532926 ENSG00000202374
0.0132
-1.61
1.42
2.1
0.9953
20522039 hsa-miR-5703
0.0133
-1.91
1.2
2.13
0.9953
20537868 hsa-mir-7152
0.0133
1.53
2.13
1.52
0.9953
20533760 ENSG00000239157
0.0134
-1.23
1.38
1.68
0.9953
20519075 hsa-miR-3973
0.0137
-1.27
1.64
1.99
0.9953
20533280 ENSG00000238428
0.014
-2.15
1.33
2.43
0.9953
20538115 SNORD125
0.0142
-1.49
1.88
2.46
0.9953
20536560 hsa-mir-3656
0.0142
-1.7
1.94
2.71
0.9953
20536557 hsa-mir-3653
0.0142
-1.49
1.88
2.46
0.9953
20536963 hsa-mir-4727
0.0145
-1.5
1.42
2.01
0.9953
20537143 hsa-mir-3680-2
0.0148
1.53
1.83
1.21
0.9953
20536583 hsa-mir-3680-1
0.0148
1.53
1.83
1.21
0.9953
20533583 ENSG00000238888
0.0149
1.39
1.39
0.92
0.9953
20520568 hsa-miR-5189-5p
0.015
-1.93
2.32
3.27
0.9953
20500448 hsa-miR-181c-5p
0.0152
-1.37
1.51
1.97
0.9953
20533980 ENSG00000252526
0.0153
-1.36
1.36
1.81
0.9953
20519408 hsa-miR-4633-3p
0.0157
-1.56
1.26
1.9
0.9953
20504553 hsa-miR-671-3p
0.0158
-1.74
2.04
2.84
0.9953
20533810 ENSG00000251836
0.0158
1.55
1.92
1.29
0.9953
20501274 hsa-miR-340-3p
0.0159
1.25
2.03
1.71
0.9953

Chromosome
chr4
chr9
chr1
chr22
chr15
chr1
chr19
chr12
chr4
chr2
chr10
chr20
chr11
chr2
chr22
chr11
chr22
chr17
chr16
chr16
chr2
chr16
chr19
chr16
chr5
chr7
chr10
chr5
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Table A.2. Small RNAs significantly altered following FUS Knockdown.
ID
Transcript ID(Array P-val
Fold Change
siFUS Avg (log2)
SCR Avg (log2) FDR PDesign)
val
20500454 hsa-miR-187-5p
0.016
-1.53
1.96
2.57
0.9953
20518943 hsa-miR-548an
0.0161
1.32
1.48
1.08
0.9953
20506708 hsa-miR-1178-5p
0.0163
-1.26
1.06
1.39
0.9953
20538215 U61
0.0165
1.28
3.24
2.88
0.9953
20536605 hsa-mir-3909
0.0165
1.57
1.97
1.31
0.9953
20537011 hsa-mir-4769
0.0166
-1.38
1
1.46
0.9953
20538270 U90
0.0168
-1.45
1.74
2.28
0.9953
20533654 ENSG00000238996
0.0168
1.46
1.65
1.1
0.9953
20533156 ENSG00000221300
0.0169
1.31
1.36
0.97
0.9953
20537517 hsa-mir-6774
0.017
-1.6
1.67
2.35
0.9953
20537221 hsa-mir-5699
0.017
1.33
2.01
1.6
0.9953
20533047 ENSG00000212229
0.017
-1.22
1.33
1.62
0.9953
20537519 hsa-mir-6776
0.0171
1.47
4.53
3.97
0.9953
20533594 ENSG00000238900
0.0171
1.26
1.31
0.98
0.9953
20517819 hsa-miR-3612
0.0173
-1.25
0.89
1.21
0.9953
20515608 hsa-miR-3179
0.0174
-1.41
1.15
1.65
0.9953
20506789 hsa-miR-1238-5p
0.0175
-1.6
1.33
2.01
0.9953
20535246 hsa-mir-545
0.0175
1.34
1.72
1.3
0.9953
20524051 hsa-miR-6130
0.0177
-1.11
0.98
1.13
0.9953
20521782 hsa-miR-4524b-3p
0.0184
-1.3
1.18
1.56
0.9953
20534194 ENSG00000268145
0.0185
1.41
1.78
1.29
0.9953
20533963 ENSG00000252441
0.0185
1.41
1.78
1.29
0.9953
20519695 hsa-miR-4797-5p
0.0187
1.42
2
1.49
0.9953
20533808 ENSG00000251830
0.0187
-1.38
1.42
1.89
0.9953
20536580 hsa-mir-3677
0.0189
1.21
2.16
1.89
0.9953
20533952 ENSG00000252405
0.0189
1.26
1.32
0.99
0.9953
20525732 hsa-miR-6885-3p
0.0193
1.66
1.74
1.01
0.9953
20518785 hsa-miR-4417
0.02
-2.11
1.94
3.01
0.9953

Chromosome
chr18
chrX
chr12
chrX
chr22
chrX
chr3
chr9
chr2
chr16
chr10
chr6
chr17
chr10
chr12
chr16
chr19
chrX
chr21
chr17
chrHG1462_PATCH
chrX
chr3
chr6
chr16
chr16
chr19
chr1
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Table A.2. Small RNAs significantly altered following FUS Knockdown.
ID
Transcript ID(Array P-val
Fold Change
siFUS Avg (log2)
SCR Avg (log2) FDR PDesign)
val
20534360 hsa-mir-20a
0.02
1.21
1.47
1.2
0.9953
20537226 hsa-mir-5692b
0.0204
1.36
1.4
0.95
0.9953
20504374 hsa-miR-626
0.0209
-1.26
0.98
1.31
0.9953
20505755 hsa-miR-889-3p
0.0211
1.16
1.18
0.97
0.9953
20537538 hsa-mir-6795
0.0211
1.4
1.59
1.11
0.9953
20536759 hsa-mir-4487
0.0212
-1.74
1.29
2.09
0.9953
20532571 14qI-6
0.0214
1.17
1.53
1.3
0.9953
20506008 hsa-miR-938
0.0216
1.35
1.41
0.97
0.9953
20520217 hsa-miR-5009-3p
0.0218
1.29
1.26
0.89
0.9953
20535360 hsa-mir-613
0.0218
1.21
1.76
1.48
0.9953
20534083 ENSG00000252985
0.022
-1.25
1.46
1.78
0.9953
20535393 hsa-mir-643
0.0225
1.48
1.49
0.93
0.9953
20511549 hsa-miR-2110
0.0228
-2.23
3.11
4.26
0.9953
20519564 hsa-miR-4725-5p
0.023
-1.52
1.35
1.96
0.9953
20536853 hsa-mir-4633
0.023
1.89
2.45
1.53
0.9953
20519432 hsa-miR-4650-3p
0.0231
-1.22
1.17
1.46
0.9953
20535838 hsa-mir-1302-1
0.0232
1.18
1.21
0.98
0.9953
20518928 hsa-miR-4528
0.0237
1.29
1.24
0.87
0.9953
20535673 hsa-mir-374b
0.0242
-1.53
1.49
2.11
0.9953
20538236 U71a
0.0244
-1.29
2.13
2.5
0.9953
20536966 hsa-mir-4730
0.0247
-1.36
2.09
2.54
0.9953
20518919 hsa-miR-4521
0.0248
2.76
5.28
3.81
0.9953
20537229 hsa-mir-5706
0.0248
-1.36
1.18
1.62
0.9953
20504421 hsa-miR-654-3p
0.0249
1.55
2.01
1.38
0.9953
20506710 hsa-miR-1179
0.0251
1.42
1.18
0.67
0.9953
20532880 ENSG00000201710
0.0251
-1.16
1.08
1.29
0.9953
20517721 hsa-miR-4267
0.0257
1.12
1.51
1.34
0.9953
20519587 hsa-miR-4738-5p
0.0258
1.42
1.77
1.26
0.9953

Chromosome
chr13
chr21
chr15
chr14
chr19
chr11
chr14
chr10
chr15
chr12
chr9
chr19
chr10
chr17
chr5
chr7
chr12
chr18
chrX
chr20
chr17
chr17
chr5
chr14
chr15
chr14
chr2
chr17
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Table A.2. Small RNAs significantly altered following FUS Knockdown.
ID
Transcript ID(Array P-val
Fold Change
siFUS Avg (log2)
SCR Avg (log2) FDR PDesign)
val
20536602 hsa-mir-3689b
0.0258
-2.26
1.55
2.72
0.9953
20532737 ENSG00000199411
0.026
-1.32
1.43
1.83
0.9953
20536873 hsa-mir-4652
0.0261
-1.41
1.09
1.59
0.9953
20535353 hsa-mir-606
0.0261
1.49
1.74
1.16
0.9953
20533768 ENSG00000239172
0.0261
-1.19
1.32
1.57
0.9953
20533626 ENSG00000238954
0.0261
-1.19
1.32
1.57
0.9953
20533471 ENSG00000238712
0.0261
-1.19
1.32
1.57
0.9953
20525747 hsa-miR-6893-5p
0.0262
-1.6
1.94
2.62
0.9953
20535926 hsa-mir-1322
0.0262
1.39
1.44
0.97
0.9953
20536327 hsa-mir-3201
0.0263
1.24
1.36
1.05
0.9953
20537167 hsa-mir-5590
0.0264
-1.18
0.82
1.05
0.9953
20505746 hsa-miR-874-3p
0.0265
-1.54
2.96
3.59
0.9953
20501178 hsa-miR-296-5p
0.0265
-1.21
1
1.27
0.9953
20534006 ENSG00000252646
0.0265
1.32
1.71
1.31
0.9953
20501278 hsa-miR-328-3p
0.0266
-2.5
2.34
3.66
0.9953
20501163 hsa-miR-200a-3p
0.0268
-1.13
1.17
1.35
0.9953
20534534 hsa-mir-217
0.0268
1.19
1.5
1.25
0.9953
20533092 ENSG00000212445
0.0268
-1.64
1.51
2.23
0.9953
20504283 hsa-miR-562
0.0269
1.22
1.25
0.96
0.9953
20538016 hsa-mir-8058
0.0269
1.6
2.01
1.32
0.9953
20533869 ENSG00000252083
0.0269
1.49
1.9
1.32
0.9953
20533068 ENSG00000212363
0.0269
1.28
1.24
0.89
0.9953
20502446 hsa-miR-451a
0.027
-1.44
1.49
2.02
0.9953
20519694 hsa-miR-4796-3p
0.0273
1.47
1.55
0.99
0.9953
20506886 hsa-miR-1288-3p
0.0277
-1.62
1.46
2.15
0.9953
20534829 hsa-mir-26a-2
0.0278
-1.33
1.28
1.7
0.9953
20500794 hsa-miR-190a-3p
0.0282
-1.49
1.03
1.6
0.9953
20533596 ENSG00000238902
0.0284
1.28
1.45
1.09
0.9953

Chromosome
chr9
chr9
chr7
chr10
chr16
chr16
chr16
chr8
chr8
chr22
chr2
chr5
chr20
chr1
chr16
chr1
chr2
chr16
chr2
chr16
chr5
chr5
chr17
chr3
chr17
chr12
chr15
chr3
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Table A.2. Small RNAs significantly altered following FUS Knockdown.
ID
Transcript ID(Array P-val
Fold Change
siFUS Avg (log2)
SCR Avg (log2) FDR PDesign)
val
20525421 hsa-miR-6729-3p
0.0286
1.19
1.25
1
0.9953
20525706 hsa-miR-6872-3p
0.0297
-1.73
1.93
2.72
0.9953
20537984 hsa-mir-4433b
0.0302
-1.09
1.18
1.29
0.9953
20532729 ENSG00000199282
0.0302
-1.32
1.17
1.57
0.9953
20533761 ENSG00000239157
0.0306
-1.46
1.16
1.71
0.9953
20504313 hsa-miR-584-3p
0.0307
1.48
2.05
1.48
0.9953
20535198 hsa-mir-527
0.0308
-1.25
1.28
1.6
0.9953
20504429 hsa-miR-659-5p
0.031
-1.62
0.96
1.65
0.9953
20535071 hsa-mir-196b
0.031
1.36
1.91
1.47
0.9953
20532625 ACA16
0.031
1.37
2.68
2.22
0.9953
20525605 hsa-miR-6822-5p
0.0311
-1.29
1.31
1.68
0.9953
20529565 hsa-miR-7974
0.0312
-1.43
1.35
1.87
0.9953
20506873 hsa-miR-1276
0.0316
1.41
1.31
0.82
0.9953
20500779 hsa-miR-146a-3p
0.0317
-1.33
1.4
1.82
0.9953
20536648 hsa-mir-3942
0.0319
1.63
1.97
1.26
0.9953
20537228 hsa-mir-5705
0.0321
1.38
1.77
1.3
0.9953
20519707 hsa-miR-4804-5p
0.0324
-1.15
1.15
1.34
0.9953
20537444 hsa-mir-6513
0.0326
1.53
2.03
1.42
0.9953
20536480 hsa-mir-4265
0.0326
1.29
1.64
1.28
0.9953
20532963 ENSG00000206901
0.0328
1.33
1.82
1.41
0.9953
20537464 hsa-mir-6722
0.033
1.17
5.32
5.08
0.9953
20537446 hsa-mir-6515
0.033
1.34
1.81
1.39
0.9953
20535324 hsa-mir-584
0.0332
-1.18
1.46
1.7
0.9953
20501233 hsa-miR-373-5p
0.0334
1.24
1.65
1.34
0.9953
20537219 hsa-mir-5697
0.0336
1.33
1.68
1.27
0.9953
20536865 hsa-mir-4645
0.0336
-1.37
1.64
2.09
0.9953
20524053 hsa-miR-6132
0.0337
-1.11
2.22
2.37
0.9953
20537030 hsa-mir-4777
0.0337
-1.2
1
1.26
0.9953

Chromosome
chr1
chr3
chr2
chr13
chr20
chr5
chr19
chr22
chr7
chr1
chr3
chr19
chr15
chr5
chr15
chr4
chr5
chr2
chr2
chr2
chr9
chr19
chr5
chr19
chr1
chr6
chr7
chr2
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Table A.2. Small RNAs significantly altered following FUS Knockdown.
ID
Transcript ID(Array P-val
Fold Change
siFUS Avg (log2)
SCR Avg (log2) FDR PDesign)
val
20534582 hsa-mir-125b-1
0.0339
1.28
1.81
1.45
0.9953
20537575 hsa-mir-6831
0.034
1.26
1.85
1.52
0.9953
20537524 hsa-mir-6781
0.034
1.39
2.06
1.59
0.9953
20525685 hsa-miR-6861-3p
0.0341
1.52
1.84
1.24
0.9953
20519602 hsa-miR-4746-5p
0.0344
1.66
2.26
1.53
0.9953
20533477 ENSG00000238722
0.0345
-1.32
1.38
1.79
0.9953
20537213 hsa-mir-5692a-2
0.0347
-1.09
1.42
1.55
0.9953
20537212 hsa-mir-5692a-1
0.0347
-1.09
1.42
1.55
0.9953
20533729 ENSG00000239111
0.0359
-1.2
1.49
1.75
0.9953
20500748 hsa-miR-141-3p
0.036
-1.21
1.1
1.37
0.9953
20505788 hsa-miR-744-3p
0.0364
1.79
2.25
1.41
0.9953
20533412 ENSG00000238620
0.0365
-1.41
1.15
1.64
0.9953
20535310 hsa-mir-570
0.0369
1.55
1.56
0.93
0.9953
20533821 ENSG00000251866
0.0369
-1.31
1.7
2.09
0.9953
20500764 hsa-miR-9-3p
0.037
1.09
1.13
1.01
0.9953
20535101 hsa-mir-450a-1
0.037
1.21
1.19
0.91
0.9953
20533677 ENSG00000239033
0.037
-1.07
1.2
1.31
0.9953
20533330 ENSG00000238506
0.0371
-1.39
1.23
1.7
0.9953
20536506 hsa-mir-4287
0.038
1.31
1.74
1.36
0.9953
20533179 ENSG00000222185
0.0381
1.27
1.22
0.87
0.9953
20532897 ENSG00000201853
0.0381
1.24
1.53
1.21
0.9953
20537083 hsa-mir-5091
0.0383
1.54
2.09
1.47
0.9953
20521817 hsa-miR-548at-3p
0.0386
-1.23
1.27
1.57
0.9953
20532798 ENSG00000200422
0.0387
-1.36
1.04
1.49
0.9953
20504190 hsa-miR-544a
0.0391
1.17
1.11
0.88
0.9953
20535684 hsa-mir-933
0.0392
-1.48
1.72
2.29
0.9953
20536616 hsa-mir-3914-2
0.0393
1.34
1.39
0.96
0.9953
20532598 14qII-26
0.0397
-1.11
1.24
1.39
0.9953

Chromosome
chr11
chr5
chr17
chr12
chr19
chr2
chr8
chr7
chr1
chr12
chr17
chr10
chr3
chr1
chr1
chrX
chr12
chr7
chr8
chr14
chr2
chr4
chr17
chrX
chr14
chr2
chr7
chr14
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Table A.2. Small RNAs significantly altered following FUS Knockdown.
ID
Transcript ID(Array P-val
Fold Change
siFUS Avg (log2)
SCR Avg (log2) FDR PDesign)
val
20515610 hsa-miR-3180-3p
0.0398
-1.35
2.67
3.1
0.9953
20535453 hsa-mir-766
0.0404
1.27
1.63
1.28
0.9953
20532748 ENSG00000199666
0.0406
-1.31
1.42
1.8
0.9953
20505798 hsa-miR-543
0.0407
1.3
1.52
1.14
0.9953
20519481 hsa-miR-4679
0.0409
1.25
1.41
1.09
0.9953
20533532 ENSG00000238806
0.041
1.19
1.36
1.11
0.9953
20535826 hsa-mir-1289-2
0.0411
-1.34
1.24
1.66
0.9953
20529147 hsa-miR-7855-5p
0.0413
1.17
1.65
1.43
0.9953
20500489 hsa-miR-224-5p
0.0413
1.29
1.46
1.09
0.9953
20538460 spike_in-control-17
0.0414
1.21
1.7
1.42
0.9953
20502455 hsa-miR-409-5p
0.0415
1.43
1.86
1.34
0.9953
20534617 hsa-mir-126
0.0415
1.11
2.2
2.06
0.9953
20518872 hsa-miR-548ak
0.0417
1.16
1.15
0.93
0.9953
20501294 hsa-miR-324-5p
0.0417
-2.62
2.55
3.94
0.9953
20535873 hsa-mir-1260a
0.0418
-1.4
1.54
2.02
0.9953
20533695 ENSG00000239058
0.0418
1.19
1.29
1.05
0.9953
20536748 hsa-mir-4479
0.0419
-1.65
1.18
1.9
0.9953
20534005 ENSG00000252646
0.0419
1.42
1.64
1.14
0.9953
20537591 hsa-mir-6846
0.0424
-1.41
1.37
1.86
0.9953
20536702 hsa-mir-4449
0.0424
-1.36
4.46
4.91
0.9953
20520580 hsa-miR-5197-3p
0.0425
1.14
1.08
0.89
0.9953
20520219 hsa-miR-5010-3p
0.0426
-1.27
1.51
1.86
0.9953
20537580 hsa-mir-6780b
0.0428
1.67
2.15
1.42
0.9953
20506857 hsa-miR-1263
0.043
-2.57
2.45
3.81
0.9953
20532771 ENSG00000200026
0.0431
-1.34
2.23
2.66
0.9953
20535683 hsa-mir-509-3
0.0433
-1.37
1.22
1.67
0.9953
20535638 hsa-mir-509-2
0.0433
-1.37
1.22
1.67
0.9953
20535218 hsa-mir-509-1
0.0433
-1.37
1.22
1.67
0.9953

Chromosome
chr16
chrX
chr1
chr14
chr10
chr17
chr5
chr14
chrX
chr14
chr9
chr10
chr17
chr14
chrX
chr9
chr1
chr8
chr4
chr5
chr17
chr6
chr3
chr9
chrX
chrX
chrX
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Table A.2. Small RNAs significantly altered following FUS Knockdown.
ID
Transcript ID(Array P-val
Fold Change
siFUS Avg (log2)
SCR Avg (log2) FDR PDesign)
val
20536576 hsa-mir-3672
0.0435
-1.23
1.17
1.46
0.9953
20538233 U70G
0.0438
1.33
1.55
1.14
0.9953
20533088 ENSG00000212428
0.044
1.21
1.36
1.08
0.9953
20533022 ENSG00000212144
0.0443
-1.18
1.12
1.35
0.9953
20504296 hsa-miR-573
0.0444
1.39
1.57
1.1
0.9953
20536893 hsa-mir-4668
0.0444
1.38
1.32
0.85
0.9953
20519441 hsa-miR-4656
0.0446
1.98
3.27
2.29
0.9953
20525673 hsa-miR-6856-5p
0.0447
-1.57
1
1.65
0.9953
20504310 hsa-miR-582-3p
0.0447
-1.1
1.18
1.32
0.9953
20520215 hsa-miR-5008-3p
0.0448
-2.41
2.29
3.55
0.9953
20501240 hsa-miR-377-5p
0.0448
-1.52
1.22
1.83
0.9953
20536757 hsa-mir-4485
0.0448
1.07
3.14
3.05
0.9953
20537488 hsa-mir-6745
0.0452
1.56
1.99
1.35
0.9953
20533534 ENSG00000238807
0.0452
1.33
2.01
1.6
0.9953
20533007 ENSG00000207299
0.0452
1.33
1.61
1.19
0.9953
20535131 hsa-mir-376b
0.0454
-1.4
1.05
1.54
0.9953
20535350 hsa-mir-603
0.0455
-1.4
1.04
1.52
0.9953
20533849 ENSG00000252000
0.0457
1.42
1.94
1.44
0.9953
20536615 hsa-mir-3914-2
0.0459
1.3
1.35
0.97
0.9953
20533958 ENSG00000252433
0.0459
1.36
1.41
0.96
0.9953
20525492 hsa-miR-6765-3p
0.046
1.32
1.86
1.46
0.9953
20520564 hsa-miR-5186
0.046
1.27
1.11
0.77
0.9953
20515515 hsa-miR-3120-3p
0.0466
1.3
1.47
1.09
0.9953
20515645 hsa-miR-3200-3p
0.0467
-1.48
2.23
2.8
0.9953
20506833 hsa-miR-548f-5p
0.0467
1.21
1.44
1.16
0.9953
20538031 hsa-mir-8072
0.0467
-1.05
1.94
2.01
0.9953
20532576 14qII-10
0.0467
1.37
1.25
0.8
0.9953
20533384 ENSG00000238575
0.0468
-1.09
1.19
1.32
0.9953

Chromosome
chrX
chr12
chr15
chr1
chr4
chr9
chr7
chr9
chr5
chr1
chr14
chr11
chr11
chr17
chr11
chr14
chr10
chr2
chr7
chr1
chr14
chr3
chr1
chr22
chr10
chr12
chr14
chr18
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Table A.2. Small RNAs significantly altered following FUS Knockdown.
ID
Transcript ID(Array P-val
Fold Change
siFUS Avg (log2)
SCR Avg (log2) FDR PDesign)
val
20532731 ENSG00000199321
0.0468
1.32
1.39
0.99
0.9953
20533853 ENSG00000252016
0.0474
1.5
1.97
1.38
0.9953
20536982 hsa-mir-4744
0.0478
-1.23
1.17
1.46
0.9953
20537064 hsa-mir-5000
0.0479
-1.29
1.33
1.7
0.9953
20532819 ENSG00000200891
0.0479
-1.41
1.39
1.89
0.9953
20524999 hsa-miR-6500-5p
0.048
1.14
1.78
1.6
0.9953
20535810 hsa-mir-1204
0.0481
1.23
1.93
1.63
0.9953
20504551 hsa-miR-1264
0.0483
1.22
1.41
1.13
0.9953
20536287 hsa-mir-3176
0.0483
-1.57
1.78
2.44
0.9953
20500445 hsa-miR-181a-2-3p
0.0484
-2.11
1.72
2.8
0.9953
20538234 U70G
0.0487
1.29
1.54
1.17
0.9953
20500135 hsa-miR-19a-3p
0.0488
1.29
1.25
0.88
0.9953
20532744 ENSG00000199566
0.0494
1.22
1.98
1.69
0.9953
20537597 hsa-mir-6852
0.0495
1.58
2.1
1.44
0.9953
20504356 hsa-miR-615-5p
0.0496
-1.28
2
2.35
0.9953
20533762 ENSG00000239159
0.0498
-1.24
1.06
1.37
0.9953
20533966 ENSG00000252448
0.0499
1.13
1.38
1.21
0.9953
20533892 ENSG00000252170
0.0499
-1.2
1.53
1.79
0.9953

Chromosome
chr10
chrX
chr18
chr2
chr10
chr1
chr8
chrX
chr16
chr9
chr12
chr13
chr12
chr9
chr12
chr5
chr1
chr3

294

295

Appendix B
Other scientific contributions
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Amyotrophic lateral sclerosis (ALS) is a debilitating
neurodegenerative disease that is defined by the progressive
loss of motor function due to degeneration of upper and
lower motor neurons in the brain and spinal cord tissue,
respectively, with an average life-expectancy of 2–5 years
post-diagnosis (1). Riluzole and edaravone are currently the
only two FDA approved drugs for patients with ALS, but
these drugs have minimal effect, extending life only for a
matter of months (2).
In 1993, the first causative mutations of ALS were
identified in the SOD1 gene (3). Today, mutations in SOD1 is
the second most common cause of genetic ALS (~5–6% of all
ALS cases), only falling behind the hexanucleotide repeat
expansions observed in C9ORF72 (~12–14% of all ALS
cases). However, the vast majority of ALS cases (~80%)
have no known genetic background giving no clear
indication on the causative factor that results in the disease
development (1). In the last decade, miRNAs have been
increasingly implicated in the pathogenesis of ALS due to
the mass dysregulation of these molecules observed in ALS
spinal cord and motor neurons (4-8).
MiRNAs are small RNA molecules (~22–25 nucleotides)
that are primarily responsible for post-transcriptional genesilencing generally through interactions with the 3’
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untranslated region (UTR) of messenger RNA (mRNA) (9).
Their interactions are highly dependent on environmental
cues. Therefore, cell development, cell type, cell stress, and
aging all have an impact on mRNA post-transcriptional
regulation via miRNAs. This is an especially true for
neurons which have spatiotemporal needs within the cell
where post-transcriptional regulation via miRNAs differs
depending on soma, dendritic and axonal needs (9,10).
Further, miRNAs are also regulated by other non-coding
RNAs (i.e., long non-coding RNAs, circular RNAs, etc.)
which work together to control the degree of expression of a
gene (11), highlighting the sophistication of these noncoding
RNA networks (Figure 1). Not surprisingly, because of
miRNAs dynamic nature in these RNA networks, it has
become increasingly of interest to determine the
contribution of miRNAs in disease.
As mentioned, miRNAs have become increasingly
implicated in ALS pathogenesis. This has mainly stemmed
from observations that in sporadic ALS (sALS) spinal cord
and motor neurons there are pools of miRNAs that are
reduced (4-6). In contrast, mutant SOD1 (mtSOD1) ALS
cases and rodent models have observed that miRNAs are
generally upregulated, suggesting inhibition of these
miRNAs may have therapeutic effects (7,12,13). In
particular, high levels of miR-155 in mtSOD1 rodent models
has been reported to promote neuroinflammation.
Interestingly, inhibition of this miRNA via antisense
oligonucleotides (ASOs) has been shown to decrease
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Figure 1 MiRNA biogenesis and regulation. The canonical biogenesis pathway (represented by bold arrows): MiRNAs are transcribed from
the genome via RNA polymerase (RNA pol.) II/III producing a primary miRNA (pri-miRNA). Interestingly, both circular and long noncoding RNAs (circRNAs and lncRNAs, respectively) are known to assist in RNA pol. II transcription indicating these class of non-coding
RNAs may assist in miRNA transcription. Further, these pri-miRNAs can be transcribed into small nucleolar RNA (snoRNA) and transfer
RNA (tRNA) transcripts. Once produced, pri-miRNAs are processed by the DROSHA/DCGR8 complex into a pre-miRNA which is shuttled
from the nucleus to the cytoplasm via XPO5 and RAN-GTP. Both DROSHA processing and pre-miRNA nuclear export have been shown to
be inhibited by lncRNAs. Cytoplasmic pre-miRNAs are then processed by DICER/TRBP/PACT complex to produce a miRNA duplex which
is unwound via AGO1-4 creating a mature miRNA. Non-canonical biogenesis pathway: There are 3 major non-canonical pathways – I) premiRNAs are produced directly from the spliceosome after pre-mRNA processing skipping DROSHA/DCGR8 processing; II) cytoplasmic
pre-miRNAs need to get mono-uridylated by TUT2/4/7 proteins before being processed by DICER/TRBP/PACT; or III) cytoplasmic premiRNAs get processed by AGO1-4/PARN rather than DICER/TRBP/PACT to produce the miRNA duplex. MiRNA regulation: Once
produced miRNA are: (I) incorporated into the RNA-induced silencing complex (RISC) and generally target the 3’UTR of mRNA to suppress
translation OR induce mRNA degradation. This represents the primary function of miRNAs; (II) bind to the 3’UTR of mRNA to promote
translation and mRNA stability usually with proteins not associated with the RISC complex (non-RISC). However, this is far less common
than gene silencing; (III) targeted by circRNAs and lncRNAs that act as sponges to prevent miRNAs from reaching their mRNA targets;
(IV) MiRNAs can be incorporated into the AGO complex and transported back into the nucleus via IPO8 and XPO1 to either promote or
suppress transcription by binding to promoter/enhancer regions of the genome. While presumed that GTP converts to GDP via IPO8 to
allow entry of the miRNA in the nucleus, this has yet to be shown in the literature. This figure highlights this highly sophisticated RNA
network between circRNAs/lncRNAs/snoRNAs/ mRNAs that are responsible for regulating miRNA biogenesis and function ensuring gene
expression is tightly controlled.

neuroinflammation and alleviate ALS-like phenotypes in
rodent models (7). Others have used miRNAs to reduce
SOD1 expression, and in turn reduce mtSOD1s toxic effects,
by intrathecally delivering artificial miRNAs that were
cloned into an Adeno-associated virus (AAV) and target the
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SOD1 transcript. Use of SOD1 targeting artificial miRNAs
has been shown to have therapeutic effects in both rodent
and macaque models (14,15). However, the effectiveness of
theses therapeutics in humans is still unknown. This
previous research provides evidence of the utility of
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miRNAs as potential therapeutic targets, and further,
highlights the use of either ASOs or AAV-miRNAs as ways
to develop therapeutics that will potentially treat
neurodegeneration.
Recent work published by Loffreda et al., 2020 in
Progress in Neurobiology highlights miR-129-5p as another
upregulated miRNA in rodent models of mtSOD1 ALS
which, if inhibited using an ASO, could have therapeutic
effects for patients with ALS (16). The research group
looked at mtSOD1 (SOD1 G93A) in vitro neuronal cell
models in addition to in vivo mouse models and determined
that mtSOD1 causes an increase in miR-129-5p levels.
Further, they observed increased levels of miR-129-5p in
peripheral blood mononuclear cell (PMBC) samples of
sALS patients, suggesting that this phenomenon may be
related to ALS more broadly rather than just those who
contain mutations in SOD1. These researchers reported that
increased levels of miR-129-5p in both their in vitro and in
vivo models correlates with decreased levels of ELAVL4,
otherwise known as HuD—a protein critical for neuronal
cell identity, maturation, axogenesis, dendrite growth,
plasticity and survival (17). Through robust experimental
analyses, the authors were able to show that increased levels
of miR-129-5p were directly responsible for the reduced
levels of HuD, identifying the biological mechanism by
which high levels of miR-129-5p may contribute to
neurodegeneration. Having made this observation, the
authors then examined the ability of an ASO targeting
miR129-5p to reduce its levels in mtSOD1 rodent models.
Administration of the ASO via intracerebroventricular
injection at an early symptomatic stage (post-natal 80 days)
led to increased survival, improved motor capabilities, and
increased neuromuscular junction connections. However, it
only had a mild effect on preventing motor neuron
degeneration which was not statistically significant. The
authors concluded that while reducing levels of miR-1295p
may have some therapeutic effects, the most optimal
approach may be to pair their ASO with another
miRNAbased therapeutic currently in development—an
ASO targeting miR-155 (7,18).
ASO-based therapeutics have become popular as an
approach to treat neurodegenerative diseases due to the
success in treating Spinal Muscular Atrophy (SMA)—a
juvenile neurodegenerative disease caused by loss of lower
motor neurons —using an ASO targeting SMN2 (19).
Several modifications to the nucleotide backbone of an ASO
can be done to increase its affinity to its target and make it
resistant to nucleases. For example, morpholino
modifications were used to develop the SMN2 ASO and the

© Non-coding RNA Investigation. All rights reserved.

miR-129-5p ASO (16,19). Morpholino modifications alter
the sugar-phosphate backbone by changing the sugar ring
from a five-membered to a six-membered ring and the sugar
rings are linked to phosphoramidates groups rather than
phosphate groups. These modifications have been proven to
be beneficial to develop ASOs that either knockdown
expression of a specific gene, as seen in Loffreda et al., 2020,
or alter mRNA splicing as seen for the ASO that targets
SMN2 (16,19). Moreover, the ASO produced in Loffreda et
al., 2020 is called an antagomir—an ASO that targets a
miRNA—and they have been increasingly shown to be
effective therapeutics. For example, the drug miravirsen,
which has completed phase II clinical trials, is an antagomir
targeting miR-122 and has been shown to prevent
propagation of hepatitis C virus (HCV) RNA in the liver
highlighting the potential use of antagomirs in clinical
practice (20). Despite these developments, ASOs still have
their limitations which include their potential off-target
affects, their expense to develop, and their inability to cross
the blood-brain barrier; making them difficult to administer
for neurological diseases (21). However, the current success
of ASO treatments thus far has sparked more innovative
research to determine whether further modifications to
these oligos will allow us to overcome these limitations,
offering new opportunities for therapeutic development.
Loffreda et al., 2020 provides clear evidence that
increased levels of miR-129-5p is caused by mtSOD1 and
that lowering its levels in mtSOD1 mice has some
therapeutic effects; however, it is unclear whether reduction
of miR-129-5p would be a good ALS therapeutic more
broadly (16). The authors identified increased levels of miR129-5p in sALS patient PBMCs, but not in human spinal
cord or motor neurons (16). As mentioned previously, the
environmental context matters when discussing miRNA
regulation (9). Further, in the several studies that have
examined miRNA expression in the spinal cord and motor
neurons of sALS cases, upregulation of miR-129-5p has not
been observed (4-6). Thus, it is unclear whether this
observation of increased levels of miR-129-5p in PBMCs is
relevant to the dysfunction of motor neurons, or more
broadly, the central nervous system of the sALS patient
group within their study.
Further, the use of an ASO to suppress miR-129-5p
expression should be approached with caution. In the
central nervous system, miR-129-5p has been shown to
suppress apoptosis and alleviate neuroinflammation (22).
Low levels of miR-129-5p have been reported in the
degenerating brain of patients with Alzheimer’s Disease,
and lack of this miRNA creates an inflammatory response
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that can be neurotoxic (23). Thus, too much or too little of
miR129-5p could be damaging to the central nervous
system. This is likely because miRNAs can target several
transcripts to regulate a network of genes, which can make
cells sensitive to fluctuations in miRNA expression. In this
case, the authors showed that miR-129-5p regulates HuD
levels, but miR-129-5p has also been shown to regulate
critical neuronal genes involved in synaptic plasticity
(FMR1) and neuroinflammation (HMGB1) (22,24). All this
suggests that further work needs to be done to ensure
reduction of this miRNA will not have long-term effects that
may be more damaging than therapeutic.
Loffreda et al., 2020 proposed that while their ASO had
some beneficial effects in their mtSOD1 models, matching it
with an ASO that inhibits miR-155 may have the greatest
overall therapeutic effect (16). This points to the idea that
simply targeting one miRNA may not be enough to
ameliorate ALS. In fact, as mentioned previously, several
miRNAs have been shown to be upregulated in mtSOD1
models (7,12,13). Further, the article provides data
indicating that mtSOD1 increased the levels of DICER, a
critical protein in miRNA biogenesis, which may explain
why miRNAs are upregulated in mtSOD1 models (16).
Therefore, there seems to be a systemic issue with miRNA
production in the presence mtSOD1. Thus, lowering levels
of DICER might seem to be a better target to slow the
production and reduce the toxicity of these upregulated
miRNAs in mtSOD1 ALS cases. However, knockout of
DICER in mouse motor neurons has been shown to lead to
motor neuron degeneration, and thus, reducing levels of
DICER should be approached with caution as well (25).
Overall, while this latest work by Loffreda et al., 2020
provides another interesting avenue for miRNAbased
therapeutics for ALS, this work still has far to go before we
can think about administering it to patients. Large-scale
preclinical studies still need to be done to determine if
inhibition
of
miR-129-5p
prevents
motor
neurodegeneration, helps alleviate ALS-like phenotypes in
several models of ALS or just SOD1-related models, and
finally, determine whether downregulation of this miRNA
has any potential negative long-term outcomes (i.e., chronic
neuroinflammation). Further, we still do not know whether
miR-129-5p is upregulated within the spinal cord or motor
neurons of mtSOD1 ALS cases, which will be necessary to
address to ensure development of this ASO as a therapeutic
is not in vain. All this taken together, miR129-5p could be a
potential therapeutic for ALS, but in agreeance with the
authors, it is unlikely that targeting this miRNA alone will
be enough to completely halt the disease progression (16).
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However, the mere identification of this miRNA, its
biological network and its potential relevance to disease will
be incredibly important to our understanding of
mechanisms associated with ALS progression, opening more
avenues for potential therapeutics.
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o Awarded: May 10th, 2018 | From: London Health Research Academic Committee
Poster Award Finalist
o Awarded: April 30th, 2018 | From: ALS Canada
Queen Elizabeth II Graduate Scholarship in Science and Technology ($15,000 CAD)
o Awarded: April 30th, 2018 | From: The School of Graduate and Postdoctoral Studies
CIHR Doctoral Award – Fredrick Banting and Charles Best Canada Graduate Scholarship ($105,000
CAD)
o Awarded: April 17th, 2018 | From: Canadian Institute of Health Research
Neuroscience Travel Award ($500 CAD)
o Awarded: October 2nd, 2017 | From: Neuroscience Program, Western University
Robarts Research Institute Trainee Award ($100 CAD)
o Awarded: May 26th, 2017 | From: Robarts Research Institute Award
Ontario Graduate Scholarship (OGS) valued at $15,000 CAD (Sept. 2017)
o Awarded: May 26th, 2017 | From: The School of Graduate and Postdoctoral Studies
Neuroscience Travel Award ($500 CAD)
o Awarded: February 1st, 2017 | From: Neuroscience Program, Western University
Poster Award Finalist
o Awarded: April 28th, 2016 | From: ALS Canada
Deans Undergraduate Research Opportunities Program award valued at $6,000 CAD (May 2015)
o Awarded: April 15th, 2015 | From: Schulich School of Medicine and Dentistry

Publications (h-index - 4)
1) Campos-Melo, D., Hawely, ZCE. & Strong, MJ. RNA species are active players in stress granules
dynamic and function. Under revision in Front. Cell Devel. Biol. (2020).
2) Hawely, ZCE., Campos-Melo, D. & Strong, MJ. Negative feedback network between TDP-43 and
multiple microRNAs is dependent on TDP-43 nuclear localization. Accepted in J. Mol. Biol.
(2020).
3) Hawely, ZCE., Campos-Melo, D. & Strong, MJ. MiR-129-5p: A novel therapeutic for ALS?. Noncoding RNA Investigation. Accepted (2020).
4) Hawely, ZCE., Campos-Melo, D. & Strong, MJ. MiR-105 and miR-9 regulate the mRNA stability of
neuronal intermediate filaments. Implications for the pathogenesis of amyotrophic lateral
sclerosis (ALS). Brain Res. (2019). doi.org/10.1016/j.brainres.2018.10.032.
5) Campos-Melo, D*., Hawley, ZCE*. & Strong, MJ. Dysregulation of human NEFM and NEFH
mRNA stability by ALS-linked miRNAs. Mol. Brain (2018). doi.org/10.1186/s13041-018-0386-3.
(*shared first author).
6) Hawely, ZCE., Campos-Melo, D. & Strong, MJ. Novel miR-b2122 regulates several ALS-related
RNA-binding proteins. Mol. Brain (2017). doi.org/10.1186/s13041-017-0326-7.
7) Hawely, ZCE*., Campos-Melo, D*., Droppelmann CA. & Strong, MJ. MotomiRs: miRNAs in motor
neuron function and disease. Front. Mol. Neurosci. (2017). doi:10.3389/fnmol.2017.00127.
(*shared first author).
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Platform Presentations
1)
2)
3)
4)
5)
6)
7)
8)

†

mRNA Turnover: Mechanisms, Regulation, and Implications in Age-Related Diseases –
Montreal, QC, Canada (Jun. 2019).
†
London Health Research Day – London, ON, Canada (May 2018).
Eukaryotic RNA Turnover – Oxford, England (May 2017).
†
Robarts Research Retreat – London, ON, Canada. (May 2017).
Society for Neuroscience (SfN) – San Diego, CA, USA. (Nov. 2016).
Regulatory & Non-Coding RNA Meeting – Cold Spring Harbor Laboratories, NY, USA. (Aug. 2016)
Robarts Research Retreat – London, ON, Canada. (May 2016).
Western’s Neuroscience Research Day – London, ON, Canada (Apr. 2016).

*All presentations were selected through as competitive selection process based on abstract
†
Award-winning presentations

Poster Presentations
1)
2)
3)
4)
5)
6)
7)
8)
9)
10)
11)
12)
13)

15th Andre-Delambre Annual Symposium – Montreal, QC, Canada. (Sept. 2019).
Canadian Student Health Research Forum – Winnipeg, MAN, Canada. (Jun. 2019).
Cell Symposium: Regulatory RNAs – Berlin, Germany. (May 2019).
London Health Research Day – London, ON, Canada. (May 2019).
International Symposium on ALS/MND – Glasgow, Scotland. (Dec. 2018).
Toronto RNA Enthusiasts Day (TREnDs) – Toronto, ON, Canada. (Aug. 2018).
RNA Society – Berkeley, CA, USA. (May 2018).
ALS Canada Research Forum – Toronto, ON, Canada. (Apr. 2018).
Toronto RNA Enthusiasts Day (TREnDs) – Toronto, ON, Canada. (Aug. 2017).
London Health Research Day – London, ON, Canada. (May 2017).
RNA Metabolism in Neurological Diseases – San Diego, CA, USA. (Nov. 2016).
Robarts Research Retreat – London, ON, Canada. (May 2016).
ALS Canada Research Forum – Toronto, ON, Canada. (Apr. 2016).

Teaching Experiences
o
o
o

Elementary Student Activity Leader | Canadian Medical Hall of Fame
Teaching Assistant | Principles of Neuroscience Graduate Course
Teaching Assistant | Neuroscience Undergraduate Thesis Course

Sept. 2015 – Jan. 2020
Jan. 2016 – Apr. 2017
Sept. 2015 – Apr. 2016

Reviewing Experience
o
o
o
o
o
o

Neuroscience Research Blog Reviewing Editor
Manuscript Reviewer – Annals of Neurology
Manuscript Reviewer – Brain Communications
Scholarship Q&A Session Volunteer
Manuscript Reviewer – Journal of Neuroscience
Manuscript Reviewer – Journal of Neurochemistry

Jun. 2019 - present
April 2020
October 2019
September 2018/2019
July 2018
October 2017
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Leadership Experience
o
o
o
o
o
o

Robarts Association for Trainees Chair | Robarts Research Institute
Leadership & Academic Mentorship Program Leader | Success Center
Associate Vice President of Orientation | University Student Council
Residence Orientation Coordinator | Housing, Western University
Head Orientation Leader | Housing, Western University
Orientation Leader | Housing, Western University

Jan. 2016 – Apr. 2017
Jan. 2016 – Apr. 2016
Arp. 2014 – May 2015
Jan. 2013 – Apr. 2014
Feb. 2012 – Apr. 2013
Mar. 2011 – Apr. 2012

Interviews and Media Relations
o
o
o

Radio Interview: Current research in Amyotrophic Lateral Sclerosis (ALS). Gradcast, CHRW 94.9
FM (February 2016)
Radio Interview: Genes, ALS, and that new Grad Student Smell with Zach Hawley. Gradcast,
CHRW 94.9 FM (July 2015)
News Article: Why is it important to vote in the federal election. Schulich School of Medicine and
Dentistry Newsletter (October 2015)

